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1. INTRODUCTION 
The picornavirus family represent one of the largest families of 
human and animal viral pathogens. Based on similarities in virion 
physico-chemicals properties, RNA sequence and genome 
organization these viruses are currently classified in twelve 
established and five proposed genera.  
The established genera are:  
 
• Enterovirus (Human enterovirus A, B, C, D (HEV-A, B, C, 
D), unclassified Simian enterovirus A (SEV-A), Bovine 
enterovirus A, B, Porcine enterovirus B, Human rhinovirus A, 
B, C (HRV-A, B, C));  
• Hepatovirus (Hepatitis A virus (HAV)); 
• Parechovirus (Human parechovirus (HPeV) and Ljungan 
virus); 
• Kobuvirus (Aichi virus, Bovine kobuvirus, Porcine kobuvirus);  
• Cardiovirus (Encephalomiocarditis virus (EMCV), Theilovirus 
(ThV)); 
• Aphtovirus (Foot-and-mouth disease virus (FMDV), Equine 
rhinitis A virus, Bovine rhinitis A and B virus); 
• Erbovirus (Equine rhinitis B virus); 
• Teschovirus (Porcine Teschovirus); 
• Sapelovirus (Porcine sapelovirus, Simian sapelovirus and 
Avian sapelovirus); 
• Avihepatovirus (Duck hepatitis A virus); 
• Senecavirus (Seneca Valley virus); 
• Tremovirus (Avian encephalomyelitis virus); 
 
The proposed genera are:  
 
• Cosavirus (Human Cosavirus (HCoSV A) and a number of 
candidate species); 
• Aquamavirus (Aquamavirus A); 
• Dicipivirus (Cadicivirus A); 
• Megrivirus (Melegrivirus A); 
• Salivirus (Salivirus A). 
 
Six genera of this family include pathogens infecting humans: 
Enterovirus, Parechovirus, Hepatovirus, Cardiovirus, Kobuvirus, 
Aphtovirus.  
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2. VIROLOGY 
 
Picornaviruses are small, non–enveloped, positive stranded 
RNA viruses whose diameter varies between 28 and 34 nm.1 The 
RNA is surrounded by a capsid consisting of a densely-packed 
icosahedral arrangement of 60 protomers, each constituted by 4 
proteins, called VP1 (viral protein 1), VP2, VP3 and VP4. The three 
larger proteins (VP1, VP2, VP3, ~30 kDa each) are located on the 
external surface of the virus and one smaller protein (VP4, ~7 kDa) 
lies on the inner surface, interfacing with VP1-3 and RNA.2  
The complete virion derives from the assembly of the different 
protein units (figure 1): 
 
• VP1, VP2, VP3 and VP4 form a protomer, the smallest 
subunit of capsid; 
• Five protomers form a capsomer; 
• Twelve capsomers form the icosahedral capsid. 
 
The major capsid proteins VP1 to VP3 are each folded into 
eight-stranded antiparallel β-sheets with a jelly-roll topology. These 
β-barrels of five copies of VP1 are located around the fivefold axis, 
while VP2 and VP3 are around the threefold axis. The smaller protein 
VP4 have a less ordered structure and, being located on the inner 
surface of the capsid, anchors the RNA genoma (figure 2). 
 
Figure. 1. Structure of capsid 
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Figure 2. Structure of protomer 
 
The virion’s surface presents a plateau star-shaped at the top of each 
axis of pentaicosahedric symmetry, surrounded by a deep depression 
called "canyon" (figure 3). The canyon is formed by the folding of 
aminoacid chains with highly conserved sequences. Under  the floor 
of the canyon, inside VP1, there is a hydrophobic pocket that 
represents the binding site for anti-picornavirus compounds called 
capsid-binders.3 Moreover, attachment of the virus to the host cell 
occurs through binding of the cellular receptors into this canyon. 
 
 
 
 
 
Figure 3.  Canyon’s structure. To the left: it is shown the 
binding to the receptor; to the right: it is shown the binding 
to the antibodies. 
 
2.1. Viral genome  
 
All picornaviruses share a similar genomic organization that consists 
of a single-stranded, positive sense RNA molecule of approximately 
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6700-8850 nucleotides4-9 (figure 4). The genome contains a single 
open reading frame (ORF) preceded by a long 5’-untranslated region 
(5’ UTR) whose sequences tend to be strongly conserved among the 
different viral species. In a subset of picornaviruses, a region L 
follows 5’ UTR. A relatively short region 3'-UTR follows the ORF, it 
varies in length from 14 to 126 bases and probably contains signals 
for the binding of the replicase, essential to initiate the synthesis of 
new RNA chains. At its end there is a polyadenilated tract (poly-A), 
heterogeneous in length (on average 35-100 residues), important for 
the synthesis of the negative-stranded RNA.10 
 
 
Figure 4. Principal organization of picornavirus genomes. The actual genome 
organization may deviate in some picornaviruses 
 
A small viral protein, VPg, is covalently linked to the 5’ end of 
the viral genome. The VPg is involved in the replication of the viral 
genome but it is not essential for infectivity, in fact if it is removed by 
treatment with viral protease the viral infectivity is not reduced.11  
The ORF is translated into a long polyprotein (approximately 
2200 amino-acid residues) that was cleaved nascently by viral 
proteases into structural and non-structural proteins, divided into three 
primary precursors (P1, P2, and P3). The viral capsid proteins VP1-
VP4 are formed by the cleavage of the P1 region. Seven non-
structural proteins involved in the replication of the genome or with 
enzymatic activity (2A- 2C and 3A, 3B- 3D) are formed from P2 and 
P3 cleavage, respectively.  
 
2.2. Replication cycle	  	  
Picornavirus replication occurs entirely in the cytoplasm in a 
single-step growth. The viral multiplication cycle begins with the 
attachment of the virus to the host cell surface through interaction 
with cellular receptors. 
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Figure 5. Replicative cycle of the Picornavirus.	  	  
During the last few year, several cellular receptors for different 
groups of picornaviruses have been identified (table 1). The major 
group of HRVs and several coxsackieviruses use intercellular 
adhesion molecule 1 (ICAM-1) as cellular receptor, while poliovirus 
(PV) bounds to poliovirus receptor (PVR or CD155). These receptors 
belong to the immunoglobulin superfamily (IgSF) whose extracellular 
regions consist of between two to five Ig domains. The N-terminal 
domain binds to the viral surface, and the carboxy-terminal domain 
comprises a transmembrane portion and a short cytoplasmic region. 
The sites of attachment on the viral surface are represented by 
canyons inside VP1, as demonstrated by studies of site-specific 
mutagenesis.12 The change of even a single amino acid in the portion 
forming the canyon shows an altered pattern of affinity for the cellular 
receptor. The receptor ICAM-1 is expressed on the surface of many 
tissues, including the nasal epithelium that is the site of penetration of 
the rhinoviruses. The expression of ICAM-1 is controlled by cellular 
factors, such as cytokines.13 The infection caused by rhinoviruses 
increases the expression of ICAM-1. The antibodies anti-ICAM-1 can 
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block the infection of HeLa cells caused by rhinoviruses. On the basis 
of these observations, a soluble form of ICAM-1, that can inhibit viral 
growth, in vitro, in high and specific way, was produced and 
purified.14,15  
 
Table 1. Different  picornavirus cellular receptor. 
Virus: Serotypes: Receptor: Description: 
Human 
Rhinovirus 
91 ICAM-1 (Intracellular 
Adhesion Molecule 1) 
Immunoglobulin-like 
molecule; 5 domains 
Human 
Rhinovirus 
10 LDLR (Low Density Lipoprotein Receptor) 
Poliovirus 3 CD155 Immunoglobulin-like 
molecule; 3 domains 
Coxsackie A 3 ICAM-1 
Echo 2 VLA-2 Integrin-like molecule 
Echo 6 DAF (Decay Accelerating 
Factor) 
- 
EMCV 1 VCAM-1 (Vascular Cell 
Adhesion Molecule) 
- 
 
Binding of cellular receptors into the canyon induces the release 
of the pocket factor, if present, and induces conformational changes in 
the capsid that initiate the uncoating process. After attachment, the 
viral genomic RNA enters	  the cytoplasm of the host cell and serves as 
a template for viral protein translation and RNA replication. RNA 
replication occurs in small membranous vesicles. A single negative 
strand intermediate serves as a template for the production of several 
positive strand RNAs. New viral particles are formed by association 
of new positive strand RNA and viral structural protein, and are 
subsequently released by lysis of the host cell.  
The minor group of rhinoviruses (12 serotypes) interacts with 
several members of the superfamily of low-density lipoproteins 
receptor (LDLR). These receptors are highly conserved between 
species and almost ubiquitously expressed. The LDLRs do not belong 
to the IgSF and interact with the outer part of the canyons without 
interfering with the stability of the capsid and uncoating. Therefore, 
the release of the RNA genome for minor group of HRVs is triggered 
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by the internal acidity of the endosome that causes conformational 
changes of the virion surface.  
The time required for a complete cycle of replication, generally 
ranges from 5 to 12 hours and it depends on virus strain and on some 
factors like pH, temperature and host cell type.	  
The Picornavirus infectivity is not modified by organic solvents 
while it is sensitive to the pH variation and the stability to the different 
pH characterizes the different picornaviruses. Enteroviruses A, B, C 
and D, Cardiovirus, Parechovirus and Epatovirus can survive to pH = 
1-3, therefore they are capable of overcoming the stomach acidity and 
to reach the intestine where they can multiply. Rhinoviruses or 
Aphthoviruses are fleeting at pH below 6 because they replicate in the 
nose and in the oropharynx (pH = 6.8-7.3) and do not require stability 
in an acid environment. Moreover, rhinoviruses are more thermostable 
than the other enteroviruses. It can survive up to 50 °C even if, in 
order to obtain an optimal propagation in cell cultures, an incubation 
temperature of 33 °C is required (table 2). 
 
Table 2. Properties of Rhino- and other Entero- viruses.	  
 pH 
sensitivity 
Optimum 
growth 
temperature 
Detergent 
sensitivity 
Serotypes Transmission Site of 
primary 
infection 
Rhino 
viruses 
labile to 
acid pH 
33 degrees C 
(approx) 
 >100 aerosol upper 
respiratory 
tract 
Other 
Entero 
viruses 
resistant to 
acid pH 
37 degrees C 
(approx) 
Resistant 72 oro-fecal gut 
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3. PATHOGENESIS AND CLINICAL SIGNIFICANCE 
 
The family Picornaviridae is one of the largest family of viral 
pathogens, implicated in an extensive range of clinical manifestations 
that affect humans as well animals. The syndromes caused by 
Picornaviruses range from mild upper respiratory tract infections such 
as common colds, fever and rush to more serious and life-threatening 
infections such as meningitis, poliomyelitis, myocarditis, pericarditis 
and neonatal sepsis, just to name a few.1,2	  Enterovirus infections in 
their most virulent forms, are physically debilitating and can be fatal 
for immuno-suppressed or elderly patients or in early childhood. 	  
Among the picornavirus genera, Aphthovirus, Cardiovirus, 
Parechovirus, Hepatovirus and  Enterovirus are the most clinically and 
economically significant. 
 
3.1 Aphthovirus 
 
The genus Aphthovirus consist of four species, foot-and-mouth 
disease virus (FMDV), bovine rhinitis A virus (BRAV), bovine 
rhinitis B virus (BRBV) and equine rhinitis A virus (ERAV). 
The major member of this genus is FMDV which causes severe 
infection in cloven-hoofed animals, including domestic and wild 
bovids. The disease is characterized by acute fever, followed by the 
development of blisters chiefly in the mouth and on the feet.3 
Unfortunately, the inactivated vaccines presently available are not 
entirely effective due to the high variability of the virus. Vaccination 
blocks disease symptoms but does not always block transmission of 
the virus to other animals. FMDV is transmissible to humans, but it 
crosses the species barrier with difficulty4 and the experience of the 
human infection is limited. Symptoms in humans are mostly mild and 
self limiting, mainly uncomfortable tingling blisters on the hands but 
also fever, sore throat, and blisters on the feet and in the mouth, 
including tongue.4 
 
3.2  Cardiovirus. 
 
The genus Cardiovirus consist of two species, 
Encephalomyocarditis virus (EMCV) and Theiloviruses (ThV). 
EMCV is represented by a single serotype with the same name. This 
virus is an important pathogen of rodents associate with myocarditis 
and encephalitis. EMCV infection in man has been rarely reported. 
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ThVs are classified into four types: Theiler’s murine 
encephalomyelitis virus (TMEV), Thera virus (TRV) Vilyuisk human 
encephalomyelitis virus (VHEV), and Saffold virus (SAF-V) 1-8. The 
last two types infect humans causing gastroenteritis, respiratory 
diseases, myocarditis, acute and chronic encephalitis. There was no 
reliable evidence of cardiovirus infection in humans until 2007 when a 
virus distantly related to TMEV was identified in a fecal sample 
dating back to 1982 from an infant with fever of unknown origin.5 The 
virus was named Saffold virus. In the following two years eight types 
of Saffold-like cardioviruses were found mainly in patients with 
gastroenteritis.6-9 Serologic studies, in respiratory secretions from 
children with respiratory problems and in stools of both healthy and 
diarrheic children, indicate that asymptomatic cardiovirus infection is 
highly prevalent in infants below two years old.6 
 
3.3 Parechovirus  
 
The Parechovirus genus is comprised of two species, Human 
parechoviruses (HPeV) and Ljungan virus. People of all ages are 
infected by HPeVs, although these infections occur usually in young 
children, with a seroprevalence of 88% in children of two years.10 
Recent reports show that epidemiological and clinical features of 
HPeVs are similar to human EVs. Commonly, HPeVs cause mild 
gastrointestinal or respiratory illness, but it is occasionally implicated 
in severe disease conditions, such as flaccid paralysis, myocarditis and 
encephalitis.11 Probably, the associated spectrum of diseases is 
underestimated, since many serotypes of HPeVs have been only 
recently identified. 
 
3.4 Hepatovirus  
 
The genus Hepatovirus consists of a single species, Hepatitis A 
virus (HAV). HAV causes hepatitis A in humans and primates.12 The 
infection is usually transmitted by ingestion of contaminated food or 
water.13-15 The incubation period is 10-50 days and fever and jaundice 
are the main symptoms of the infection. In developing countries, the 
diffusion of HAV infection is high among children. However, only 
10% of infected children are symptomatic, whereas the severity of the 
disease increases with age.16 HAV, normally, causes an acute self-
limiting disease that does not progress to a chronic phase, and 
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manifestations of the disease are generally restricted to the liver. 
Although a few cases of permanent liver damage have been reported, 
99% of the cases recover completely and the fatalities are less than 
0.1%. An effective vaccine is now available for prevention of HAV 
infection. 
 
3.5. Enteroviruses	  
 
Enteroviruses (EVs) are the best known human and animal 
pathogens into the picornavirus family.  
Clinical manifestations may vary diversely with one serotype, 
while multiple serotypes can present identical symptoms and may 
mimic bacterial infections. Most enterovirus infections cause benign, 
self-limiting disease. However, they can also produce severe and 
sometimes fatal illnesses such as meningitis, encephalitis, 
myocarditis, neonatal sepsis and poliomyelitis.17,18 
This genus includes polioviruses (PV 1, 2, 3), coxsackieviruses 
(CV-A 1-22, 24, CV-B 1-6), echoviruses (E 1-21, 24-33), numbered 
enteroviruses (EV 67-71, 73) rhinoviruses (HRV-A, B, C), and hand 
foot-and-mouth disease virus (HFMDV).  
The high infectivity of HRVs is mainly due to direct contact 
between infected and susceptible host, particularly in people who do 
not have specific immnunoglobuline A (IgA) in nasal secretions. 
These viruses infect the host through the nose, mouth or eyes and they 
reache the pharynx through mucous ciliary action. The HRVs are 
unable to replicate in the gastrointestinal tract because they are 
unstable to acidic pH. Moreover, they preferentially grow at a 
temperature of 33 °C into the nasal cavity. 
The other EVs are able to replicate in both oropharynx and 
intestine. The infection usually causes mild manifestations (fever and 
malaise) into the initial site of multiplication and rapid healing. 
However, the virus can spread through the lymph circulation and 
blood circulation to target organs giving clinical situations debilitating 
and potentially fatal (figure 6). 
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Figure 6.  Enterovirus pathogenesis excluding HRVs. 
The viruses infect the host by the respiratory tract or food, they 
multiply in the oropharynx and intestine (primary viremia), and can 
spread through lymph circulation and blood circulation generating 
infection in target organs such as the meninges, skin, myocardium, 
etc. (Secondary viremia). 
 
3.5.1. Poliovirus (PV 1, 2, 3).  
 
Polioviruses are highly contagious viruses that are the etiologic 
agents of poliomyelitis, also known as infantile paralysis. There are 
three serotypes of polioviruses, PV 1, PV 2 and PV 3. Most disease 
results from type 1 poliovirus while types 2 and 3 are less 
neurovirulent. Polioviruses are spread through fecal-oral or oral 
transmission, and viral replication occurs in the gastrointestinal tract. 
Initial clinical symptoms may include fever, fatigue, headache, 
vomiting, constipation (or less commonly diarrhea). In a minority of 
patients the virus invades the central nervous system and destroys the 
motor neurons leading to temporary or permanent paralysis. In rare 
cases, paralytic poliomyelitis leads to death for respiratory arrest. 
Following the introduction of two effective vaccines, poliomyelitis 
has been eradicated from most of the world.19  
 
3.5.2. Coxsackievirus A and B (CVA-B). 
 
Group A and B of Coxsackieviruses are the principal cause of 
many clinical event including vescicular pharyngitis called 
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“erpangina”, a severe feverish pharyngitis accompanied by vomiting 
and ulcerative lesions of the soft palate and uvula, and foot and mouth 
disease, a rash vesicular type.19,20 Aseptic meningitis is a more severe 
syndrome, characterized by headache and irritation of the meninges 
(stiff-neck) accompanied by skin rash and petechiae.  The majority of 
children with Coxsackievirus infections completely resolves the 
symptoms in about 10-12 days. The development of autoimmune 
diabetes mellitus has been recently associated with alterations of the 
pancreatic β cells caused by CV infections.21   
 
3.5.3. Echovirus (E) 
 
Echoviruses (Enteric Cytopathic Human Orphan viruses) are the 
principal causes of rash, pharyngitis and acute feverish diseases in 
infants and children. Moreover, they are the most common cause of 
aseptic meningitis. Infection of an infant may cause severe systemic 
diseases, and is associated with high infant mortality rates.22 In this 
population, death usually results from overwhelming liver failure or 
myocarditis rather than infection of the central nervous system. The 
fecal-oral route is the predominant mode of transmission, although 
transmission sometimes occurs via respiration of oral secretions such 
as saliva. An indirect transmission occurs through water, food, and 
objects.  
 
3.5.4. Enterovirus 68-71, 73 (EV) 
 
EV 68-71 and EV73 have been associated with vesicular rash, 
meningo-encephalitis and respiratory infections such as pneumonia 
and bronchiolitis.23,24 The EV70 apparently does not replicate in the 
intestinal tract but it is responsible for an eye infection commonly 
called “acute hemorrhagic conjunctivitis” (AHC), characterized by 
swelling, irritation, conjunctival congestion and subconjunctival 
hemorrhage. The acute hemorrhagic conjunctivitis presents an 
incubation period of 24 hours and resolution in 1-2 weeks.25 In some 
cases, the infection can lead to a neurological disease 
indistinguishable from acute poliomyelitis, suggesting that the tissue 
tropism of EV70 also includes the central nervous system.26 After the 
eradication of poliovirus from developed countries, EV71 has 
emerged as major cause of neurologic threat in the world. Although 
EV71 usually causes hand, foot and mouth disease, a mild 
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exanthematous infection occurring mainly in young children, it is also 
associated with acute neurological diseases including aseptic 
meningitis, acute flaccid paralysis and even fatal neurogenic 
pulmonary edema.1 In the last decades a significant increase in 
epidemic activity of EV71 has been observed and severe outbreaks 
have been reported in various parts of the world, particularly in the 
Asia-Pacific region.27-30 
 
3.5.5. Rhinovirus (HRV) 
 
Because of high similarity in genome sequence and genome 
organization, human rhinoviruses were only recently added to the 
genus Enterovirus. The rhinoviruses are commonly isolated from 
respiratory secretions of people with acute colds. In fact, their name 
refers the privileged place of infection, the nasal mucosa. 
The isolation of rhinoviruses was performed by Pelon and Price 
inoculating nasopharyngeal secretions of patients with colds in tissue 
cultures of kidney of rhesus monkey.31,32 The first strain to be isolated 
was named JH 2060, this strain was similar to echovirus type 28. It 
was subsequently classified as rhinovirus type 1. The isolation of 
other serotypes and the classification of rhinoviruses were facilitated 
by the reduced temperature of cells incubation at 33 °C and the use of 
culture media at pH about 7.00.33 
The genome was characterized in 198434, and the introduction of 
molecular biology techniques, such as RT-PCR, facilitated the 
identification of other serotypes.35,36  
HRVs are the leading agents of upper respiratory tract infections 
in both adults and children. Although HRV-induced respiratory 
illnesses are usually mild and self-limiting, their diffusion and 
recurrent nature can explain the high medical and socio-economic 
impact in term of healthcare and lost productivity. HRVs are also 
responsible for respiratory tract complications such as sinusitis and 
otitis media, and severe lower respiratory tract illnesses in infants, 
holder adults and immune-compromised hosts. In patients with 
chronic respiratory disorders such as asthma and chronic obstructive 
pulmonary disease (COPD), HRVs are the major factors in the 
induction of exacerbations.37,38 In adults, COPD exacerbations are 
predicted by the World Health Organization to be the world’s third 
leading cause of death by the year 2030. 
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4. SMALL MOLECULES INHIBITORS OF PICORNAVIRUS 
REPLICATION 
 
The spread and the medical and economic importance of 
infections caused by picornaviruses have stimulated the research for 
effective agents in the prevention or treatment of these infections. 
Vaccination is effective for the prevention of polioviruses, hepatitis A, 
and foot and mouth virus infections, but this approach is impractical 
for other enteroviruses owing to the multiplicity of serotypes (more 
than 100 HRV serotypes) and the high mutation rate during virus 
replication.  
For these reasons, antiviral chemotherapy remains the only 
option. Moreover, a drug for the treatment of diseases caused by 
picornaviruses should possess not only a high power and low toxicity, 
but also a broad spectrum of action.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Objectives of anti-picornavirus therapy. 
Agents that prevent (a) viral anchorage to the cellular receptor of 
the host cell, (b) inhibitors of viral uncoating  (c) inhibitors of viral 
protein synthesis.  
 
Although extensive efforts have been devoted to the search for 
effective agents, to date no drug has been approved by the FDA for 
clinical use, and the patient care remains symptomatic. Each step 
during the life cycle of Picornavirus has been considered a potential 
target for antiviral compounds, including virus adsorption, uncoating, 
RNA translation, polyprotein cleavage, RNA replication, and particle 
assembly (figure 7). However, only the inhibition of capsid functions 
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and the interruption of viral protein synthesis resulted in antiviral 
agents with demonstrated clinical efficacy. Since it is well recognized 
that the structures of viral capsid and 3C protease are relatively 
conserved among different serotypes, molecules acting on each of 
these targets could be promising anti-picornavirus agents with a 
broad-spectrum of activity.1 
 
4.1 3C protease inhibitors 
 
Picornaviruses translate their genomic information into a 
polyprotein that is co-translationally processed by virus-encoded 
proteases 2Apro, 3Cpro/3CDpro. The generation of mature structural 
protein and enzymes is essential for the viral replication. The viral 
proteases, in particular 3C protease, are attractive targets for the 
development of anti-picornavirus agents due to the highly conserved 
residues into the catalytic site and the poor sequence similarities with 
cellular proteases.  
 
  Figure 8. Structure of 3C protease inhibitors. 
 
During the last years, a variety of peptidic and nonpeptidic 
protease inhibitors (figure 8) have been discovered and developed. 
Ruprintrivir, developed by Pfizer, is a potent and irreversible 
peptidomimetic inhibitors of 3C protease.2-5 This compounds showed 
in vitro low cytotoxicity and a wide range of anti-EV activity. For 
these reasons, Ruprintivir was progressed to clinical trials. 
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Administered intranasally for its poor oral bioavailability, Rupintrivir 
was able to reduce severity of illness and viral load in HRV challenge 
trials. However, this compound was terminated for clinical 
development (phase II) due to its unsatisfying results in naturally 
infected patients.  
In order to identify orally bioavailable analogues of Rupintrivir, 
a series of non peptidic inhibitors of 3C protease were designed. 
Compound I exhibited a potent and broad spectrum anti-EV activity in 
vitro. In phase I clinical studies, it was well tolerated by healthy 
volunteers.6 However, no further clinical development of this 
compound was planned. 
 
4.2 3A protein inhibitors 
 
Nonstructural protein 3A is a small, hydrophobic protein highly 
conserved among enteroviruses.7 This indispensable protein is 
implicated in many functions including RNA replication,8 cellular 
tropism and pathogenicity.9 
Enviroxime (figure 9) is a benzimidazole derivative with a 
broad spectrum of anti-EV activity, developed by Lilly 
Pharmaceuticals.10,11 It probably inhibits the plus-strand RNA 
synthesis by targeting 3A protein. Despite its potency in vitro, 
Enviroxime resulted in modest or no benefit in clinical studies. Poor 
bioavailability and	   gastrointestinal side-effects resulted in 
discontinuance of the program. 
 
 
          Figure 9. Structure of Enviroxime 
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4.3 Compounds that bind to the capsid (capsid binders) 
 
 
Figure 10. Diagrammatic view of picornaviruses with enlargement of one 
icosahedral asymmetric unit showing the outline of the canyon and the entrance to 
the antiviral-binding pocket. 
 
As previously mentioned, capsid binding molecules are able to 
inhibit virus infectivity blocking uncoating and/or the attachment of 
the virus to the host cellular receptors. The binding site for these 
compounds is an hydrophobic pocket placed inside VP1 under the 
canyon floor (figure 10). Uncoating of a viral particle requires a 
certain degree of capsid flexibility. The insertion of a capsid binder in 
this pocket leads to an increase of viral particle stability, preventing 
conformational changes that are essential for the uncoating. The 
bottom of the canyon is also the most important binding site for 
cellular receptors, such as intercellular adhesion molecule-1 (ICAM-
1) recognized by the major group of rhinoviruses, the poliovirus 
receptor (PVR or CD155) by polioviruses, the coxsackie-adenovirus 
receptor (CAR) by Coxsackie B viruses and vascular cell adhesion 
molecule-1 (VCAM-1) by encephalomyocarditis virus (EMCV). The 
binding of these inhibitors in the VP1 pocket can induce 
conformational changes in the bottom of the canyon preventing virus 
adsorption to the host cell (figure 11). 
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Figure 11. Mechanism of action of capsid binders. Schematic representation of the 
interaction between ICAM-1 and major group rhinoviruses. Left (A): ICAM-1 binds 
into the canyon surrounding each fivefold axis, inducing conformational changes 
that eventually lead to uncoating of the virus and release of the viral RNA. Right 
(B): Binding of a “capsid binder” into the hydrophobic pocket underneath the 
canyon floor. This binding event induces conformational changes, thereby (i) 
increasing the rigidity of the virion (preventing uncoating and subsequent release of 
viral RNA) and at the same time (ii) decreasing the ability of the virion to interact 
with its receptor. 
 
4.3.1 WIN compounds. 
 
The WIN series of capsid-binding compounds, developed by 
Sterling Winthrop, played a leading role in the development of 
antiviral agents effective against human EV infections (figure 12). 
Disoxaril, also known as Win 51711, was the first compound of this 
series to reach clinical trials. In vitro, Disoxaril showed high 
inhibitory potency against many enteroviruses including 
rhinoviruses.12-17 When administered orally to mice, this molecule 
effectively prevented the paralysis and death of mice infected with 
poliovirus-2 and echovirus-9. However clinical studies were 
interrupted because of the appearance of crystallurea in phase I 
clinical studies. 
An analogue, Win 54954, was assessed (Phase II) against two 
rhinovirus (HRV 23 and HRV 39) and Coxsackievirus A21.17,18 This 
compound was able to reduce in vivo only the viral titer and the 
severity of the infection caused by Coxsackievirus A21 but it did not 
show efficacy against rhinoviruses. Win 54954 had also a very short 
half-life, presumably due to instability of the oxazoline ring in acidic 
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condition, and it was not further studied because of the onset of side 
effects (redness, skin rashes and reversible hepatitis).  
Afterward, the oxazoline ring was substituted in order to obtain 
metabolically stable compounds. These studies led to analogs 
containing a 2-methyltetrazole ring.19 The Win 61605 was the most 
promising compound of the series. Unfortunately, it caused 
hepatotoxicity after oral administration to dogs. Its toxicity is 
presumably due to the products of the tetrazole ring metabolism and 
led to the suspension of the compound evaluation in vivo. 
Bioisosteric replacement of the 2-methyltetrazole ring with a 5-
methyloxadiazoline ring, led to Win 61893 that was rapidly 
metabolized and induced reversible hepatitis.20  
Replacement of the methyl group at the oxadiazole ring with a 
trifluoromethyl group resulted in Win 63843 (pleconaril).20 This new 
analogue showed greater metabolic stability and a broader anti-EV 
spectrum than its precursors.20,21,22 In a phase III clinical trial, 
pleconaril was able to reduce the duration and the severity of common 
cold symptoms.23 However,	   the FDA did not approve pleconaril for 
marketing due to its safety profile. 24 
 
 
 
Figure 12. Structures of WIN compounds. 
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4.3.2 Pirodavir and related compounds 
 
Pirodavir (R 77975) and its predecessor R 61837 (figure 13) are 
two pyridazine analogues developed by the Janssen Foudation.25-27 
Pirodavir was 500-times more potent in vitro than R 61837 and it 
inhibits approximately 80% of 100 HRV serotypes at concentration of 
0.1 µg/mL or less. Its administration as a nasal spray, six times a day 
for 5 days, induces a significant reduction of the spread of the virus, 
but without a real clinical benefit. The lack of clinical efficacy of 
Pirodavir could be partially due to its poor water solubility that makes 
difficult its administration in an aqueous formulation compatible with 
secretions present in the airways. Moreover, the ester function rapidly 
undergoes hydrolysis to the corresponding inactive acid. 
 
	  	  
Figure 13. Structure of Pirodavir and R 61837. 
 
Although, R 61837 is less active than Pirodavir against several 
rhinovirus serotypes, it was prophylactically effective in preventing 
colds in human volunteers infected with HRV-9.27  
To circumvent the problem of the metabolic instability of ester 
function, a series of oxime ether analogs of pirodavir was synthesized 
at Biota Pharmaceuticals (figure 14). BTA 39 and BTA 188 showed 
potent activity against 56 HRV serotypes with IC50 ranging from 0.5 
to 6.7 nM.28  
 
	  
 
Figure 14. Structure of BTA series. 
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Afterwards, the benzaldehyde oxime ether moiety was replaced 
by a 2-ethoxybenzoxazole. BTA798 emerged as the most interesting 
compound within this series.29 This analogue was a potent, orally 
bioavailable, broad spectrum inhibitor of HRVs and other EVs. 
BTA798 is currently undergoing Phase II clinical trials for the 
treatment of HRV infections in asthmatic patients. 
 
4.4. Flavanoids, flavonoids and analogues.  
 
Flavonoids and flavanoids are important groups of oxygenated 
heterocycles widespread in the plant kingdom and daily consumed in 
the human diet. They contribute to the colour of many flowers and 
vegetables, and are involved in defensive system of plants. In addition, 
several medicinal plants and herbs used in folk medicine contain 
flavanoids and flavonoids.30 Natural compounds, together with a 
number of synthetic analogues, are responsible for a great variety of 
biological and pharmacological activities, including antipicornavirus 
properties.30-32  
 
 
  
 
 
    
Figure 15. Structure of flavanoids and flavonoids 
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The structure of these compounds is derived from a heterocyclic 
hydrocarbon, chromane, by substitution in position 2 or 3 with a 
phenyl group forming flavan and isoflavan, respectively. Then, the 
basic structure consists of 15 carbon atoms arranged in three rings 
(C6-C3-C6), which are labelled A, B, and C ring. The various classes 
of flavonoids differ in the level of oxidation and pattern of substitution 
of the C ring, while individual compounds whitin a class differ in the 
pattern of substitution of the A and B rings (figure 15). In addition, 
chalcones, homoisoflavones, and 2-styrylchromones are classified as 
flavanoids. Chalcones are bicyclic compounds with C ring opened 
while, in homoisoflavonoids and styrylchromones, the B ring is not 
directly linked to the heterocycle (figure 16). 
       
 
 
Figure 16. Structure of chalcones, homoisoflavones, and 2-styrylchromones 
 
4’,6-Dichloroflavano (BW683C), was the first synthetic 
flavanoids showing a potent antirhinovirus activity.32  This compound 
inhibited the prevalent serotypes of HRV (1A, 1B, 2, 15, 29 and 31) 
with IC50 values ranging from 0.007 to 0.17 µM. Studies on the 
mechanism of action of BW683C suggested that it blocks viral 
replication inhibiting a stage immediately following the entrance of 
virus into the host cell.32      
 
4’, 6 dichloroflavano (BW683C) 
O O O
O O O
HOMOISOFLAVONOIDS
O
Chalcones
O
O
2-Styrylchromones
O
Cl
Cl
34	  	  
Unfortunately, the clinical trial produced disappointing results. 
In fact 4’,6 dichloroflavan was  unable to prevent the HRV infection 
after oral or intranasal administration.33          
Among the different classes of flavonoids and flavanoids, we 
studied the antipicornavirus activity of flavans, isoflavans, isoflavenes, 
flavones, flavanones, homoisoflavones and 2-styrylchromones. 
Several synthetic flavanoids and flavonoids exhibited a broad 
antipicornavirus spectrum, although flavonoids were found less potent 
then flavanoids.34-40 
Among flavanoids, 3(2H)-isoflavenes generally were more 
potent against EVs, while isoflavans against HRVs and hepatitis A 
virus. Among flavans, 4’,6-dicyanoflavan was selectively active 
against HRVs, while 6-chloro-4’-cyanoflavan and 4’-chloro-6-
cyanoflavan showed a broad spectrum of antipicornavirus activity in 
the micro or submicromolar range.34-38  
Studies on the mechanism of action of selected flavanoids on 
HRV and PV infections suggested that they specifically interfered 
with some early events of viral replication. In the case of HRV, 4’,6-
dicyanoflavan delayed the uncoating kinetic of neutral-red 
encapsidated virus and prevented mild acid or thermal inactivation of 
virus infectivity, suggesting an action at the uncoating level due to a 
stabilising effect on virus capsid conformation.41 In the case of 
poliovirus, 3(2H)-isoflavene was found to exert its action during the 
uncoating step.42 Analysis of mutations conferring resistance provides 
strong evidence that 3(2H)-isoflavene inserts into the hydrophobic 
pocket inside capsid VP1, increasing the stability of the viral particle 
and rendering the virus more resistant to uncoating.43 
Also flavonoids presented a wide spectrum of anti-picornavirus 
activity. While flavanones were generally less effective than flavones, 
3-methoxy or 3-hydroxyflavones and their esters with natural 
occurring hydroxybenzoic and hydroxycinnamic acids were more 
active than 3-unsubstituted flavones. 39,40 
Afterwards, we synthesized analogues of two small classes of 
natural flavonoids: homoisoflavonoids (3-benzylidenchroman-4-ones, 
3-benzylchroman-4-ones, and 3-benzyl-4-chromanones) and 2-
styrylchromones. 44-46 
Homoisoflavonoids were weakly effective against poliovirus 2, 
while they exhibited a variable degree of activity against HRV 1B and 
14, selected as representative serotypes for groups B and A of HRVs, 
respectively. The two groups of HRVs were identified by a different 
susceptibility of all the serotypes to a panel of antirhinovirus 
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compounds. Group B contains twice as many serotypes as group A, 
and accounts for five times as many colds as group A.47,48 HRV 1B 
was much more susceptible than HRV14 to the action of 
homoisoflavonoids, and the presence of one or more chlorine atoms 
increased the antiviral effect. Only the activity of 3-benzyl-4’,5,7-
trichlorochroman-4-one and of chloro-substituted 3-benzyl-4-
chromanones extended to both HRV serotypes tested and to 
poliovirus.44 
2-Styrylchromones were synthesized as vinylogues of flavones, 
in order to assess whether the replacement of 2-phenyl substituent on 
the chromone ring by the 2-styryl would affect the antiviral properties. 
In addition, the influence of the substituent in position 3 was also 
evaluated for this class of flavonoids, since the introduction of a 3-
hydroxy or 3-methoxy group was previously found to positively affect 
the antipicornavirus potency of flavones.31,39 Antiviral results indicate 
that 2-styrylchromones can be considered a new class of antirhinovirus 
flavonoids with activity against both rhinovirus groups A and B.45,46 
As expected, the introduction of a 3-hydroxy or a 3-methoxy group 
improves antirhinovirus activity.46 
Flavans, isoflavans, and 3-benzyl-4-chromanones are 
characterised by the presence of a chiral centre in position 2 or 3 of the 
chromane ring. Since they were initially synthesized and tested as 
racemates, the mixtures of selected compounds were successfully 
resolved by chiral HPLC in order to define the anti-rhinovirus activity 
of each stereoisomer. The results of the antiviral tests showed that the 
difference of activity between the two antipodes is variable and 
depend on the kind of virus tested.49-52 
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5.  SUBJECT OF PRESENT RESEARCH 
 
A novel series of (Z)-3-benzylidenechromans, 3-benzyl-2H-
chromenes and 3-benzylchromans,1 related to the most active 
synthetic 3(2H)-isoflavenes2-5 and homoisoflavones6-8 previously 
studied, were recently prepared in our laboratory.1  
 
 
   (Z)-3-benzylidenechromans       3-benzyl-2H-chromenes             3-benzylchromans 
Several of these inhibitors presented submicromolar potency 
against HRV 1B coupled with high therapeutic index. On the contrary, 
HRV 14 infection was weakly inhibited.1 Similarly to related 
flavanoids,5,9,10 these analogues behaved as capsid-binders and 
interfered with very early events of HRV multiplication.1 The 
explanation for the different sensibility of HRV 1B and 14 to these 
chromans could reside in the size of the compound-binding site which 
differs depending upon the specific serotype. Previous research on 
capsid-binding compounds demonstrated that viral group B binding 
site accommodates molecules with shorter chains, while long-chained 
compounds are routinely more active against group A.11 
To develop compounds with broad-spectrum activity, the linker 
chain length between the heterocycle and the phenyl moiety was 
modified. A linear, unsaturated chain containing two or four carbon 
atoms was introduced as a linker. Optimum activity against both HRV 
serotypes was achieved with the unsaturated 2-carbon chain 
analogues, (E)-3-styryl-2H-chromenes. Surprisingly, despite the larger 
size of the HRV 14 capsid binding site, elongation of the linker chain 
from two to four carbon atoms resulted in a loss of activity against this 
serotype.12 Mechanism of action studies indicated that also these 
compounds behaved as capsid-binders interfering with the early 
stage(s) of rhinovirus infection.12  
 Starting from these results, we focused our attention on (E)-3-
styryl-2H-chromenes as the most promising analogues to perform a 
systematic structure optimization study. 
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In particular, we examined the impact on cytotoxity and activity of: 
• nature, number and position of substituents on both aromatic 
rings; 
• level of oxidation of the heterocyclic ring; 
• modification of the linker between the two cycles; 
• bioisosteric substitution of the benzene ring with a pyridine 
ring. 
 
 
 
 
 
Figure 1. Systematic structure optimization on (E)-3-styryl-2H-chromenes. 
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(E)-3-styryl-4H-chromen-4-ones 3-[(1E,3E)-4-phenylbutan-1,3-dienyl]-4H-chromen-4-ones
3-[(1E,3E)-4-phenylbuta-1,3-dienyl]-2H-chromenes(E)-3-styryl-2H-chromenes
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The main targets of this research were: 
 
• to synthesize new small molecules with high activity and 
selectivity against picornaviruses; 
• to select compounds exhibiting a broad spectrum of anti-
picornavirus activity; 
• to study the mechanism of anti-picornavirus action of selected 
compounds. 
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5.1. Design, synthesis and in vitro evaluation of novel 
chroman-4-one, chroman, and 2H-chromene derivatives 
as human rhinovirus capsid-binding inhibitors  
 
Cinzia Contia, Luca Proietti Monacob and Nicoletta Desiderib  
Bioorg. Med. Chem. 19 (2011) 7357-7364. 	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In the present paper, we describe the synthesis, antiviral activity 
and mechanism of action of new analogues containing an unsaturated 
3-carbon chain between the two rings. The antiviral potency of the 
new (E)-3-[(E)-3-phenylallylidene]chroman-4-ones 1a-e, (E)-3-(3-
phenylprop-2-yn-1-ylidene)chroman-4-ones 2a and 2b, (Z)-3-[(E)-3-
phenylallylidene]chromans 3a-e, and (E)-3-(3-phenylprop-1-en-1-yl)-
2H-chromenes 4a-d was evaluated against infection of HeLa cells by 
HRV 1B and 14, representative serotypes for group B and A of HRVs, 
respectively.  	  
5.1.1. Results and discussion 
 
5.1.1.1. Chemistry 
 
(E)-3-[(E)-3-phenylallylidene]chroman-4-ones 1a-e and (E)-3-
(3-phenylprop-2-yn-1-ylidene)chroman-4-ones 2a and 2b were 
prepared by acid-catalyzed condensation of chroman-4-ones with 
trans-cinnamaldehydes and 3-phenylpropiolaldehyde, respectively. 
The reaction was carried out by heating the mixture in 85% 
phosphoric acid for 4h (scheme 1). The 1HNMR spectra of the new 
chromanones 1a-e suggest the trans configuration of the exocyclic 
double bond. In fact, the signals of Hα and Hβ appear around 7.5 ppm 
and 7.00 ppm, respectively. In the 1HNMR spectra of the cis-isomers, 
these signals would be shifted at higher and lower field, respectively, 
due to the effect of carbonyl group. The coupling constant values of 
Hβ and Hγ (Jβ-γ from 15.3 to 15.5 Hz) indicate also the trans 
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configuration of this double bond. The stereochemistry of these 
compounds was confirmed by 2D NOESY experiments. The strong 
NOE cross peaks between H2 and Hβ and between Hα and 
Hγ demonstrate the trans-configuration for both double bonds.  
In a similar manner, the chemical shift of the proton in the chain 
(around 7.00 ppm) indicates the trans-configuration of the exocyclic 
double bond of (E)-3-(3-phenylprop-2-yn-1-ylidene)chroman-4-ones 
2a and 2b. 
 
 
 
1,2a  R = R’ = H 
1,2b  R = Cl, R’ = H 
1c  R = R’ = Cl 
1d  R = H, R’ = Cl 
1e  R = F, R’ = H 
 
Scheme 1. Reagents and conditions: (i) 85% H3PO4, 80 °C, 4h. 
 
Subsequent reaction of (E)-3-[(E)-3-phenylallylidene]chroman-
4-ones 1a-e with lithium aluminum hydride in the presence of 
aluminum chloride, reduced the carbonyl group to a methylene group 
with some isomerization of the exocyclic double bond (5a-e) or both 
the double bonds (4a-e) (scheme 2). The presence of small amounts of 
(E)-3-(3-phenylprop-1-en-1-yl)-2H-chromenes 4a-e and 3-cinnamyl-
2H-chromenes 5a-e together with (Z)-3-[(E)-3-(3-
chlorophenyl)allylidene]chromans 3a-e was evident in the 1HNMR 
spectra of the crude reaction products. The main product was isolated 
from the mixture by column chromatography and further purified by 
crystallization. The stereochemistry of the exocyclic double bond of 
(Z)-3-[(E)-3-(3-chlorophenyl)allylidene]chromans 3a-e was 
established by 2D NOESY experiments. 
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45	  	  
 
 
The strong NOE cross peaks between H4 and Hα unequivocally 
indicate the cis configuration of this double bond. Therefore, the 
reduction of (E)-3-[(E)-3-phenylallylidene]chroman-4-ones 1a-e to 
(Z)-3-[(E)-3-(3-chlorophenyl)allylidene]chromans 3a-e occurs with 
the retention of the exocyclic double bond configuration, but the E/Z 
descriptors change because of the change in priority at C3. The 
coupling constant values of Hβ and Hγ (Jβ-γ = 15.3 or 15.4 Hz) in the 
1HNMR spectra suggest the trans configuration of the second double 
bond. The strong NOE cross peaks between Hα and Hγ confirm this 
configuration.  
As shown in scheme 3, (E)-3-(3-phenylprop-1-en-1-yl)-2H-
chromenes 4a-d were conveniently obtained by the Wittig reaction of 
the appropriate 2H-chromene-3-carbaldehyde and 
phenethyltriphenylphosphonium bromide, using sodium ethoxide as 
base. The coupling constant values of the vinylic protons (Jα-β = 15.9 
Hz) indicate the trans configuration of the double bond in the chain.  
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5.1.1.2. Antiviral tests 
 
The results of the biological evaluation of the new compounds 
(1a-e, 2a, 2b, 3a-e and 4a-d) are presented in table 1. Each compound 
was first tested for its effects on morphology, viability and growth of 
HeLa cells, a human cell line suitable for the replication of HRVs. 
Morphological alterations were scored microscopically, and the action 
of the compounds on logarithmic cell growth was determined by the 
XTT colorimetric method.1 The cytotoxicity of compounds is referred 
as maximum non-cytotoxic concentration (MNTC) and 50% cytotoxic 
concentration (TC50). The MNTC is the highest dose that did not 
produce any toxic effect or reduction of cell growth after 3 day 
incubation at 37°C. The TC50 is the concentration of compound 
reducing the cell viability by 50% as compared with the control. In 
general, all the new compounds exhibited low cytotoxicity showing 
TC50 ranging from 25 µM to 100 µM.  
The dose-dependent inhibitory activity of compounds on HRV 
1B and HRV 14 replication was evaluated in vitro by a plaque 
reduction assay, starting from the MNTC. A previous systematic 
evaluation of a panel of capsid-binding compounds against all HRVs 
established the existence of two virus groups, called groups A and B, 
with contrasting susceptibilities for these anti-rhinoviruses. Group B 
contains twice as many serotypes as group A, and accounts for five 
times as many colds as group A serotypes.2,3 In our research, we 
utilized HRV 1B and 14 as representative serotypes for group B and 
A, respectively. The results of antiviral activity are expressed as 
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compound concentration required to produce a 50% reduction of 
plaque number with respect to mock-treated virus-infected cultures 
(IC50) (table 1). When the IC50 value is not achieved up to the MNTC, 
the percentage inhibition at this dose is reported in parentheses. The 
therapeutic index (TI), expressed as TC50 versus IC50 ratio, was 
calculated and reported in Table 1. 4’,6-Dichloroflavan (BW683C), 
an inhibitor of group B serotypes, was included as a control.4  
 
Table 1. Cytotoxicity and anti-picornavirus activity of (E)-3-[(E)-3-
phenylallylidene]chroman-4-ones 1a-e, (E)-3-(3-phenylprop-2-yn-1-
ylidene)chroman-4-ones 2a and 2b, (Z)-3-[(E)-3-phenylallylidene]chromans 3a-e, 
and (E)-3-(3-phenylprop-1-en-1-yl)-2H-chromenes 4 a-d. 
aThe maximum non-cytotoxic concentration (MNTC) was the highest dose tested that did not 
 produce any cytotoxic effect and reduction in viability of HeLa cells, or on cell growth after 3 days of 
incubation at 37°C. 
bThe TC50 value was the concentration of compound which reduced the Hela cell viability by 50%, as 
compared with the control. 
c The IC50 value was the dose of compound reducing the plaque number by 50% and was calculated by 
plotting the drug concentration versus the percentage of plaque reduction. When a 50% reduction was not 
achieved, the percent of inhibition obtained at the MNTC was reported in parentheses. 
d The therapeutic index (TI) value was equal to TC50/
 IC50. 
e The saturation concentration in cell culture medium was found to be lower than TC50.  
f Not active up to the highest concentration tested (MNTC). 
 
Although BW683C is at present one of the most active 
compounds against HRV 1B and group B serotypes, it was generally 
Comp. R R’ MNTC 
(µM)a 
TC50 
(µM)b 
IC50 (µM)c 
HRV 1B 
TId IC50 (µM)c 
HRV 14 
TId 
1a  H H 12.50 25.00 0.85 29.41 12.50 (7.2%) - 
1b  Cl H 25.00 50.00 0.99 50.50 25.00 (48.6%) - 
1c  Cl Cl 12.50 25.00 3.35 7.46 1.42 17.61 
1d  H Cl 25.00 50.00 2.54 19.68 25.00 (17.1%) - 
1e  F H 25.00 50.00 4.98 10.04 17.02 2.94 
2a  H H 25.00 50.00 9.30 5.38 20.00 2.50 
2b  Cl H 50.00 75.00 7.89 9.51 30.41 2.47 
3a  H H 50.00 100.00 0.99 101.01 47.59 2.10 
3b  Cl H 25.00 50.00 2.79 17.92 25.00 (30.3%) - 
3c  Cl Cl 12.50 25.00 11.49 2.18 8.27 3.02 
3d  H Cl 25.00 50.00 1.39 35.97 6.02 8.31 
3e  F H 50.00 75.00 5.57 13.46 36.51 2.05 
4a  H H 50.00 75.00 13.59 5.52 11.09 6.76 
4b  Cl H 12.50 25.00 0.42 59.52 12.50 (23.0%) - 
4c  Cl Cl 25.00 100.00 9.73 10.28 25.00 (27.0%) - 
4d  H Cl 50.00 100.00 3.61 27.70 45.10 2.22 
BW683C   25.00 >25.00e 0.026 >961 NAf - 
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inactive against group A of HRVs.2-4 None of the new compounds 
was more potent than the reference compound BW683C against HRV 
1B. Differently, they were found to be effective also against serotype 
14 infection indicating a wider anti-HRV spectrum. 
Although HRV 1B was generally found more susceptible than 
HRV 14 to the action of the new compounds, several derivatives 
showed activity in the micromolar range against both HRV serotypes. 
Only compounds 1c, 3c and 4a exhibited a higher potency against 
serotype 14.  
In the (E)-3-[(E)-3-phenylallylidene]chroman-4-one series 1a-e, 
all the analogues showed potent anti-HRV 1B activity (IC50s ranging 
from 0.85 µM to 4.98 µM) and selectivity (TIs from 7.46 to 50.50). 
On the contrary, only 4’,6-dichloro and 6-fluoro derivatives (1c and 
1e) exhibited IC50s lower than MNTCs against HRV 14. Notably, 
compound 1c was the most potent and selective compound among all 
the new derivatives against serotype 14 (IC50 = 1.42 µM, TI = 17.61) 
while it was about two-fold less potent and selective against serotype 
1B (IC50 = 3.35 µM, TI = 7.46).  
When the chroman-4-one ring in 1a-e series was replaced by a 
chroman ring to give analogues 3a-e, the inhibitory activity against 
serotype 1B was generally retained (IC50s ranging from 0.99 to 11.49 
µM), and only the 6-chlorochroman 3b exhibited an IC50 higher than 
MNTC against serotype 14. 
In both (E)-3-[(E)-3-phenylallylidene]chroman-4-one and (Z)-3-
[(E)-3-(3 chlorophenyl)allylidene]chroman series, the replacement of 
the chlorine at the 6 position in compounds 1b and 3b with fluorine to 
give the compounds 1e and 3e resulted in a marked reduction in 
activity against HRV 1B. On the contrary, the potency against 
serotype 14 was enhanced by this substitution, although the 6-fluoro 
analogues 1e and 3e displayed a higher activity against serotype 1B. A 
similar behaviour was observed against both serotypes when the 
double bond in the chain of (E)-3-[(E)-3-phenylallylidene]chroman-4-
ones 1a and 1b was replaced by a triple bond to give the 
corresponding (E)-3-(3-phenylprop-2-yn-1-ylidene)chroman-4-ones 
2a and 2b.  
The isomerisation of both double bonds in (Z)-3-[(E)-3-(3-
chlorophenyl)allylidene]chromans 3a-d to provide inhibitors 4a-d, 
generally led to a significant loss in potency or a modest improvement 
in activity. The only exception to this generalization was the 6-chloro 
analogue 4b which was >six-fold more potent than corresponding 3b 
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against HRV 1B and showed the highest inhibitory activity (IC50 = 
0.42 µM) coupled with remarkable selectivity (TI = 59.52). 
 
5.1.1.3. Mechanism of action studies 	  
(E)-6-Chloro-3-(3-phenylprop-1-en-1-yl)-2H-chromene 4b, the 
most potent compound against HRV 1B (IC50 = 0.42 µM), was 
selected to clarify the mechanism of antiviral action by evaluating the 
effects produced on both virus particles and multiplication. 
The virus-neutralizing effect of 4b on HRV 1B infectivity was 
investigated by incubating a virus suspension at high titre with the 
compound at a concentration of 42 µM (100 times the IC50). After 
serial 10-fold dilutions to achieve non inhibitory concentrations of 
free compound, the infectivity titers of mock- and 4b-treated virus 
suspensions were found to be similar (5.33 × 106 PFU/mL and 5.11 × 
106 PFU/mL, respectively). These results indicate that 4b does not 
damage virus particles.  
In stabilization studies, 4b (42 µM) significantly protected HRV 
1B infectivity against inactivation by both mild acid and heat 
treatments. As shown in figure 1, in the absence of 4b, the infectivity 
of control virus decreased significantly when exposed to either pH 5 
(fig. 1 A) or 56 °C (fig. 1 B) (3.8 and 2.9 log PFU/mL, respectively). 
In the presence of 4b, the drop in virus infectivity was significantly 
reduced (2.8 and 1.8 log PFU/mL, respectively) and the protective 
effect towards low pH and thermal inactivation was 1.0 and 1.1 log, 
respectively. Exposure of HRVs to mild acid or heat induces 
conformational changes of the virion capsid structure similar to those 
produced during the uncoating of the viral particles inside the host 
cells.5,6 The presence of capsid-binders within the hydrophobic pocket 
of VP1 protein results in resistance to acid and thermal inactivation 
due to a reduction of capsid flexibility. 7,8 Taken together, our data 
suggest that 4b could act as a capsid-binder. However, binding of 4b 
was reversible by dilution as indicated by results on virus infectivity. 
A similar behaviour has already been described for (Z)-3-(4-
chlorobenzylidene)chroman and (E)-3-styryl-2H-chromene, two 
related compounds recently studies by us.9,10 
The antiviral action of 4b (42 µM) towards different stages of 
HRV 1B multiplication in HeLa cells was investigated under one-step 
growth conditions. 4b was present: (i) during the entire time of virus 
replication, (ii) during virus binding to the cell membrane only, (iii) 
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added or removed at different time intervals after virus attachment to 
the cells in the cold. 
 
 
 
 
 
Figure 1. Protective effect of (E)-6-chloro-3-(3-phenylprop-1-en-1-yl)-2H-
chromene 4b on acid (A) and thermal inactivation (B) of HRV 1B infectivity. 
 
The highest level of inhibition (88.5 %) was reached when 4b 
was added to cells together with the virus inoculum and maintained 
until the end of virus multiplication. A similar effect was observed 
when 4b was added immediately after virus adsorption period (1 h at 
4 °C, time 0). Also the addition of 4b 15, 30, 45 or 60 minutes after 
virus binding still produced a high reduction (above 80%) in virus 
yield. Instead, when 4b was added at later times (2, 4 or 6 hours after 
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virus binding), inhibition significantly dropped (31%, 12% and 1%, 
respectively, figure 2).  
 
 
Figure 2. Effect of varying the time of addition of 4b (42 µM) on 
the inhibition of HRV1B multiplication under one-step growth 
conditions. Virus yield was determined by plaque assay. Virus 
control titre was 2.4 . 104 PFU/mL. EC: 4b was present during the 
entire infection cycle (1 h at 4°C and 10 h at 33°C). 0’, 15’, 30’, 
45’, 1 h, 2 h, 4 h, 6 h: compound was added at different times (0’, 
15’, 30’, 45’, 1 h, 2 h, 4 h, 6 h) after the virus adsorption period (1 
h at 4°C, time 0) and maintained until the end of virus 
multiplication (up to 10 h). 
 
Pretreatment of HeLa cells with 4b before HRV infection or the 
presence of 4b during the time of virus adsorption only (1h, 4°C) 
caused only a minimal reduction in virus yield (6% and 16%, 
respectively) (data not shown). Both results indicate that 4b does not 
hinder cellular receptors for virus nor interfere with HRV 1B 
attachment to the host cell membrane. 
In experiments where 4b was added at the end of virus 
adsorption (0 time) and removed after 30 minute or 1 h treatment of 
infected cells (33°C), it produced a reduction in virus yield of 
approximately 35 %. A time-dependent increase of inhibition was 
observed when the compound was removed after longer incubation 
times and the highest inhibition (93 %) was achieved when 4b was 
removed after 6 h of incubation with the infected cells (figure 3). 
Taken together, our results demonstrate that also (E)-6-chloro-3-
(3-phenylprop-1-en-1-yl)-2H-chromene (4b) exerts an early activity 
during HRV multiplication, although it does not interfere with cell 
receptor recognition by the virus. Maximal reduction in virus yield is 
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achieved when 4b is added to infected cells within the first hour of 
infection or removed from infected cells after 6 hours of treatment. 
These data suggest an interference by 4b during the uncoating 
process. 
 
 
Figure 3. Effect of varying the time of removal of 4b (42 µM) on 
the inhibition of HRV1B replication under one-step growth 
conditions. Virus yield was determined by plaque assay. Virus 
control titre was 2.4 . 104 PFU/mL. 15’, 30’, 45’, 1 h, 2 h, 4 h, 6 h: 
compound 4b was added after virus adsorption (1 h at 4°C, time 0) 
and removed after different lengths of incubation (15’, 30’, 45’, 1 
h, 2 h, 4 h, 6 h) at 33 °C. 
 
The results obtained with the chromene 4b significantly differ 
from those previously described for related compounds such as (Z)-3-
(4-chlorobenzylidene)chroman and (E)-3-styryl-2H-chromene.9,10 
Maximal inhibition of virus yield was observed when both these 
compounds were present during the time of virus adsorption only. A 
similar reduction was noticed when compounds were removed 30 min 
after virus binding.9,10 On the contrary, both analogues did not modify 
virus yield when added only 1 h after virus infection. Therefore, 
modification in shape and length of the backbone as in the new (E)-6-
chloro-3-(3-phenylprop-1-en-1-yl)-2H-chromene 4b does not allow 
interaction of this molecule with virus capsid structures involved in 
receptor recognition. 
 
5.1.2. Conclusion 	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In the present study we focused our attention onto the design, 
synthesis and anti-HRV activity of new series of (E)-3-[(E)-3-
phenylallylidene]chroman-4-ones 1a-e, (E)-3-(3-phenylprop-2-yn-1-
ylidene)chroman-4-ones 2a and 2b, (Z)-3-[(E)-3-
phenylallylidene]chromans 3a-e, and (E)-3-(3-phenylprop-1-en-1-yl)-
2H-chromenes 4a-d. As expected several compounds exhibited a wide 
spectrum of anti-HRV activity coupled with a high therapeutic index. 
The data obtained from stabilization and time of addition/removal 
studies are in agreement with the capsid-binder hypothesis. Time of 
addition/removal experiments suggest an   interference   with the 
uncoating process of viral genome without an action on HRV 
adsorption to the host cell membrane. 
 
5.1.3. Experimental 	  
5.1.3.1. Chemistry 	  
Chemicals were purchased from Sigma-Aldrich or Alfa Aesar 
and used without further purification. Melting points were determined 
on a Stenford Research Systems OptiMelt (MPA-100) apparatus and 
are uncorrected. 1H NMR and 13C NMR spectra were detected with a 
Bruker AM-400 spectrometer, using TMS as internal standard. IR 
spectra were recorded on a FT-IR PerkinElmer Spectrum 1000. All 
compounds were routinely checked by thin-layer chromatography 
(TLC) and 1H NMR. TLC was performed on silica gel or aluminium 
oxide fluorescent coated plates. Components were visualised by UV 
light. Elemental analyses (C, H, Cl) of all new compounds were 
within ±0.4% of theoretical values. 2H-Chromene-3-carbaldehyde10, 
6-chloro-2H-chromene-3-carbaldehyde10, 
phenethyltriphenylphosphonium bromide11 and 4-
chlorophenethyltriphenylphosphonium bromide11 were synthesized 
following the procedure previously described. 
 
5.1.3.1.1. General procedure for the synthesis of the (E)-3-
[(E)-3-phenylallylidene]chroman-4-ones (1a-e) and (E)-3-(3-
phenylprop-2-yn-1-ylidene)chroman-4-ones (2a, b) 
 
A mixture of the appropriate chroman-4-one (10 mmol) and 
trans-cinnamaldehyde (10 mmol) or 3-phenylpropiolaldehyde (10 
mmol), in 85% phosphoric acid (63 mL) was heated at 80 °C for 4 h 
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while stirring. After cooling the mixture was diluted with ice and 
water. The precipitate was filtered off, washed with water and 
crystallized.  
 
5.1.3.1.1.1. (E)-3-[(E)-3-Phenylallylidene]chroman-4-one (1a). 
Yield: 80%, mp = 115-119 °C from ethyl alcohol. IR (KBr): 1664 cm-
1. 1H NMR (CDCl3, 400 MHz): δ (ppm) 8.01 (dd, 1H, H5, J5-6 = 7.8 
Hz, J5-7 = 1.8 Hz), 7.54-7.45 (m, 4H, H2’, H6’, H7, Hα), 7.40-7.34 
(3H, H3’-H5’), 7.09 (d, 1H, Hγ, Jβ-γ = 15.5 Hz), 7.08-6.97 (m, 3H, H6, 
H8, Hβ), 5.26 (d, 2H, H2, J2-α = 1.6 Hz). 13C NMR (CDCl3, 100 
MHz): δ (ppm) 181.92, 161.44, 143.30, 136.06, 135.97, 135.56, 
129.52, 128.92, 127.92, 127.67, 127.45, 122.45, 121.88, 121.64, 
117.86, 66.99. Anal. Calcd for C18H14O2: C, 82.42; H, 5.38. Found: C, 
82.58; H, 5.46. 
 
5.1.3.1.1.2. (E)-6-Chloro-3-[(E)-3-phenylallylidene]chroman-4-one 
(1b). Yield: 85%, mp = 159-160 °C from ethyl alcohol. IR (KBr): 
1669 cm-1. 1H NMR (CDCl3, 400 MHz): δ (ppm) 7.96 (d, 1H, H5, J5-7 
= 2.7 Hz), 7.54-7.49 (3H, H2’, H6’, Hα), 7.43-7.35 (m, 4H, H7, H3’-
H5’), 7.11 (d, 1H, Hγ, Jβ-γ = 15.4 Hz), 6.99 (dd, 1H, Hβ Jα-β = 11.6 Hz, 
Jβ-γ = 15.4 Hz), 6.95 (d, 1H, H8, J7-8 = 8.8 Hz), 5.26 (d, 2H, H2, J2-α = 
1.6 Hz). 13C NMR (CDCl3, 100 MHz): δ (ppm) 180.81, 159.85, 
143.98, 136.79, 135.93, 135.35, 129.71, 128.96, 128.82, 127.54, 
127.38, 127.31, 123.27, 121.46, 119.58, 67.14. Anal. Calcd for 
C18H13ClO2: C, 72.85; H, 4.42; Cl, 11.95. Found: C, 72.97; H, 4.45; 
Cl, 11.80. 
 
5.1.3.1.1.3. (E)-6-Chloro-3-[(E)-3-(4-chlorophenyl)allylidene] 
chroman-4-one (1c). Yield: 81%, mp = 168-176 °C from ethyl 
acetate. IR (KBr): 1654 cm-1. 1H NMR (CDCl3, 400 MHz): δ (ppm) 
7.95 (d, 1H, H5, J5-7 = 2.7 Hz), 7.50-7.44 (3H, H2’, H6’, Hα), 7.41 
(dd, 1H, H7, J7-8 = 8.8 Hz, J5-7 = 2.7 Hz), 7.36 (d, 2H, H3’, H5’, J2’-3’ 
= 8.5 Hz), 7.05 (d, 1H, Hγ, Jβ-γ = 15.3 Hz), 7.03-6.92 (m, 2H, H8, Hβ), 
5.25 (d, 2H, H2, J2-α = 1.6 Hz). 13C NMR (CDCl3, 100 MHz): δ (ppm) 
180.80, 159.85, 142.34, 136.35, 135.60, 135.47, 134.42, 129.23, 
128.72, 128.64, 127.46, 127.23, 123.20, 121.97, 119.61, 67.10. Anal. 
Calcd for C18H12Cl2O2: C, 65.28; H, 3.65; Cl, 21.41. Found: C, 65.59; 
H, 3.73; Cl, 21.64.               
                                                                            
5.1.3.1.1.4. (E)-3-[(E)-3-(4-Chlorophenyl)allylidene]chroman-4-
one (1d). Yield: 83%, mp = 160-163 °C from ethyl acetate. IR (KBr): 
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1665 cm-1. 1H NMR (CDCl3, 400 MHz): δ (ppm) 8.01 (dd, 1H, H5, J5-
6 = 7.8 Hz, J5-7 = 1.8 Hz), 7.51-7.43 (4H, H7, H2’, H6’, Hα), 7.34 (d, 
2H, H3’, H5’, J2’-3’ = 8.6 Hz), 7.07 (ddd, 1H, H6, J5-6 = 7.8 Hz, J6-7 = 
7.2 Hz, J6-8 = 1.1 Hz), 7.02-6.93 (m, 3H, H8, Hβ, Hγ), 5.26 (d, 2H, 
H2, J2-α = 1.6 Hz). 13C NMR (CDCl3, 100 MHz): δ (ppm) 181.88, 
161.45, 141.66, 135.66, 135.51, 135.31, 134.57, 129.68, 129.19, 
128.56, 127.94, 122.41, 122.17, 121.96, 117.90, 66.97. Anal. Calcd 
for C18H13ClO2: C, 72.85; H, 4.42; Cl, 11.95. Found: C, 73.09; H, 
4.37; Cl, 11.78.                            
   
5.1.3.1.1.5. (E)-6-Fluoro-3-[(E)-3-phenylallylidene]chroman-4-one 
(1e). Yield: 90%, mp = 182-185 °C from ethyl acetate. IR (KBr): 1669 
cm-1. 1H NMR (CDCl3, 400 MHz): δ (ppm) 7.65 (dd, 1H, H5, J5-F = 
8.3 Hz, J5-7 = 2.9 Hz), 7.54-7.49 (m, 3H, H2’, H6’, Hα), 7.42-7.33 
(3H, H3’-H5’), 7.19 (ddd, 1H, H7, J7-8 = 7.8 Hz, J7-F = 9.0 Hz, J5-7 = 
2.9 Hz), 7.11 (d, 1H, Hγ, Jβ-γ = 15.5 Hz), 7.04-6.95 (m, 2H, H8, Hβ), 
5.24 (d, 2H, H2, J2-α = 1.3 Hz). 13C NMR (CDCl3, 100 MHz): δ (ppm) 
181.20, 157.64, 157.62 (d, J = 244.0 Hz), 143.86, 136.55, 135.96, 
129.68, 128.96, 128.47, 127.53, 123.07 (d, J = 7.0 Hz), 122.99 (d, J = 
23.0 Hz), 121.54, 119.49 (d, J = 7.0 Hz), 112.87 (d, J = 23.0 Hz), 
67.12. Anal. Calcd for C18H13FO2: C, 77.13; H, 4.67; F, 6.78. Found: 
C, 77.44; H, 4.59. 
 
5.1.3.1.1.6. (E)-3-(3-Phenylprop-2-yn-1-ylidene)chroman-4-one 
(2a). Yield: 50%, mp = 140 °C from n-hexane. IR (KBr): 2183, 1662 
cm-1. 1H NMR (CDCl3, 400 MHz): δ (ppm) 8.00 (dd, 1H, H5, J5-6 = 
7.8 Hz, J5-7 = 2.6 Hz), 7.55-7.48 (m, 3H, H2’, H6’, H7), 7.42-7.35 (m, 
3H, H3’-H5’), 7.07 (ddd, 1H, H6, J5-6 = 7.8 Hz, J6-7 = 8.0 Hz, J6-8 = 
1.1 Hz), 7.03-7.05 (m, 2H, H8, Hα), 5.34 (d, 2H, H2, J2-α = 1.9 Hz). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 180.43, 161.78, 139.54, 
136.13, 132.00, 129.66, 128.60, 127.89, 122.12, 122.07, 121.68, 
118.14, 116.92, 104.71, 85.28, 68.60. Anal. Calcd for C18H12O2: C, 
83.06; H, 4.65. Found: C, 83.37; H, 4.50.       
                                
5.1.3.1.1.7.  (E)-6-Chloro-3-(3-phenylprop-2-yn-1-ylidene) 
chroman-4-one (2b). Yield: 60%, mp = 127-131 °C from n-hexane. 
IR (KBr): 2185, 1661 cm-1. 1H NMR (CDCl3, 400 MHz): δ (ppm) 7.95 
(d, 1H, H5, J5-7 = 2.6 Hz), 7.53 (dd, 2H, H2’, H6’, J2’-3’ = 7.9 Hz, J2’-5’ 
= 1.6 Hz), 7.44 (dd, 1H, H7, J7-8 = 9.0 Hz, J5-7 = 2.6 Hz), 7.41-7.36 
(m, 3H, H3’-H5’), 7.03 (t, 1H, Hα, J2-α = 1.9 Hz), 6.97 (d, 1H, H8, J7-8 
= 9.0 Hz), 5.33 (d, 2H, H2, J2-α = 1.9 Hz). 13C NMR (CDCl3, 100 
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MHz): δ (ppm) 179.39, 160.18, 138.60, 135.93, 132.04, 129.81, 
128.63, 127.59, 127.12, 122.46, 121.96, 119.86, 117.78, 105.45, 
85.16, 68.73. Anal. Calcd for C18H11ClO2: C, 73.35; H, 3.76; Cl, 
12.03. Found: C, 73.08; H, 3.91; Cl, 11.95.  
 
5.1.3.1.2. General procedure for the synthesis of the (Z)-3-[(E)-3-
phenylallylidene]chromans (3a-e).  
 
A solution of the appropriate (E)-3-[(E)-3-
phenylallylidene]chroman-4-one (1a-e) (10 mmol) in dry ethyl ether 
(120 mL) was added dropwise to a suspension of lithium aluminium 
hydride (17.5 mmol) and aluminium chloride (35.0 mmol) in dry ethyl 
ether (20 mL). After complete addition, the mixture was stirred at 
room temperature for 1 h and refluxed for 2.5 h. After cooling, excess 
of reducing reagent was destroyed by adding ethyl acetate at 0 °C, and 
the mixture was poured into 2N hydrochloric acid. The organic layer 
was washed with saturated aqueous sodium bicarbonate and brine, 
than it was dried over anhydrous sodium sulphate, filtered and 
evaporated to dryness. The residue was chromatographed on silica gel 
column eluting with ethyl acetate/light petroleum (1:5 for 3a and 3e, 
1:8 for 3b, 1:10 for 3c, 1:20 for 3d) and purified by crystallization. 
 
5.1.2.1.2.1. (Z)-3-[(E)-3-Phenylallylidene]chroman (3a). Yield: 
54%, mp = 102-104 °C from n-hexane. 1H NMR (CDCl3, 400 MHz): 
δ (ppm) 7.43 (dd, 2H, H2’, H6’, J2’-3’ = 8.2 Hz, J2’-4’ = 1.3 Hz), 7.34-
7.23 (m, 3H, H3’-H5’), 7.11-7.05 (m, 2H, H5, H7), 7.03 (dd, 1H, Hβ, 
Jα-β = 11.1 Hz, Jβ-γ = 15.4 Hz), 6.91-6.84 (m, 2H, H6, H8), 6.58 (d, 
1H, Hγ, Jβ-γ = 15.4 Hz), 6.32 (dd, 1H, Hα, Jα-β = 11.1 Hz, J2-α = 0.9 
Hz), 4.86 (d, 2H, H2, J2-α = 0.9 Hz), 3.59 (s, 2H, H4). 13C NMR 
(CDCl3, 100 MHz): δ (ppm) 154.86, 137.25, 133.20, 131.87, 128.93, 
128.67, 128.73, 127.31, 126.44, 126.31, 123.15, 122.79, 121.02, 
116.78, 65.33, 34.23. Anal. Calcd for C18H16O: C, 87.06; H, 6.49. 
Found: C, 87.36; H, 6.63.                                     
 
5.1.3.1.2.2. (Z)-6-Chloro-3-[(E)-3-phenylallylidene]chroman (3b). 
Yield: 49%, mp = 121-124 °C from n-hexane. 1H NMR (CDCl3, 400 
MHz): δ (ppm) 7.42 (d, 2H, H2’, H6’, J2’-3’ = 7.7 Hz), 7.35-7.22 (m, 
3H, H3’-H5’), 7.07-7.04 (m, 2H, H5, H7), 7.00 (dd, 1H, Hβ, Jα-β = 
11.2 Hz, Jβ-γ = 15.3 Hz), 6.78 (d, 1H, H8, J7-8 = 8.4), 6.60 (d, 1H, Hγ, 
Jβ-γ = 15.3 Hz), 6.33 (d, 1H, Hα, Jα-β = 11.2 Hz), 4.84 (s, 2H, H2), 
3.56 (s, 2H, H4). 13C NMR (CDCl3, 100 MHz): δ (ppm) 153.50, 
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137.10, 133.68, 130.56, 128.69, 128.48, 127.85, 127.28, 126.85, 
126.48, 125.67, 124.31, 122.88, 118.07, 65.39, 34.03. Anal. Calcd for 
C18H15ClO: C, 76.46; H, 5.35; Cl, 12.54. Found: C, 76.68; H, 5.38; Cl, 
12.30.                                     
 
5.1.3.1.2.3. (Z)-6-Chloro-3-[(E)-3-(4-chlorophenyl)allylidene] 
chroman (3c). Yield: 36 %, mp = 142-146 °C from ethyl acetate/light 
petroleum. 1H NMR (CDCl3, 400 MHz): δ (ppm) 7.34 (d, 2H, H2’, 
H6’, J2’-3’ = 8.5 Hz), 7.29 (d, 2H, H3’, H5’, J2’-3’ = 8.5 Hz), 7.07-7.04 
(m, 2H, H5, H7), 6.97 (dd, 1H, Hβ, Jα-β = 11.1 Hz, Jβ-γ = 15.4 Hz), 
6.76 (d, 1H, H8, J7-8 = 8.0), 6.54 (d, 1H, Hγ, Jβ-γ = 15.4 Hz), 6.31 (d, 
1H, Hα, Jα-β = 11.1 Hz), 4.83 (s, 2H, H2), 3.56 (s, 2H, H4). 13C NMR 
(CDCl3, 100 MHz): δ (ppm) 153.42, 135.57, 133.44, 132.26, 131.24, 
128.87, 128.48, 127.60, 127.32, 126.58, 125.71, 124.17, 123.42, 
118.07, 65.31, 34.05. Anal. Calcd for C18H14Cl2O: C, 68.15; H, 4.45; 
Cl, 22.35. Found: C, 67.91; H, 4.62; Cl, 22.46.                                                                                                             
 
5.1.3.1.2.4. (Z)-3-[(E)-3-(4-Chlorophenyl)allylidene]chroman (3d). 
Yield: 42%, mp = 135-136 °C from ethyl acetate/light petroleum. 1H 
NMR (CDCl3, 400 MHz): δ (ppm) 7.34 (d, 2H, H2’, H6’, J2’-3’ = 8.5 
Hz), 7.29 (d, 2H, H3’, H5’, J2’-3’ = 8.5 Hz), 7.14-7.05 (m, 2H, H5, 
H7), 6.98 (dd, 1H, Hβ, Jα-β = 11.1 Hz, Jβ-γ = 15.4 Hz), 6.92 - 6.84 (m, 
2H, H6, H8, J7-8 = 8.0), 6.53 (d, 1H, Hγ, Jβ-γ = 15.4 Hz), 6.31 (d, 1H, 
Hα, Jα-β = 11.1 Hz), 4.86 (s, 2H, H2), 3.61 (s, 2H, H4). 13C NMR 
(CDCl3, 100 MHz): δ (ppm) 154.74, 135.70, 133.11, 131.78, 131.55, 
130.95, 129.47, 128.84, 127.57, 127.35, 126.08, 123.66, 121.09, 
116.77, 65.21, 34.23. Anal. Calcd for C18H15ClO: C, 76.46; H, 5.35; 
Cl, 12.54. Found: C, 76.71; H, 5.23; Cl, 12.74.            
 
5.1.3.1.2.5. (Z)-6-Fluoro-3-[(E)-3-phenylallylidene]chroman (3e). 
Yield: 40%, mp = 121-123 °C from ethyl acetate/light petroleum. 1H 
NMR (CDCl3, 400 MHz): δ (ppm) 7.42 (d, 2H, H2’, H6’, J2’-3’ = 7.9 
Hz), 7.35-7.22 (m, 3H, H3’-H5’), 7.00 (dd, 1H, Hβ, Jα-β = 11.2 Hz, Jβ-γ 
= 15.4 Hz), 6.81-6.76 (m, 3H, H5, H7, H8), 6.59 (d, 1H, Hγ, Jβ-γ = 
15.4 Hz), 6.32 (d, 1H, Hα, Jα-β = 11.2 Hz), 4.83 (s, 2H, H2), 3.57 (s, 
2H, H4). 13C NMR (CDCl3, 100 MHz): δ (ppm) 157.30 (d, J = 236.0 
Hz), 150.97, 137.17, 133.53, 131.13, 128.69, 127.82, 126.56, 126.47, 
124.12 (d, J = 8.0 Hz), 122.98, 117.66 (d, J = 8.0 Hz), 114.79 (d, J = 
23.0 Hz), 113.95 (d, J = 23.0 Hz), 65.48, 34.22. Anal. Calcd for 
C18H15FO: C, 81.18; H, 5.68; F, 7.13. Found: C, 81.23; H, 5.72; Cl, 
7.00.  
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5.1.3.1.3. General procedure for the synthesis of the (E)-3-(3-
phenylprop-1-en-1-yl)-2H-chromenes (4a-d). 
 
A 0.5 M solution of sodium ethoxide (25 mL) was added 
dropwise to a stirred suspension of the appropriate 
phenethyltriphenylphosphonium bromide (10 mmol) in ethyl alcohol 
(50 mL). After stirring for 45 min at room temperature, a solution of 
the appropriate 2H-chromene-3-carbaldehyde (10 mmol) in ethyl 
alcohol (85 mL) was added dropwise and the mixture was refluxed for 
2.5 h. After cooling, water was added, ethyl alcohol was removed 
under reduced pressure and the residue was extracted with ethyl 
acetate. The organic layer was washed with brine, dried over 
anhydrous sodium sulphate, filtered and evaporated to dryness. The 
residue was purified by column chromatography on silica gel eluting 
with ethyl acetate/light petroleum (1:4). The product was further 
purified by crystallization from n-hexane. 
 
5.1.3.1.3.1. (E)-3-(3-Phenylprop-1-en-1-yl)-2H-chromene (4a). 
Yield: 45%, mp = 89-90 °C from n-hexane. 1H NMR (CDCl3, 400 
MHz): δ (ppm) 7.31 (t, 2H, H3’, H5’, J2’-3’ = J3’-5, = 7.5 Hz), 7.25-7.19 
(m, 3H, H2’, H4’, H6’), 7.07 (ddd, 1H, H7, J7-8 = 8.0 Hz, J6-7 = 7.4 
Hz, J5-7 = 1.6 Hz), 6.97 (dd, 1H, H5, J5-6 = 7.4 Hz, J5-7 = 1.6 Hz), 6.85 
(dt, 1H, H6, J5-6 = J6-7 = 7.4 Hz, J6-8 = 1.1 Hz), 6.78 (dd, 1H, H8, J7-8 
= 8.0 Hz, J6-8 = 1.1 Hz), 6.32 (s, 1H, H4), 6.19 (d, 1H, Hα, Jα-β = 15.9 
Hz), 5.74 (dt, 1H, Hβ, Jα-β = 15.9 Hz, Jβ-γ = 6.9 Hz), 4.93 (s, 2H, H2), 
3.50 (d, 2H, Hγ, Jβ-γ = 6.9 Hz). 13C NMR (CDCl3, 100 MHz): δ (ppm) 
159.86, 142.39, 136.26, 135.54, 135.02, 134.42, 129.23, 128.73, 
128.64, 127.56, 126.59, 123.20, 121.73, 119.52, 67.09, 42.91. Anal. 
Calcd for C18H16O: C, 87.06; H, 6.49. Found: C, 86.95; H, 6.63.  
 
5.1.3.1.3.2. (E)-6-Chloro-3-(3-phenylprop-1-en-1-yl)-2H-chromene 
(4b). Yield: 43%, mp = 80 -81 °C from n-hexane. 1H NMR (CDCl3, 
400 MHz): δ (ppm) 7.34 (t, 2H, H3’, H5’, J2’-3, = J3’-5’ =  7.9 Hz), 
7.26-7.19 (m, 3H, H2’, H4’, H6’), 7.02 (dd, 1H, H7, J7-8 = 8.5 Hz, J5-7 
= 2.5 Hz), 6.95 (d, 1H, H5, J5-7 = 2.5 Hz), 6.72 (d, 1H, H8, J7-8 = 8.5 
Hz), 6.25 (s, 1H, H4), 6.19 (d, 1H, Hα, Jα-β = 15.9 Hz), 5.78 (dt, 1H, 
Hβ, Jα-β = 15.9 Hz, Jβ-γ = 6.8 Hz), 4.94 (s, 2H, H2), 3.52 (d, 2H, Hγ, 
Jβ-γ = 6.8 Hz). 13C NMR (CDCl3, 100 MHz): δ (ppm) 152.00, 139.52, 
137.16, 131.73, 130.25, 128.92, 128.66, 128.61, 128.22, 126.41, 
126.06, 124.10, 120.95, 116.59, 65.79, 39.53. Anal. Calcd for 
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C18H15ClO: C, 76.46; H, 5.35; Cl, 12.54. Found: C, 76.71; H, 5.22; Cl, 
12.31. 
 
5.1.3.1.3.3. (E)-6-Chloro-3-[3-(4-chlorophenyl)prop-1-en-1-yl]-2H-
chromene (4c). Yield: 41%, mp = 135-143 °C from n-hexane. 1H 
NMR (CDCl3, 400 MHz): δ (ppm) 7.28 (d, 2H, H3’, H5’, J2’-3’ = 8.1 
Hz), 7.12 (d, 2H, H2’, H6’, J2’-3’ = 8.1 Hz), 7.01 (dd, 1H, H7, J7-8 = 
8.5 Hz, J5-7 = 2.5 Hz), 6.95 (d, 1H, H5, J5-7 = 2.5 Hz), 6.71 (d, 1H, H8, 
J7-8 = 8.5 Hz), 6.25 (s, 1H, H4), 6.16 (d, 1H, Hα, Jα-β = 15.9 Hz), 5.72 
(dt, 1H, Hβ, Jα-β = 15.9 Hz, Jβ-γ = 6.7 Hz), 4.91 (s, 2H, H2), 3.46 (d, 
2H, Hγ, Jβ-γ = 6.7 Hz). 13C NMR (CDCl3, 100 MHz): δ (ppm) 152.06, 
137.96, 132.28, 131.52, 130.01, 129.49, 129.33, 128.74, 128.37, 
126.14, 124.02, 121.31, 116.64, 65.77, 38.79. Anal. Calcd for 
C18H14Cl2O: C, 68.15; H, 4.45; Cl, 22.35. Found: C, 68.35; H, 4.25; 
Cl, 22.51. 
 
5.1.3.1.3.4. (E)-3-[3-(4-Chlorophenyl)prop-1-en-1-yl]-2H-
chromene (4d). Yield: 48%, mp = 90-91 °C from n-hexane. 1H NMR 
(CDCl3, 400 MHz): δ (ppm) 7.28 (d, 2H, H3’, H5’, J2’-3’ = 8.3 Hz), 
7.13 (d, 2H, H2’, H6’, J2’-3’ = 8.3 Hz), 7.08 (dd, 1H, H7, J7-8 = 8.2 Hz, 
J6-7 = 7.4 Hz, J5-7 = 1.6 Hz), 6.98 (dd, 1H, H5, J5-6 = 7.4 Hz, J5-7 = 1.6 
Hz), 6.86 (dt, 1H, H6, J5-6 = J6-7 = 7.4 Hz, J6-8 = 1.1 Hz), 6.78 (dd, 1H, 
H8, J7-8 = 8.2 Hz, J6-8 = 1.1 Hz), 6.32 (s, 1H, H4), 6.17 (d, 1H, Hα, Jα-
β = 15.9 Hz), 5.68 (dt, 1H, Hβ, Jα-β = 15.9 Hz, Jβ-γ = 6.9 Hz), 4.92 (s, 
2H, H2), 3.46 (d, 2H, Hγ, Jβ-γ = 6.8 Hz). 13C NMR (CDCl3, 100 
MHz): δ (ppm) 153.77, 138.25, 131.43, 130.96, 129.06, 128.66, 
128.21, 128.17, 127.49, 126.76, 125.56, 123.29, 121.56, 115.49, 
67.00, 42.52. Anal. Calcd for C18H15ClO: C, 76.46; H, 5.35; Cl, 12.54. 
Found: C, 76.63; H, 5.21; Cl, 12.30. 
 
5.1.3.2. Virology   	  
5.1.3.2.1. Cells 	  
HeLa (Ohio) cells were grown at 37 °C using Eagle’s 
Minimum Essential Medium (MEM) supplemented with 100 µg/mL 
of streptomycin and 100 U/mL of penicillin G and 8% heat-
inactivated foetal calf serum (FCS) (growth medium). The 
concentration was reduced to 2% for cell maintenance (maintenance 
medium). 	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5.1.3.2.2. Compounds  	  
Stock solutions were made up in ethanol (1, 0.5 or 0.1 mg/mL) 
and further diluted in cell culture medium shortly before use.  
 
5.1.3.2.3. Virus  	  
Reference strains of HRV type 1B and 14 were purchased from 
American Type Culture  Collection (ATCC). Virus stocks were 
prepared infecting HeLa (Ohio) cell monolayers at a multiplicity of 
infection of 0.1 PFU/cell. Infected cells were incubated at 33 °C. 
When the viral-induced cytopathic effect involved most of the cells, 
the cultures were freeze-thawed three times and the clarified 
supernatants titrated by plaque assay, essentially as described by Fiala 
and Kenny.12 The virus was stored at -80 °C until used. 
 
5.1.3.2.4. XTT assay for cellular cytotoxicity 	  
A tetrazolium-based (XTT) colorimetric assay was used to 
measure the cytotoxicity of compounds, as previously described.1 
Briefly, HeLa cells were seeded in 96-well tissue culture plates (2 x 
103 cells/well) in 100 µL of growth medium with or without 
compounds in twofold dilutions, starting from the maximum soluble 
concentration in cell culture medium. Triplicate wells were used for 
each drug concentration to be tested. In parallel, media containing the 
same concentrations of ethanol were used as control in order to 
evaluate the residual toxicity of ethanol. The plates were incubated at 
37 °C in 5% CO2-air until the untreated monolayers were confluent (3 
days). Then, 50 µL of XTT labelling mixture was added to each well 
(final XTT concentration 0.15 mg/mL) and the cells incubated for 4 h 
at 37 °C. The spectrophotometric absorbance of the samples was 
measured using an ELISA reader at 492 nm with a reference 
wavelength at 690 nm. Cytotoxicity was also scored microscopically 
as morphological alterations on the third day of incubation in the 
presence of compounds. The highest concentration of compound that 
did not produce any modification of morphology and viability on 
100% of cells was the maximum non-cytotoxic concentration. The 
50% cytotoxic concentration (TC50) was indicated as the 
concentration of compound reducing the cell viability by 50%, as 
compared with mock-treated cells. 	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5.1.3.2.5. Determination of the 50% inhibitory concentration 
(IC50) 	  
The IC50 values were determined as described previously.
13 
Briefly, monolayers of HeLa cells in 6-well plates were infected with 
a virus suspension producing approximately 100 plaques per well. 
After 1 h of incubation at 33 °C, the virus inoculum was removed and 
the cells were overlaid with medium for plaques, in the presence or 
absence of fourfold dilutions of drugs.  After three days of incubation 
at 33 °C, the cells were stained with a neutral red solution (0.2 
mg/mL) in pH 7.4 phosphate buffered saline (PBS) and the plaques 
were counted. The IC50 was expressed as the concentration of drug 
reducing the plaque number by 50% as compared with mock-treated 
control. It was calculated from a dose/response curve obtained by 
plotting the percentage of plaque reduction, with respect to the control 
plaque count, versus the logarithm of compound dose. Triplicate wells 
were utilized for each drug concentration. 
 
5.1.3.2.6. Virus inactivation and stabilization  	  
For virus inactivation studies, HRV 1B suspensions with or 
without 4b (42 µM) were incubated at 33 °C for 1 h. After serial 10-
fold dilutions, virus titres were measured by plaque assay on HeLa 
cell monolayers.For virus stabilization studies, the virus was 
incubated with or without 4b (42 µM) for 1 h at 33 °C before mild 
acid or thermal treatment. For mild acid treatment, the pH of the 
mixtures was adjusted to 5 by adding 0.2 M acetate buffer (pH 5). 
After incubation at 33 °C for 30 min, the mixtures were neutralized 
with 0.85 M Tris base. For thermal treatment, the mixtures were 
incubated for 20 min at 56 °C (pH 7.2) and then refrigerated on ice. 
All samples were diluted 10-fold serially and titrated by plaque assay 
on HeLa cell monolayers. 
 
5.1.3.2.7. Virus yield reduction assays 	  
Confluent monolayers of HeLa cells in 24-well plates were 
infected at a multiplicity of five in the presence or absence of 4b (42 
µM). The infection was synchronized by allowing HRV 1B to bind in 
the cold (4°C). After 1 h, the inoculum was removed by washing 
thrice with cold PBS. The end of virus binding is indicated as 0 time. 
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Then, MEM with or without the compound (42 µM) was added and 
the temperature raised to 33 °C to permit internalization. Single-cycle 
conditions were achieved by incubating the cells at 33 °C for 10 h 
post-infection (p.i.). The cultures were freeze- thawed three times, cell 
debris removed by low-speed centrifugation in the cold and the 
supernatants titrated by plaque assay on HeLa cell monolayers. To 
determine which stage of virus replication was affected by 4b, the 
drug was added or removed from HRV-infected cells at various times 
p.i. (0, 15’, 30’, 45’, 1 h, 2 h, 4 h, 6 h) and the cultures incubated at 33 
°C up to 10 h p.i.. The virus yield was determined as above. 
	  
Acknowledgements 
 
We gratefully acknowledge the financial support from “Istituto 
Pasteur-Fondazione Cenci Bolognetti”, Università degli Studi di Roma 
“La Sapienza”. We also thank Dr. Ivano Pindinello for technical 
assistance. 
 
References 
	  
1. Scudiero, D. A.; Shoemaker, R. H.; Paull, K.D.; Monks, A.; Tierney, S.; 
Nofziger, T. H.; Currens, M. J.; Seniff, D.; Boyd, M. R. Cancer Res. 1988, 48, 
4827. 
2. Andries, K.; Dewindt, B.; Snoeks, J.; Wouters, L.; Moereels, H.; Lewi, P. J.; 
Janssen, P. A. J. J. Virol. 1990, 64, 1117. 
3. Andries, K.; Dewindt, B.; Snoeks, J.; Willebrords, R.; Stokbroekx, R; Lewi, P. 
J. Antiviral Res. 1991, 16, 213. 
4. Bauer, D.J.; Selway, J.W.T.; Batchelor, J.F.; Tisdale, M.; Caldwell, J.C.; 
Young, D.A.B. Nature. 1981, 292, 369. 
5. Lonberg-Holm, K.; Korant, B.D. J. Virol.1972, 9, 29. 
6. 6. Lonberg-Holm, K.; Yin, F.H. J. Virol.1973, 12, 114. 
7. Rombaut, B.; Vrijsen, R.; Boeye, A. Antiviral Res. 1985, Suppl. 1, 67. 
8. Rombaut, B.; Andries, K.; Boeye, A. J. Gen. Virol. 1991, 72, 2153. 
9. Conti, C.; Desideri, N.  Bioorg. Med. Chem. 2009, 17, 3720 
10. Conti, C.; Desideri, N.  Bioorg. Med. Chem. 2010, 18, 6480. 
11. Morgan, T. K. Jr. U.S. Patent 45993441, 1986. 
12. Fiala, M.; Kenny, G.E. J.Bacteriol., 1966, 92, 1710. 
13. Desideri,	   N.;	   Conti,	   C.;	   Sestili,	   I.;	   Tomao,	   P.;	   Stein,	   M.L;	   Orsi,	   N.	   Antiviral	  
Chem.	  Chemother.	  1992,	  3,	  195. 
 
 
 
 
63	  	  
5.2. Synthesis, anti-rhinovirus efficacy and mechanism of 
action studies of novel 3-[2-(pyridinyl)vinyl]-substituted 
2H-chromenes and 4H-chromen-4-ones. 	  
Cinzia Contia, Luca Proietti Monacob and Nicoletta Desiderib  
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Chimica e Tecnologie del Farmaco, Università “La Sapienza” di 
Roma, P.le A. Moro, 00185 Rome, Italy 
 
In this paper, we describe the synthesis of a new series of [2-(2H-
chromen-3-yl)vinyl]pyridines (5a, 5b, 6a, 6b, 7a, 7b, 8a, 9a) and 3-[2-
(pyridinyl)vinyl]-4H-chromen-4-ones (11a, 11b, 12a, 12b, 13a, 13b) 
designed to explore the impact on activity and/or selectivity of the 
bioisosteric replacement of the phenyl moiety by a pyridine ring. The 
antiviral potency of the new synthesized compounds has been 
evaluated against infection by HRV 1B and 14 in cell cultures. Among 
these derivatives, (E)-2-[2-(2H-chromen-3-yl)vinyl] pyridine 5a has 
been selected for preliminary studies to elucidate their mechanism of 
action against both HRV serotypes. 
 
 
5.2.1. Results and discussion 
 
5.2.1.1. Chemistry  
 
As described in scheme 1, the [2-(2H-chromen-3-
yl)vinyl]pyridines (5a, 5b, 6a, 6b, 7a, 7b, 8a, 9a) were obtained by 
the Wittig reaction of the 2H-chromene-3-carbaldehydes (1a, 1b) with 
the appropriate pyridilmethyltriphenylphosphonium chloride (2, 3, 4). 
The reaction was performed in dry THF using potassium tert-butoxide 
as base. E/Z-mixtures (6a/8a and 7a/9a) were separated into their 
individual isomers by column chromatography on silica gel. For the 
analogues 5a, 5b, 6b and 7b only the E isomers could be isolated. The 
stereochemistry of compounds was established on the basis of the 
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coupling constant values of the protons in the chain (about 16 Hz and 
12 Hz for E and Z isomers, respectively) (scheme 1). 
Using the same synthetic strategy, the 3-[2-(pyridinyl)vinyl]-
4H-chromen-4-ones (11a, 11b, 12a, 12b, 13a, 13b) were prepared 
starting from the commercially available 4-oxo-4H-chromen-4-ones 
(10a, 10b) and the appropriate pyridilmethyltriphenylphosphonium 
chloride (2, 3, 4). 
 
 
 
The 2-(pyridin-3-yl)vinyl derivatives (13 a, 13 b) could be 
isolated by column chromatography only as Z isomers while, for the 
analogues 11 a, 11 b, 12 a and 12 b, only the E isomers could be 
obtained from E/Z-mixtures. The stereochemical assignment was 
based on the coupling constant values of the protons in the chain 
(about 16 Hz and 12 Hz for E and Z isomers, respectively) (scheme 2). 
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5.2.1.2. Antiviral tests 
 
In table 1 are reported the results of the biological evaluation of 
the new compounds (5a, 5b, 6a, 6b, 7a, 7b, 8a, 9a, 11a, 11b, 12a, 
12b, 13a, 13b).  
Initially, each compound was tested for its effects on 
morphology, viability and growth of HeLa cells, a human cell line 
suitable for HRV replication. The maximum non-cytotoxic 
concentration (MNTC) is the highest dose that did not produce any 
toxic effect or reduction of cell growth after 3 day incubation at 37°C. 
The 50% cytotoxic concentration (TC50) is the concentration of 
compound reducing the cell viability by 50% as compared with the 
control. In general, all the new compounds exhibited low cytotoxicity. 
For several analogues (5a, 5b, 11a, 11b, 12a and 13a), both MNTC 
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and TC50 were found to be higher than the saturation concentration in 
cell culture medium.  
 
Table 1. Cytotoxicity and anti-rhinovirus activity of [2-(2H-chromen-3-
yl)vinyl]pyridines (5a, 5b, 6a, 6b, 7a, 7b, 8a, 9a) and 3-[2-(pyridinyl)vinyl]-4H-
chromen-4-ones (11a, 11b, 12a, 12b, 13a, 13b). 
aThe maximum non-cytotoxic concentration (MNTC) was the highest dose tested that did not produce 
any cytotoxic effect and reduction in viability of HeLa cells, or on cell growth after 3 days of incubation 
at 37°C. 
bThe TC50 value was the concentration of compound which reduced the cell viability by 50%, as 
compared with the control. 
c The IC50 value was the dose of compound reducing the plaque number by 50% and was calculated by 
plotting the log of drug concentration versus the percentage of plaque reduction. When a 50% reduction 
was not achieved, the percent of inhibition obtained at the MNTC was reported in parentheses. 
d The therapeutic index (TI) value was equal to TC50/
 IC50. 
e The saturation concentration in cell culture medium was found to be lower than MNTC and TC50. 
f Not active up to the highest concentration tested (MNTC). 
 
The dose-response effect of new compounds was evaluated on 
HRV 1B and HRV 14 plaque formation in HeLa cells. These 
serotypes have been selected as representatives for group B and A of 
HRVs, respectively, as defined on the bases of the contrasting 
susceptibility of all serotypes to a panel of capsid-binding 
compounds.5,6 Group B contains twice as many serotypes as group A, 
and accounts for five times as many colds as group A serotypes.5,6 In 
Comp. R MNTC 
(µM)a 
TC50 
(µM)b 
IC50 (µM)c 
HRV 1B 
TId IC50 (µM)c 
HRV 14 
TId 
5a  H >50.00e >50.00e 1.70 >29.41 2.93 >17.06 
5b  Cl >50.00e >50.00e 1.69 >29.59 8.96 >5.58 
6a  H 25.00 75.00 4.57 16.41 3.88 19.33 
6b Cl 25.00 37.50 4.34 8.64 4.27 8.78 
7a H 50.00 75.00 1.96 38.26 3.03 24.75 
7b  Cl 50.00 75.00 4.74 15.82 6.71 11.17 
8a  H 25.00 37.50 0.98 38.26 9.37 4.00 
9a  H 25.00 50.00 0.71 70.42 2.90 17.24 
11a  H >200.00e >200.00e 5.15 >38.84 7.08 >28.25 
11b Cl >50.00e >50.00e 1.60 >31.25 5.10 > 9.80 
12a H >100.00e >100.00e >100 (22%) - 92.12 >1.08 
12b Cl 100.00 150 19.05 7.87 15.62 9.60 
13a H >200.00e >200.00e 46.77 >4.28 15.41 >12.98 
13b Cl 25.00 50.00 4.26 11.74 10.12 4.94 
BW683C  25.00 > 25.00e 0.025 >1000 NAf - 
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table 1 are reported IC50 and therapeutic index (TI) values. 4’,6-
Dichloroflavan (BW683C), a well known inhibitor of group B 
serotypes, was included as a control.7 All the new compounds 
interfered with the replication of both HRV serotypes at micromolar 
or submicromolar concentrations.	   Only for the chromen-4-one 12a, 
the reduction of HRV 1B plaque number was found lower than 50%  
up to the NMTC, therefore the percentage inhibition at this dose is 
reported in parentheses. 12a showed also low activity against serotype 
14 (IC50 = 92.12 µM). Within the 3-[2-(pyridinyl)vinyl]-4H-chromen-
4-one series (11a, 11b, 12a, 12b, 13a and 13b), the presence of a 
chlorine atom at the 6 position (11b, 12b, 13b) always resulted in a 
marked enhancement in activity against both serotypes compared to 
the unsubstituted analogues (11a, 12a, 13a). The same substitution in 
the [2-(2H-chromen-3-yl)vinyl]pyridine series (5a, 5b, 6a, 6b, 7a, 7b, 
8a and 9a) generally led to a significant loss in potency against 
serotype 14 and a modest improvement in activity against serotype 
1B. The only exception to this generalization was the 6-chloro 
analogue 7b that was more than 2-fold less potent than corresponding 
7a against both serotypes. Although HRV 1B was generally more 
susceptible than HRV 14 to the action of the [2-(2H-chromen-3-
yl)vinyl]pyridines (5a, 5b, 6a, 6b, 7a, 7b, 8a and 9a), all these 
compounds showed potent activity and selectivity against both 
serotypes. When the 2H-chromene ring in this series was replaced by 
a chroman-4-one ring to give analogues 11a, 11b, 12a, 12b, 13a and 
13b, the inhibitory activity against both serotypes was generally 
reduced. Only the chroman-4-one 11b exhibited a higher potency than 
the corresponding 2H-chromene 5b against serotype 14. 
A comparison among the activity of E and Z isomers (6a/8a and 
7a/9a) showed that the Z isomers (8a and 9a) exhibited a higher 
activity than corresponding E isomers (6a and 7a) against HRV 1B. On 
the contrary, the pair of isomers 7a/9a presented almost the same 
potency, while the Z isomer 8a was less active than E isomer 6a toward 
serotype 14.     
 
5.2.1.3. Mechanism of action studies 
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(E)-2-[2-(2H-chromen-3-yl)vinyl]pyridine 5a was selected to 
investigate the mechanism of the antiviral action because of its potent 
in vitro activity against HRV serotype 1B and 14 (IC50 = 1.70 µM and 
2.93 µM, respectively) and high therapeutic indexes (TI > 50.00 and > 
17.06, respectively). The effects produced by 5a either on virus 
particles or multiplication were evaluated at a concentration of 43 µM 
and 58 µM, approximately 25 and 20 times the IC50 against serotype 
1B and 14, respectively.  
The neutralizing effect of 5a on infectivity was investigated by 
incubating HRV 1B and 14 suspensions at high titre with the 
compound. After ten-fold dilutions to achieve no inhibitory 
concentrations of free compound, the infectivity titers of mock- and 
5a-treated virus suspensions were found to be similar (serotype 1B: 
2.38 ×107 PFU/mL and 2.15 ×107 PFU/mL, respectively; serotype 14: 
4.27 ×107 PFU/mL and 4.13 ×107 PFU/mL, respectively).  
Instead, in stabilization studies, 5a significantly protected HRV 
infectivity against inactivation by both mild acid and heat treatments. 
As shown in figure 2 A, exposure to mild acid produced a drop in 
infectivity of 4.1 log and 3.8 log for serotype 1B and 14, 
respectively. In the presence of 5a, the reduction in infectivity was 
lower and the protective effect was 1.0 log and 0.9 log, respectively. In 
a similar manner, the infectivity of both serotypes was significantly 
lowered by heat treatment (3.1 log and 3.7 log, respectively) and the 
presence of 5a again exerted a protective effect of 1.1 log and 0.9 log, 
respectively (fig. 2 B). Therefore, data from these experiments strongly 
suggest that 5a behaves as a capsid binder towards both 
serotypes although the action was reversible by dilution. Exposure to 
mild acid or heat is known to promote conformational changes of the 
rhinovirus capsid structure similar to those observed during the 
uncoating of the viral genome.8,9 Binding of so-called capsid-binders in 
a pocket immediately underneath the floor of the canyon, results in 
resistance to acid and thermal inactivation due to a reduction of capsid 
flexibility.10,11 
In order to determine whether 5a interfered with a specific 
period of HRV life cycle, the action of compound addition or removal 
at different time intervals was investigated in infected HeLa cells under 
one-step growth conditions. Data represented in fig. 3 indicate that 5a 
was significantly effective toward both serotypes when added at the 
beginning of infection or at the end of the adsorption period and 
maintained for the entire time of virus multiplication. At later times, 
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although the shape of inhibition curves was similar, half-maximal 
reduction of virus yield was observed at 45 min p.i. for serotype 1B 
and at more than 1 h for serotype 14. Susceptibility to compound 
disappeared when 5a was added after 2 h for 1B serotype and 4 h for 
serotype 14. Similar behaviours were observed when 5a was removed 
from HRV 1B or 14 infected cultures after different times of treatment 
(fig 4). Also under these experimental conditions, half maximal 
inhibition was recorded after 45 min of contact for serotype 1B and 
after more than 1 h for serotype 14. Maximal inhibition was achieved 
after a 4 h treatment for HRV 1B and a 6 h treatment in the case of 
serotype 14.  
 
 
C: untreated viruses, T: viruses exposed to pH 5.0,       5a: viruses  
exposed to pH 5.0 in the presence of 5a	  
 
C: untreated viruses, T: viruses incubated at 56 °C for 20 min, 
                                                                                        5a: viruses incubated 56°C for 20 min in the presence of 5a. 
 
Figure 2.	  Protective effect of 5a on acid (A) and thermal inactivation (B) of HRV 
1B and HRV 14, respectively.  
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Figure 3. Effect of addition of 5a at different times during HRV 1B and 
14 multiplication under one-step growth conditions.  
Virus yield was determined by plaque assay. Virus control titre was 3.04 
. 104 PFU/mL and 2.83 . 104 PFU/mL for HRV 1B and HRV 14, 
respectivelly. - 1: 5a was present during the entire infection cycle (1 h at 
4°C and 10 h at 33°C). 0’, 15’, 30’, 45’, 1 h, 2 h, 4 h, 6 h: 5a  was added 
at different times (0’, 15’, 30’, 45’, 1 h, 2 h, 4 h, 6 h, 8 h) after the virus 
adsorption (1 h at 4°C, time 0) and maintained until the end of virus 
multiplication (up to 10 h pi). 
 	  Both HRV 1B and 14 were shown to efficiently infect the cells 
when 5a was applied to the cultures during the virus absorption period 
only (14% and 16% reduction of HRV 1B and HRV 14 yield, 
respectively) or for 1h before infection (24% and 1% reduction for 
HRV 1B and HRV 14, respectively) (data not shown). The slight 
reduction of virus yield observed during the binding step could be due 
to residual compound that could interfere with the following steps. 
Collectively, all these data suggest that the action of 5a is exerted 
on the early events of HRV 1B and 14  multiplication but not on cell 
membrane receptor recognition. More likely, interaction of viruses 
with 5a could increase the stability of viral shell thus preventing 
disassembly of the capsid and subsequent release of the core RNA into 
the cell cytoplasm. In agreement, data from the time-course of 
inhibition suggest an action at the uncoating level. Therefore, in our 
experiments, interference with RNA uncoating by drug binding 
appears to be independent of receptor grouping. Receptors and low 
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endosomal  pH are known to differently contribute to the uncoating of 
the various HRV serotypes.12 Nevertheless, on infection, minor group 
HRVs undergo similar structural changes as do major group viruses 
although this is not triggered by the receptors.13 Conversion in altered 
subviral A and B particles is believed to be an essential intermediate 
for cell entry, uncoating and successfull infection. Differences in time-
course of inhibition curves could be related to a different dependence 
on receptor function for HRV1B and 14 and to a different pathway for 
internalization into host cells.12,13 
 
 
Figure 4.	  Effect of removal of 5a at different times during HRV 1B 
and 14 multiplication under one-step growth conditions.  
Virus yield was determined by plaque assay. Virus control titre was 
3.04 . 104 PFU/mL and 4.68 . 104 PFU/mL for HRV 1B and HRV 14, 
respectively. 15’, 30’, 45’, 1 h, 2 h, 4 h, 6 h: 5a was added after virus 
adsorption (1 h at 4°C, time 0) and removed after different lengths of 
incubation (15’, 30’, 45’, 1 h, 2 h, 4 h, 6 h) at 33 °C. Infected cultures 
were incubated at 33 °C up to 10h pi in maintenance medium. 
 
A comparison of the mechanism of action of 5a with previously 
studied (E)-3-styryl-2H-chromene1 shows that both 2H-chromenes 
behaved as capsid-binders and interfered with early events of virus 
multiplication. However, (E)-3-styryl-2H-chromene was able to 
interfere also with virus binding to its cellular receptor. Therefore, the 
bioisosteric substitution of the phenyl with a pyridine ring abrogates 
the efficacy on binding. 
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5.2.2. Conclusion 
 
A new series of potent and selective HRV 1B and 14 inhibitors 
has been designed and synthesized. Similarly to related 2H-
chromenes1, (E)-2-[2-(2H-chromen-3-yl)vinyl]pyridine 5a behaves as a 
capsid-binder and interferes with early events of virus multiplication. 
However, differently from previously described (E)-3-styryl-2H-
chromene, 5a was unable to affect virus binding to its cellular 
receptors. Therefore, bioisosteric substitution of the phenyl with a 
pyridine ring causes a relevant change in inhibition mechanism.  
 
5.2.3. Materials and methods 
 
5.2.3.1. Chemistry 	  
Chemicals were purchased from Sigma-Aldrich and used 
without further purification. Melting points were determined on a 
Stanford Research Systems OptiMelt (MPA-100) apparatus and are 
uncorrected. 1H NMR spectra were detected with a Bruker AM-400 
spectrometer, using TMS as internal standard. IR spectra were 
recorded on a FT-IR PerkinElmer Spectrum 1000. All compounds 
were routinely checked by thin-layer chromatography (TLC) and 1H 
NMR. TLC was performed on silica gel or aluminium oxide 
fluorescent coated plates (Fluka, DC-Alufolien Kieselgel or aluminum 
oxide F254). Components were visualised by UV light. Compounds 
purity was determined by elemental analysis and was confirmed to be 
>95% for all the tested compounds. Analytical results are within 
±0.40% of the theoretical values. 2H-Chromene-3-carbaldehydes (1a 
and 1b)1 and pyridilmethyltriphenylphosphonium chlorides (2, 3 and 
4)2 were synthesized according to literature procedures. 
 
5.2.3.1.1. General procedure for the synthesis of [2-(2H-chromen-
3-yl)vinyl]pyridines (5a, 5b, 6a, 6b, 7 a, 7b, 8a, 9a) and 3-[2-
(pyridinyl)vinyl]-4H-chromen-4-ones (11a, 11b, 12a, 12b, 13a, 
13b)  
 
Potassium tert-butoxide (20 mmol) was added to a stirred 
suspension of the appropriate pyridilmethyltriphenylphosphonium 
chloride (2, 3 or 4) (10 mmol) in dry THF (63 mL). After stirring for 
10 min at room temperature, a solution of the appropriate 2H-
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chromene-3-carbaldehyde (1a or 1b) (10 mmol) or 4-oxo-4H-
chromene-3-carbaldehyde (10a or 10b) (10 mmol) in dry THF (43 
mL) was added dropwise. The resulting mixture was stirred at room 
temperature for 20 h. After this period, water was added, THF was 
removed under reduced pressure and the residue was extracted with 
ethyl acetate. The combined organic phases were washed with brine, 
dried over anhydrous sodium sulphate, filtered and evaporated to 
dryness.  
In the cases of 3-[2-(2H-chromen-3-yl)vinyl]pyridines (6a, 8a) 
and 4-[2-(2H-chromen-3-yl)vinyl]pyridines (7a, 9a), the obtained 
mixtures of (E) and (Z) isomers were separated by column 
chromatography on silica gel, eluting with ethyl acetate/light 
petroleum (1:1). The (Z) isomer was eluted at first. For the other 
compounds only one isomer was purified eluting with ethyl 
acetate/light petroleum (1:1) (6b, 12b), (1:2) (5a, 11a), or (1:3) (5b, 
7b, 11b, 12a, 13a,13b). Compounds 11a, 11b, 13a and 13b were 
crystallized as hydrochlorides. 
 
5.2.3.1.1.1. (E)-2-[2-(2H-chromen-3-yl)vinyl]pyridine (5a). Yield: 
47%, mp = 115-116°C from ethyl acetate. 1H NMR (DMSO D6, 
400MHz): δ (ppm) 8.58 (dd, 1H, J = 4.8, 2.0 Hz), 7.65 (dt, 1H, J = 
7.7, 2.0 Hz), 7.37 (d, 1H, J =16.1 Hz), 7.32 (d, 1H, J = 7.8 Hz), 7.15 - 
7.10 (m, 2H), 7.05 (dd, 1H, J = 7.5, 1.7 Hz), 6.89 (dt, 1H, J = 7.5, 1.0 
Hz), 6.83 (d, 1H, J = 7.8 Hz), 6.63 (s, 1H), 6.51 (d, 1H, J =16.1 Hz), 
5.11 (s, 2H). Anal. Calcd for C16H14ClNO: C, 70.72; H, 5.19; Cl, 
13.05; N, 5.15. Found: C, 70.90; H, 5.32; Cl, 12.90; N, 5.04.  
 
5.2.3.1.1.2. (E)-2-[2-(6-chloro-2H-chromen-3-yl)vinyl]pyridine 
(5b). Yield: 97%, mp = 156-161°C from ethyl acetate. 1H NMR 
(CDCl3, 400MHz): δ (ppm) 8.59 (dd, 1H, J = 4.8, 2.0 Hz), 7.65 (dt, 
1H, J = 7.6, 2.0 Hz), 7.36 (d, 1H, J =16.0 Hz), 7.32 (d, 1H, J = 7.6 
Hz), 7.15 (ddd, 1H, J = 7.6, 4.8, 1.2 Hz), 7.06 (dd, 1H, J = 8.4, 2.4 
Hz), 7.02 (d, 1H, J = 2.4 Hz), 6.75 (d, 1H, J = 8.4 Hz), 6.56 (s, 1H), 
6.53 (d, 1H, J =16.0 Hz), 5.10 (d, 2H, J = 1.2 Hz). Anal. Calcd for 
C16H12ClNO: C, 71.25; H, 4.48; Cl, 13.14; N, 5.19. Found: C, 71.33; 
H, 4.31; Cl, 12.96; N, 5.30. 
 
5.2.3.1.1.3. (E)-3-[2-(2H-chromen-3-yl)vinyl]pyridine (6a). Yield: 
32%, mp = 89-90°C. 1H NMR (CDCl3, 400MHz): δ (ppm) 8.61 (d, 
1H, J = 2.4 Hz), 8.44 (dd, 1H, J = 4.8, 1.6 Hz), 7.68 (ddd, 1H, J = 8.0, 
2.4, 2.0 Hz), 7.21 (dd, 1H, J = 8.0, 4.8 Hz), 7.10 (dt, 1H, J = 8.0, 8.0, 
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1.6 Hz), 7.00 (dd, 1H, J = 8.0, 1.6 Hz), 6.88 - 6.80 (m, 3H), 6.49 (s, 
1H), 6.32 (d, 1H, J =16.8 Hz), 5.04 (s, 2H). Anal. Calcd for 
C16H13NO: C, 81.68; H, 5.57; N, 5.95. Found: C, 81.84; H, 5.67; N, 
6.12. 
 
5.2.3.1.1.4. (Z)-3-[2-(2H-chromen-3-yl)vinyl]pyridine (8a). Yield: 
24%, mp = 46-47 °C. 1H NMR (CDCl3, 400MHz): δ (ppm) 8.48-8.46 
(m, 2H), 7.55 (dt, 1H, J = 7.6, 2.4 Hz), 7.19 (ddd, 1H, J = 8.0, 4.8, 0.8 
Hz), 7.08 (dt, 1H, J = 7.6, 7.6, 1.6 Hz), 6.97 (dd, 1H, J = 7.6, 1.6 Hz), 
6.86 (dt, 1H, J = 7.6, 7.6, 1.2 Hz), 6.75 (d, 1H, J = 8 Hz), 6.49 (s, 1H), 
6.47 (d, 1H, J = 12.0 Hz), 6.30 (d, 1H, J = 12.0 Hz), 4.42 (d, 2H, J = 
1.2 Hz). Anal. Calcd for C16H13NO: C, 81.68; H, 5.57; N, 5.95. 
Found: C, 81.53; H, 5.72; N, 6.13. 
 
5.2.3.1.1.5. (E)-3-[2-(6-chloro-2H-chromen-3-yl)vinyl]pyridine 
(6b) Yield: 31 %, mp = 142-143°C from ethyl acetate. 1H NMR 
(CDCl3, 400MHz): δ (ppm) 8.69 (d, 1H, J = 2.4 Hz), 8.50 (dd, 1H, J = 
4.8, 1.6 Hz), 7.87 (ddd, 1H, J = 8.0, 2.4, 2.0 Hz), 7.08 (dd, 1H, J = 
8.4, 2.5 Hz), 7.03 (d, 1H, J = 2.5 Hz), 6.93 (d, 1H, J = 16.5 Hz), 6.77 
(d, 1H, J = 8.4 Hz), 6.53 (s, 1H), 6.43 (d, 1H, J = 16.5 Hz), 5.09 (s, 
2H,). Anal. Calcd for C16H12ClNO: C, 71.25; H, 4.48; Cl, 13.14; N, 
5.19. Found: C, 71.07; H, 4.56; Cl, 13.26; N, 5.31. 
 
5.2.3.1.1.6. (E)-4-[2-(2H-chromen-3-yl)vinyl]pyridine (7a). Yield: 
41%, mp = 129-130°C. 1H NMR (CDCl3, 400MHz): δ (ppm) 8.55 (d, 
2H, J = 6.0 Hz), 7.28 (d, 2H, J = 6.0 Hz), 7.15 (td, 1H, J = 8.0,  8.0, 
1.6 Hz), 7.07 - 7.01 (m, 2H), 6.90 (td, 1H, J = 7.6, 7.6, 1.2 Hz), 6.84 
(d, 1H, J = 8.4 Hz), 6.62 (s, 1H), 6.33 (d, 1H, J = 16.4 Hz), 5.08 (s, 
2H). Anal. Calcd for C16H13NO: C, 81.68; H, 5.57; N, 5.95. Found: C, 
81.41; H, 5.72; N, 6.03. 
 
5.2.3.1.1.7. (Z)-4-[2-(2H-chromen-3-yl)vinyl]pyridine (9a). Yield: 
10%, mp = 46-48 °C. 1H NMR (CDCl3, 400MHz): δ (ppm) 8.53 (d, 
2H, J = 6.0 Hz), 7.14 (d, 2H, J = 6.0 Hz), 7.10 (dt, 1H, J = 8.0, 8.0, 1.6 
Hz), 6.98 (dd, 1H, J = 7.6, 1.6 Hz), 6.87 (dt, 1H, J = 7.6, 7.6, 1.2 Hz), 
6.77 (d, 1H, J = 8.0 Hz), 6.51 (s, 1H), 6.45 (d, 1H, J =12.4 Hz), 6.32 
(d, 1H, J = 12.4 Hz), 4.46 (s, 2H). Anal. Calcd for C16H13NO: C, 
81.68; H, 5.57; N, 5.95. Found: C, 81.50; H, 5.45; N, 5.92. 
 
5.2.3.1.1.8. (E)-4-[2-(6-chloro-2H-chromen-3-yl)vinyl]pyridine 
(7b). Yield: 33 %, mp = 145-147°C from ethyl acetate. 1H NMR 
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(CDCl3, 400MHz): δ (ppm) 8.56 (d, 2H, J = 6.0 Hz), 7.28 (d, 2H, J = 
6.0 Hz), 7.08 (dd, 1H, J = 8.5 = 2.5 Hz), 7.03 - 6.99 (m, 2H), 6.76 (d, 
1H, J = 8.5 Hz), 6.53 (s, 1H), 6.35 (d, 1H, J = 16.4 Hz), 5.07 (s, 2H). 
Anal. Calcd for C16H12ClNO: C, 71.25; H, 4.48; Cl, 13.14; N, 5.19. 
Found: C, 71.42; H, 4.53; Cl, 12.94; N, 5.03. 
 
5.2.3.1.1.9. (E)-3-[2-(pyridin-2-yl)vinyl]-4H-chromen-4-one 
hydrochloride (11a). Yield: 30 %, mp = 201-202 °C from ethyl 
alcohol/diethyl ether. IR (KBr): 1639 cm-1. 1H NMR (DMSO D6, 
400MHz): δ (ppm) 8.79 (s, 1H), 8.66 (d, 1H, J = 4.8 Hz), 8.26-8.16 
(m, 2H), 8.09 (d, 1H, J = 16.2 Hz), 8.01 (d, 1H, J = 7.8 Hz), 7.86 (t, 
1H, J = 8.1 Hz), 7.72 (d, 1H, J = 8.1 Hz), 7.66 (d, 1H, J = 16.2 Hz), 
7.63-7.54 (m, 2H). Anal. Calcd for C16H12ClNO2: C, 67.26; H, 4.23; 
Cl, 12.41; N, 4.90. Found: C, 67.50; H, 4.35; Cl, 12.38; N, 5.07.  
 
5.2.3.1.1.10. (E)-6-chloro-3-[2-(pyridin-2-yl)vinyl]-4H-chromen-4-
one hydrochloride (11b). Yield: 56 %, mp = 178 - 181 °C from ethyl 
alcohol/diethyl ether. IR (KBr): 1659 cm-1.  1H NMR (DMSO D6, 
400MHz): δ (ppm) 8.84 (s, 1H), 8.64 (d, 1H, J = 4.8 Hz), 8.10 (d, 1H, 
J = 2.6 Hz), 8.02-7.80 (m, 2H), 7.90 (dd, 1H, J = 8.9, 2.6 Hz), 7.80 (d, 
1H, J = 8.9 Hz), 7.71 (d, 1H, J = 7.8 Hz), 7.60 (d, 1H, J = 16.1 Hz), 
7.43 (dd, 1H, J = 7.5, 4.8 Hz). Anal. Calcd for C16H11Cl2NO2: C, 
60.02; H, 3.46; Cl, 22.15; N, 4.37. Found: C, 59.85; H, 3.49; Cl, 
22.36; N, 4.20.  
 
5.2.3.1.1.11. (E)-3-[2-(pyridin-4-yl)vinyl]-4H-chromen-4-one (12a).  
IR (KBr): 1644 cm-1. Yield: 34 %, mp = 150-151 °C from ethyl 
acetate. 1H NMR (CDCl3, 400MHz): δ (ppm) 8.58 (d, 2H, J = 5.8 Hz), 
8.30 (dd, 1H, J = 8.0, 1.7 Hz), 8.14 (s, 1H), 7.74-7.67 (m, 2H), 7.50-
7.41 (m, 2H), 7.37 (d, 2H, J = 5.8 Hz), 7.11 (d, 1H, J = 16.3 Hz). Anal. 
Calcd for C16H11NO2: C, 77.10; H, 4.45; N, 5.62. Found: C, 76.95; H, 
4.49; N, 5.72. 
 
5.2.3.1.1.12. (E)-6-chloro-3-[2-(pyridin-4-yl)vinyl]-4H-chromen-4-
one (12b). Yield: 37 %, mp = 221-222 °C from ethyl acetate. IR 
(KBr): 1643 cm-1. 1H NMR (CDCl3, 400MHz): δ (ppm) 8.69 (d, 2H, J 
= 5.7 Hz), 8.26 (d, 1H, J = 2.6 Hz), 8.15 (s, 1H), 7.72 (d, 1H, J = 16.3 
Hz), 7.64 (dd, 1H, J = 8.9, 2.6 Hz), 7.46 (d, 1H, J = 8.9 Hz), 7.40 (d, 
2H, J = 5.7 Hz), 7.10 (d, 1H, J = 16.3 Hz). Anal. Calcd for 
C16H10ClNO2: C, 67.74; H, 3.55; Cl, 12.50; N, 4.94. Found: C, 67.50; 
H, 3.45; Cl, 12.32; N, 5.07.  
76	  	  
 
5.2.3.1.1.13. (Z)-3-[2-(pyridin-3-yl)vinyl]-4H-chromen-4-one  
hydrochloride (13a). Yield: 59 %, mp = 204-209 °C from ethyl 
alcohol/diethyl ether. IR (KBr): 1636 cm-1. 1H NMR (DMSO D6, 
400MHz): δ (ppm) 8.84 (d, 1H, J = 1.8 Hz), 8.70 (d, 1H, J = 5.6 Hz), 
8.44-8.39 (m, 2H), 8.05 (dd, 1H, J = 8.0, 1.7 Hz), 7.90-7.81 (m, 2H), 
7.67 (dd, 1H, J = 8.5, 1.0 Hz), 7.52 (dt, 1H, J = 8.1, 1.0 Hz), 6.90 (d, 
1H, J = 12.2 Hz), 6.71 (d, 1H, J = 12.2 Hz). Anal. Calcd for 
C16H12ClNO2: C, 67.26; H, 4.23; Cl, 12.41; N, 4.90. Found: C, 67.09; 
H, 4.35; Cl, 12.62; N, 5.02. 
 
5.2.3.1.1.14. (Z)-6-chloro-3-[2-(pyridin-3-yl)vinyl]-4H-chromen-4-
one hydrochloride (13b). Yield: 31 %, mp = 192-193 °C from ethyl 
alcohol/diethyl ether. IR (KBr): 1642 cm-1. 1H NMR (DMSO D6, 
400MHz): δ (ppm) 8.77 (s, 1H), 8.64 (d, 1H, J = 5.2 Hz), 8.43 (s, 1H), 
8.25 (d, 1H, J = 8.4 Hz), 7.98 (dd, 1H, J = 2.7, 0.9 Hz), 7.90-7.73 (m, 
3H), 6.88 (d, 1H, J = 12.2 Hz), 6.65 (d, 1H, J = 12.2 Hz). Anal. Calcd 
for C16H11Cl2NO2: C, 60.02; H, 3.46; Cl, 22.15; N, 4.37. Found: C, 
59.84; H, 3.51; Cl, 22.01; N, 4.25. 
 
5.2.3.2. Virology   	  
5.2.3.2.1. Cells 	  
HeLa (Ohio) cells were grown at 37 °C using Eagle's Minimum 
Essential Medium (MEM) supplemented with 100 mg/ml of 
streptomycin and 100 U/ml of penicillin G and 8% heat-inactivated 
foetal calf serum (growth medium). The serum concentration was 
reduced to 2% for cell maintenance (maintenance medium). 
 
5.2.3.2.2. Compounds  
 
Stock solutions were made up in ethanol (1, 0.5 or 0.1 mg/ml) 
and further diluted in cell culture medium shortly before use. 
 
5.2.3.2.3. Viruses  
 
Reference strains of HRV type 1B and 14 were purchased from 
American Type Culture Collection (ATCC). Virus stocks were 
prepared infecting HeLa (Ohio) cell monolayers at a multiplicity of 
infection of 0.1 PFU/cell. Infected cells were incubated at 33 °C. When 
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the viral-induced cytopathic effect involved most of the cells, the 
cultures were freeze-thawed three times and the clarified supernatants 
titrated by plaque assay, essentially as described by Fiala and Kenny 
(1966). The virus was stored at -80 °C until used. 
 
5.2.3.2.4. XTT assay for cellular cytotoxicity 
 
 A tetrazolium-based (XTT) colorimetric assay was used to 
measure the cytotoxicity of compounds, as previously described.3 
Briefly, HeLa cells were seeded in 96 well tissue culture plates (2x103 
cells/well) in 100 ml of growth medium with or without compounds in 
two-fold dilutions, starting from the maximum soluble concentration in 
cell culture medium. Triplicate wells were used for each drug 
concentration to be tested. The plates were incubated at 37 °C in 5% 
CO2-air until the untreated monolayers were confluent (3 days). Then, 
50 mL of XTT labelling mixture was added to each well (final XTT 
concentration 0.15 mg/ml) and the cells incubated for 4 h at 37 °C. The 
spectrophotometric absorbance of the samples was measured using an 
ELISA reader at 492 nm with a reference wavelength at 690 nm. 
Cytotoxicity was also scored microscopically as morphological 
alterations on the third day of incubation in the presence of 
compounds. The highest concentration of compound that did not 
produce any modification of morphology and viability in 100% of cells 
was the maximum non-cytotoxic concentration (MNTC). The 50% 
cytotoxic concentration (TC50) was indicated as the concentration of 
compound reducing the cell viability by 50%, as compared with mock-
treated cells. 
 
5.2.3.2.5. Determination of the 50% inhibitory concentration (IC50) 
 
The IC50 values were determined as described previously.
4 
Briefly, monolayers of HeLa cells in 6-well plates were infected with a 
virus suspension producing approximately 100 plaques per well. After 
1h of incubation at 33 °C, the virus inoculum was removed and the 
cells were overlaid with medium for plaques, in the presence or 
absence of four-fold dilutions of drugs, starting from the MNTC or 
alternatively from the saturation concentration in cell culture medium. 
After three days of incubation at 33 °C, the cells were stained with a 
neutral red solution (0.2 mg/ml) in pH 7.4 phosphate buffered saline 
(PBS) and the plaques were counted. The IC50 was expressed as the 
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concentration of drug reducing the plaque number by 50% as compared 
with mock-treated control. It was calculated from dose/response curves 
obtained by plotting the percentage of plaque reduction, with respect to 
the control plaque count, versus the logarithm of compound dose. 
Triplicate wells were utilized for each drug concentration. 
 
5.2.3.2.6. Virus inactivation and stabilization  
 
For virus inactivation studies, HRV suspensions with or without 
5a (43 µM and 58 µM for serotype 1B and 14, respectively) were 
incubated at 33 °C for 1h. After serial ten-fold dilutions, virus titres 
were measured by plaque assay on HeLa cell monolayers. 
For virus stabilization studies, the virus was incubated with or 
without 5a (43 µM and 58 µM for serotype 1B and 14, respectively) 
for 1h at 33 °C before mild acid or thermal treatment. For mild acid 
treatment, the pH of the mixtures was adjusted to 5 by adding 0.2 M 
acetate buffer (pH 5). After incubation at 33 °C for 30 min, the 
mixtures were neutralized with 0.85 M Tris base. For thermal 
treatment, the mixtures were incubated for 20 min at 56 °C (pH 7.2) 
and then refrigerated on ice. Samples were diluted ten-fold serially 
and titrated by plaque assay. 
 
5.2.3.2.7. Virus yield reduction assays 
 
Confluent monolayers of HeLa cells were infected at a 
multiplicity of 5 in the presence or absence of 5a (43 µM and 58 µM 
for serotype 1B and 14, respectively). Infection was synchronized by 
allowing HRV to bind in the cold (4 °C). After 1h, the inoculum was 
removed by washing thrice with cold PBS. The end of virus binding 
was taken as 0 time. Then, MEM with or without the compound (43 
µM and 58 µM for serotype 1B and 14, respectively) was added and 
the temperature raised to 33 °C to permit internalization. Single-cycle 
conditions were achieved by incubating the cells at 33 °C for 10 h post 
infection (p.i.). The cultures were freeze-thawed three times, cell 
debris removed by low-speed centrifugation in the cold and the 
supernatants titrated by plaque assay. To determine which stage of  
virus replication was affected by 5a, the drug was added or removed 
from HRV-infected cells at various times p.i. (0, 15’, 30’, 45’, 1 h, 2 
h, 4 h, 6 h) and the cultures incubated at 33 °C up to 10 h p.i. The 
virus yield was determined as above. 
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5.3. Synthesis and antiviral activity of 3-styryl-2H-
chromenes, 3-phenylalkyl-2H-chromenes and 3-(3-
phenylalkyl)chromans 
 
The results of previous researches prompted us to further 
explore the effect of simple structural modifications on 3-styryl-2H-
chromene scaffold.  
 
5.3.1. Results and discussion 
 
5.3.1.1. Chemistry 
 
(E)-3-(2H-Chromen-3-yl)-1-phenylprop-2-en-1-one 2a and (E)-
3-styryl-2H-chromenes 2b-n were synthesized according to the two 
step procedure shown in scheme 1. The 2H-chromene-3-
carbaldehydes 1a-n were initially prepared with some modifications 
of the literature procedures,1,2 by refluxing the appropriate 2-
hydroxybenzaldehyde and acrolein in the presence of potassium 
carbonate (method A).  
 
 
 
1, 2a R1 = R2 = H                     1, 2h R1 = Cl, R2 = F 
1, 2b R1 = H, R2 = Br               1, 2i R1 = Br, R2 =  H 
1, 2c R1 = H, R2 = NO2            1, 2j R1 = R2 = F 
1, 2d R1 = R2 = Br                    1, 2k R1 = F, R2 = Br 
1, 2e R1 = Cl, R2 = H                1, 2l R1 = NO2, R2  = Br 
1, 2f R1 = R2 = Cl                     1, 2m R1 = Br, R2 = NO2 
1, 2g R1 = Br, R2 = Cl               1, 2n R1 = NO2, R2 = H 
 
Scheme 1. Reagents and conditions: (method A) K2CO3, dry dioxane, reflux, 5h; 
(method B) DABCO, CHCl3/H2O (1:1), rt, 7 days; (i) NaH, dry THF, rt, 20 h. 
 
With the aim to improve the yield of this reaction, a more efficient 
procedure was developed. The reaction was performed in the presence 
of 1,4–diazabicyclo-[2.2.2]-octane (DABCO) in chloroform and water 
(1:1), at room temperature (method B). The subsequent Horner–
Wadsworth–Emmons reaction of 2H-chromene-3-carbaldehydes 1a-n 
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with commercially available diethyl (2-oxo-2-
phenylethyl)phosphonate or diethyl benzylphosphonate, carried out 
using sodium hydride as base in dry THF, provided only the (E) 
isomers 2a-n. The stereochemistry of compounds was established on 
the basis of the coupling constant values of the protons in the chain 
(Jα-β = 16.0 Hz and ~16.5 Hz for 2a and 2b–n, respectively).  
E and Z 3-styryl-2H-chromenes were prepared by the Wittig 
reaction of 2H-chromen-3-carbaldehyde (1a) with the appropriate 
benzylthiphenylphosphonium halide (3a-n). While 
benzyltriphenylphosponium chloride (3a), and 4-
nitrobenzyltriphenylphosponium bromide (3n) are commercially 
available, the analogues (3b-m) were prepared by reaction of the 
corresponding benzyl alcohol with triphenylphosphine hydrobromide 
in dry CH3CN.  
 
3, 4, 5, 6a  R3 = R4 = R5 = R6 = R7 = H              3, 4, 6h R3 = Cl, R4 = R5 = R6 = R7 = H 
3, 4, 6b R3 = CF3, R4 = R5 = R6 = R7 = H   3, 4, 5, 6i R4 = Cl, R3 = R5 = R6 = R7 = H 
3, 4, 6c R4 = CF3, R3 = R5 = R6 = R7 = H      3, 4, 6j R5 = Cl, R3 = R4 = R6 = R7 = H 
3, 4, 6d  R5 = CF3, R3 = R4 = R6 = R7 = H      3, 4, 6k R3 = Br, R4 = R5 = R6 = R7 = H 
3, 4, 5, 6e  R3 = R5 = Cl, R4 = R6 = R7 = H     3, 4, 5, 6l  R4 = Br, R3 = R5 = R6 = R7 = H 
3, 4, 5, 6f  R4 = R6 = Cl, R3 = R5 = R7 = H   3, 4, 5, 6m R5 = Br, R3 = R4 = R6 = R7 = H 
3, 4, 6g  R3 = R7 = Cl, R4 = R5 = R6 = H        3, 4, 5n R5 = NO2, R3 = R4 = R6 = R7 = H 
       
Scheme 2. Reagents and conditions: (i) tert-BuOK, dry THF, rt, 23h; (ii) Pd/C 10%, 
dry dioxane, rt, 30 min. 
 
The Wittig reaction was conducted in the presence of potassium 
tert-butoxide in dry THF, at room temperature. The E/Z-mixtures 
O
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(4/5a, 4/5e-f, 4/5i, 4/5l-n) obtained by the Wittig reaction were 
separated into their individual isomers by column chromatography on 
silica gel. For the analogues 2’-substituted or 2’,6’-disubstituted (4g-
h, 4k) and for trifluoromethyl derivatives (4b-d), only the E isomers 
were obtained. The stereochemistry of compounds was established on 
the basis of the coupling constant values of the protons in the chain 
(about 16 Hz and 12 Hz for E and Z isomers, respectively). 
Subsequent catalytic reduction of E/Z-mixtures (4/5a, 4/5e-f, 4/5i, 
4/5l-m) or (E)-isomers (4b-d, 4g-h, 4j-k) afforded the corresponding 
3-phenethylchromans 6a-m with good yields (~	  85%) (scheme 2). 
 
 
Scheme 3. Reagents and conditions: (i) DABCO, CHCl3/H2O (1:1), rt, 7 days; (ii) 
NaBH4, MeOH, rt, 6h; (iii) triphenylphosphine hydrobromide, dry CH3CN, reflux, 
5h; (iiii) tert- BuOK, dry THF, rt, 23h. 
 
The synthesis of (E)-3-(1-phenylpropen-2-yl)-2H-chromene 10 
started from the preparation of 3-acetyl-2H-chromene (7) by reaction 
of 2-hydroxybenzaldehyde and 3-buten-2-one, according to the 
method B described for the synthesis of (E)-3-styryl-2H-chromenes 
(2b–n). Subsequent reduction of 3-acetyl-2H-chromene (7) with 
sodium borohydride in methanol provided 3-(1-hydroxyethyl)-2H-
chromene (8). This intermediate was then reacted with 
triphenylphosphine hydrobromide in dry THF, yielding [1-(2H-
chromen-3-yl)ethyl]triphenylphosphonium bromide (9) with good 
yield. Finally, the target compounds 10 was obtained by the Wittig 
reaction of benzaldehyde with the triphenylphosphonium bromide 9 
(scheme 3). 
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11, 12, 13a  n = 1, R = R1 = R2 = R3 = H                              
11, 12, 13b  n = 1, R1 = CF3, R = R1 = R2 = H  
11, 12, 13c  n = 1, R = CF3,  R1 = R2 = R3 = H                       
11, 12, 13d  n = 1, R = Cl, R1 = R2 = R3 = H                          
11, 12, 13e  n = 1, R2 = CH3, R = R1 = R3 = H                        
11, 12, 13f  n = 1, R3 = CH3, R = R1 = R2 = H 
11, 12, 13g  n = 2, R = R1 = R2 = R3 = H 
11, 12, 13h  n = 3, R = R1 = R2 = R3 = H 
11, 12, 13i  n = 4, R = R1 = R2 = R3 = H 
 
Scheme 4. Reagents and conditions: I) CO2Cl2, dry CH2Cl2, 0°C, rt, 3h; II) 
TMSCHN2, dry CH3CN, 0°C, 2h; III) HBr 48%, 0°C, rt, 18h; (method A) EtONa, 
dry EtOH, rt, 24h; (method B) tert- BuOK, dry THF, rt, 23h. 
 
Phenylalkyl-2H-chromenes (13a-i) were synthesized as reported 
in scheme 4. For this purpose, the required 1-bromomethyl-
phenylalkylketone (12a-i) was prepared in three steps starting from 
the treatment of the appropriate acid (11a-i) with oxalyl chloride in 
dry dichloromethane. The obtained acyl chloride was converted into 
the target 1-bromomethylketone (12a-i) modifying the method 
described by Gangjee.3 In our synthetic approach, the resulting acyl 
chloride was treated with trimethylsilyldiazomethane (TMSCHN2), 
used as a stable and safe substituted for hazardous diazomethane. The 
intermediate diazoketone was treated in situ with 48% aqueous HBr to 
provide the desired 12a-i in excellent yields. In addition, (2-
hydroxybenzyl)triphenylphosphonium bromide (3o) was obtained, in 
almost quantitative yield, by reaction of 2-hydroxybenzyl alcohol with 
triphenylphosphine hydrobromide in refluxing acetonitrile. 
Subsequent reaction of 12a-i with 3o in the presence of a strong base, 
allowed alkylation of the phenolic hydroxyl group and cyclization by 
an intramolecular Wittig reaction. The reaction was carried out at 
room temperature using a base such as sodium ethoxide in dry ethanol 
(compounds 13a, d) or tert-BuOK in dry THF (compounds 13b-c, 
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13e-i) (scheme 4).  
 
          
 
  13, 14g  n = 3     13, 14h  n = 4  13, 14i  n = 5 
 
Scheme 5. Reagents and conditions: (i) Pd/C 10%, dry dioxane, rt, 30 min. 
 
Subsequent catalytic hydrogenation of phenylalkyl-2H-
chromenes 13g-i afforded the corresponding 3-(3-
phenylalkyl)chromans 14g-i with high yields (scheme 5). 
As shown in scheme 6, the chloro substituted	   3-(3-
phenylpropyl)chromans (18a-c) were prepared by catalytic 
hydrogenation of the appropriate mixture of (Z)-3-[(E)-3-
phenylallylidene]-chroman, (E)-3-(3-phenyl) prop-1-en-1-yl)-2H-
chromene, and 3-cinnamyl-2H-chromene (15, 16, 17a; 15, 16, 17b or 
15, 16, 17c). As previously reported,4 these mixture were obtained by 
reduction of the appropriate (E)-3-[(E)-3-phenylallylidene]chroman-4-
one with lithium aluminum hydride. 
 
 
 
 
15, 16, 17, 18a R = Cl, R1 = H 
15, 16, 17, 18b R = R1 = Cl 
15, 16, 17, 18c R = H, R1 =Cl 
 
Scheme 6. Reagents and conditions: (i) Pd/C 10%, dry dioxane, rt, 15 min. 
 
5.3.1.2. Anti-HRV assays  
 
In preliminary studies, the cytotoxicity of all the new 
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synthesized compounds (4a-m, 5e-f, 5i, 5l-m, 6a-m, 10, 13a-i, 14g-i, 
18a-c) was determined by evaluating the effects on morphology, 
viability and growth of HeLa (Ohio) cells, a human cell line suitable 
for the replication of HRVs. Morphological alterations were scored 
microscopically, and the action of the compounds on logarithmic cell 
growth was determined by the XTT colorimetric method.5 The 
cytotoxicity of compounds is referred as maximum non-cytotoxic 
concentration (MNTC) and 50% cytotoxic concentration (TC50). The 
MNTC is the highest dose that did not produce any toxic effect or 
reduction of cell growth after 3 day incubation at 37°C. The TC50 is 
the concentration of compound reducing the cell viability by 50% as 
compared with the control.  
The inhibitory activity of all the compounds on HRV replication 
was evaluated in a plaque reduction assay, starting from the MNTC, 
as already described.6  
The results of cytotoxicity and anti-HRV activity of  (E) and (Z) 
3-styryl-2H-chromenes (4a-m, 5e-f, 5i, 5l-m) and (E)-3-(1-
phenylprop-1-en-2-yl)-2H-chromene (10) are reported in table 1. 
When the IC50 value was higher than the MNTC, the percentage 
inhibition at this dose is reported in parentheses. For comparison, 
table 1 includes previously reported data of (E)-3-styryl-2H-chromene 
(4a).         
 Within the 3-styrylchromene series, all compounds presented 
low cytotoxicity against HeLa cells showing TC50 ranging from 12.5 
µM to > 200 µM (the highest concentration tested). Moreover, the 
new synthesize analogues exhibited antiviral activity against HRV 1B 
in the micromolar or submicromolar range (table 1).  
Although the introduction of electron withdrawing substituents on 
phenyl ring did not provide improvements in potency with respect to 
unsubstituted 3-styrylchromene 4a, several analogues (4e, 5f, 4g, 4j 
and 5m) presented antiviral potency in the submicromolar range. The 
high inhibitory activity on HRV 1B coupled with the low cytotoxicity 
resulted in compounds as selective as 4a (4j, TI = 250.00) or more 
selective than 4a (4e, TI = 333.33; 5f, TI = 344.83; 5m, TI = 375.00). 
A comparison among the activity of E and Z isomers (4f/5f, 4i/5i, 
4l/5l, 4m/5m) showed that the Z isomers exhibited a higher potency 
than corresponding E isomers against HRV 1B. Only the Z isomer 4e 
was about 8-fold more active than E isomer 5e against this serotype. 
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Table 1. Cytotoxicity and anti-HRV activity of (E)-3-styryl-2H-chromenes 4a-m, 
(Z)-3-styryl-2H-chromenes 5e-f, 5i, 5l-m, and (E)-3-(1-phenylpropen-2-yl)-2H-
chromene 10. 
aThe maximum non-cytotoxic concentration (MNTC) was the highest dose tested that did not 
produce any cytotoxic effect and reduction in viability of HeLa cells, or on cell growth after 3 days 
of incubation at 37°C. 
bThe TC50 value was the concentration of compound which reduced the Hela cell viability by 50%, as 
compared with the control. 
c The IC50 value was the dose of compound reducing the plaque number by 50% and was calculated 
by plotting the log of drug concentration versus the percentage of plaque reduction. When a 50 % 
reduction was not achieved, the percent of inhibition obtained at the MNTC was reported in 
parentheses. 
d The therapeutic index (TI) value was equal to TC50/
 IC50. 
e The saturation concentration in cell culture medium was found to be lower than TC50. 
f Compounds producing a reduction in the mean viral plaque size, beside an effect on plaque number.  
g Not active up to the highest concentration tested (MNTC). 
h Not tested. 
 
 
O
R3
R4
R5
R6
R7
O
R3
R4
R5
R6
R7
4a-m 5a, 5e-f, 5i, 5l-m
Comp. R3 R4 R5 R6 R7 MNTC 
(µM)a 
TC50 
(µM)b 
IC50 (µM)c 
HRV 1B 
TId IC50 (µM)c 
HRV 14 
TId 
4a  H H H H H 25.00 50.00 0.20 250.00 1.38 36.23 
4b  CF3 H H H H 25.00 100.00 5.76 17.40 2.06 48.54 
4c  H CF3 H H H 100.00 >200.00e 4.69 >42.6 >100.00 (30%) - 
4d  H H CF3 H H 100.00 >200.00e 20.19 >9.90 >100.00 (27%) - 
4e  Cl H Cl H H 25.00 100.00 0.30 333.33 NTh - 
5e  Cl H Cl H H 25.00 100.00 2.59 38.61 NTh - 
4f H Cl H Cl H 3.12 12.50 > 3.12 (33%) - NTh - 
5f  H Cl H Cl H 25.00 100.00 0.29 344.83 NTh - 
4g  Cl H H H Cl 50.00 75.00 0.70 107.14 NTh - 
4h Cl H H H H 50.00 150.00 12.50f 12.00 2.92 51.37 
4i  H Cl H H H 50.00 75.00 50.00 1.50 2.53 29.64 
5i  H Cl H H H 25.00 36.50 4.28 8.53 25.00 1.46 
4j H H Cl H H 50.00 100.00 0.40 250.00 18.39 5.44 
4k  Br H H H H 12.50 75.00 8.28f 9.06 NTh - 
4l  H Br H H H 50.00 75.00 5.84 12.84 NTh - 
5l  H Br H H H 12.50 37.50 4.45 8.43 NTh - 
4m  H H Br H H 50.00 100.00 1.42f 70.42 NTh - 
5m H H Br H H 50.00 150.00 0.40 375.00 NTh - 
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It is noteworthy that some analogues (4b, 4h and 4i) were more 
effective against HRV14 than HRV1B. Moreover the higher potency 
were coupled with a good selectivity. 
On the contrary, the addition of a methyl group in the linker 
chain between the two cycles (10) cancel the efficacy against both 
serotypes. 
In order to evaluate the impact on activity and cytotoxicity of 
the reduction of both double bounds, the 3-phenethylchromans 6a-m 
were synthesized as racemates, and tested. The results of the 
biological evaluation are reported in table 2.  
Generally, the 3-phenethylchromans (6a-m) showed low 
cytotoxicity against HeLa cells, with four analogues (6h, 6i, 6l, 6m) 
exhibiting TC50 higher than the saturation concentration (200 µM) in 
cell culture medium. However, in this series of compounds, the more 
active analogues against HRV 1B (6a and 6e) were also the more 
cytotoxic. In particular, the reduction of both double bounds of 4a to 
give 3-phenethylchroman (6a) caused a 2-fold decrease in the 
inhibitory effect against HRV1B and a dramatic loss of activity 
against HRV14. Moreover, despite the anti-HRV1B effect within the 
submicromolar range (IC50 = 0.49 µM), 6a showed a modest 
therapeutic index (TI = 12.75) due its significant cytotoxicity (TC50 = 
6.25 µM). 
Also the 2,4-dichloro derivative 6e, exhibiting an anti-HRV1B 
effect in the submicromolar range, were about 2-fold less potent (IC50 
= 0.58 µM) and about 8-fold less selective (TI = 43.10) than the 
corresponding 3-styrylchromene 4e.  
Generally, the tested compounds exhibited higher potency 
against HRV1B than HRV14. Only the 2-trifluoromethyl derivative 
6b showed comparable potency against both HRV serotypes (IC50 = 
6.27 µM and 6.20 µM against HRV 1B and 14, respectively). 
However, the broader spectrum of anti-HRV activity was coupled 
with modest therapeutic indexes (TI = 11.96 and 12.09 against HRV 
1B and 14, respectively).  
On the contrary, the 3-chloro analogue 6i displayed higher 
efficacy against HRV14 than HRV1B (IC50 = 4.84 µM and 2.94 µM 
against HRV 1B and 14, respectively) coupled with remarkable 
selectivity (TI > 41.32 and > 68.03 against HRV 1B and 14, 
respectively). 
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Table 2. Cytotoxicity and anti-HRV activity of 3-phenylethylchromans 6a-m. 
aThe maximum non-cytotoxic concentration (MNTC) was the highest dose tested that did not produce 
any cytotoxic effect and reduction in viability of HeLa cells, or on cell growth after 3 days of incubation 
at 37°C. 
bThe TC50 value was the concentration of compound which reduced the Hela cell viability by 50%, as 
compared with the control. 
c The IC50 value was the dose of compound reducing the plaque number by 50% and was calculated by 
plotting the drug concentration versus the percentage of plaque reduction. When a 50% reduction was not 
achieved, the percent of inhibition obtained at the MNTC was reported in parentheses. 
d The therapeutic index (TI) value was equal to TC50/ IC50. e	  The saturation concentration in cell culture medium was found to be lower than TC50.	  
f Compounds producing a reduction in the mean viral plaque size, beside an effect on plaque number.  
g Not tested. 
 
A small series of 3-phenylalkyl-2H-chromenes (13a-f) were also 
prepared. The results of the biological evaluation are reported in table 
3. When compared to the corresponding 3-phenethylchroman (6a), the 
unsubstituted 3-phenylethyl-2H-chromene (13a) exhibited a similar 
potency against HRV 1B (IC50 = 0.48 µM) coupled with a better 
selectivity (TI = 103.09). The efficacy towards the serotype 14 
remained modest up to the MNTC. The introduction of a chlorine 
atom at the 4’-position resulted in compound 13d with the same 
potency than 13a against HRV 1B and 3-fold more selective. 
However, 13d were totally inactive against HRV 14. The 
O
R3
R4
R5
R6
R7
6a-m
Comp. R3 R4 R5 R6 R7 MNTC 
(µM)a 
TC50 
(µM)b 
IC50 (µM)c 
HRV 1B 
TId IC50 (µM)c 
HRV 14 
TId 
6a H H H H H 3.12 6.25 0.49 12.75 >3.12 (16%) - 
6b  CF3 H H H H 50.00 75.00 6.27  11.96 6.20 12.09 
6c  H CF3 H H H 25.00 75.00 6.49 11.55 >25.00 (26%) - 
6d H H CF3 H H 25.00 100.00 2.50 40.00 10.52 9.51 
6e  Cl H Cl H H 6.25 25.00 0.58 43.10 NTg - 
6f  H Cl H Cl H 50.00 100.00 21.16 4.73 NTg - 
6g  Cl H H H Cl 50.00 75.00 7.74 9.69 NTg - 
6h Cl H H H H 100.00 >200.00e 6.54 >30.58 20.28 >9.86 
6i  H Cl H H H 100.00 >200.00e 4.84f >41.32 2.94 >68.03 
6j H H Cl H H 50.00 200.00 1.66f 120.48 18.27 10.95 
6k Br H H H H 100.00 150.00 5.08f 29.53 NTg - 
6l  H Br H H H 200.00 >200.00e 3.83f >52.22 63.95 >3.13 
6m  H H Br H H 200.00 >200.00e 2.12f >94.34 34.27 >5.84 
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corresponding 4’-trifluoromethyl analogue 13c presented good and 
comparable efficacy against both HRV serotypes (IC50 = 1.56 µM and 
2.03 µM against HRV1B and 14, respectively), however 13c showed 
modest therapeutic indexes (TI = 12.00 and 9.23 against HRV1B and 
14, respectively). 
Also within the phenylethyl-2H-chromene series, the addition of 
a methyl group in the α-position of the linker chain between the two 
cycles (13f) resulted in a loss of activity against HRV 1B. In contrast, 
the shift of the methyl group to the β-position led to the isomer 13e 
endowed with good activity against HRV 1B (IC50 = 1.17 µM) but low 
selectivity (TI = 10.68). Both analogues exhibited a modest inhibitory 
effect on HRV 14 replication. For these reasons, branched chains into 
the spacer were not further explored.  
 
 
 Table 3. Cytotoxicity and anti-HRV activity of phenylalkyl-2H-chromenes 13a-f. 
aThe maximum non-cytotoxic concentration (MNTC) was the highest dose tested that did not produce 
any cytotoxic effect and reduction in viability of HeLa cells, or on cell growth after 3 days of incubation 
at 37°C. 
bThe TC50 value was the concentration of compound which reduced the Hela cell viability by 50%, as 
compared with the control. 
c The IC50 value was the dose of compound reducing the plaque number by 50% and was calculated by 
plotting the drug concentration versus the percentage of plaque reduction. When a 50% reduction was not 
achieved, the percent of inhibition obtained at the MNTC was reported in parentheses. 
d The therapeutic index (TI) value was equal to TC50/
 IC50. e	  Not active up to the highest concentration tested (MNTC).	  
 
In order to evaluate the impact on cytotoxicity and antiviral 
activity of the linker elongation, two new series of 3-phenylalkyl-2H-
chromenes (13g-i) and 3-phenylalkylchromanes (14g-i and 18a-c) 
were prepared and tested (table 4).  
O
R2
R3R1 R
13a-f
Comp. R R1 R2 R3 MNTC 
(µM)a 
TC50 
(µM)b 
IC50 (µM)c 
HRV 1B 
TId IC50 (µM)c 
HRV 14 
TId 
13a  H H H H 25.00 50.00 0.48 103.09 >25.00 (26%) - 
13b  H CF3 H H 12.50 37.50 >12.50 (14%) - 4.57 8.21 
13c  CF3 H H H 6.25 18.75 1.56 12.00 2.03 9.23 
13d  Cl H H H 50.00 150.00 0.48 309.28 INe - 
13e  H H CH3 H 6.25 12.50 1.17 10.68 >6.25 (5%) - 
13f  H H H CH3 12.50 25.00 INe - >12.50 (31%) - 
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The elongation up to 5 carbon atoms of the linear, 
polymethylene spacer connecting 2H-chromene with phenyl ring 
furnished analogues 13g-i showing very low cytotoxicity, potent 
inhibitory activity and high selectivity against HRV 1B. The 
corresponding chromane analogues 14g-i maintained the low 
cytotoxicity but exhibited a lower efficacy than chromenes 13g-i 
against serotype 1B. Both series of compounds were endowed with a 
weak activity against HRV14.  
 
 
 
Table 4. Cytotoxicity and anti-HRV activity of phenylalkyl-2H-chromenes 13g-i, 3-
(phenylalkyl) chromans 14g-i, and 18a-c. 
 
aThe maximum non-cytotoxic concentration (MNTC) was the highest dose tested that did not produce any 
cytotoxic effect and reduction in viability of HeLa cells, or on cell growth after 3 days of incubation at 
37°C. 
bThe TC50 value was the concentration of compound which reduced the Hela cell viability by 50%, as 
compared with the control. 
c The IC50 value was the dose of compound reducing the plaque number by 50% and was calculated by 
plotting the drug concentration versus the percentage of plaque reduction. When a 50% reduction was not 
achieved, the percent of inhibition obtained at the MNTC was reported in parentheses. 
d The therapeutic index (TI) value was equal to TC50/
 IC50. 
 
The introduction of chlorine at the 4’ and/or 6 position of the 3-
(3-phenylpropyl)chroman 14g led to derivatives 18a-c showing 
improved potency and selectivity against both serotypes, with respect 
to 14g. In particular, 3-[3-(4-chlorophenyl)propyl]chroman 18c 
showed a broad spectrum of anti-HRV activity and displayed the 
highest level of activity against both serotypes (IC50 of 0.48 µM and 
1.36 µM towards HRV 1B and 14, respectively) coupled with 
significant selectivity (TI = 206.18 and 73.26, respectively).  
Therefore, this chroman is a good candidate for further studies. 
O
R
R1
n
13g-i
O
R
R1
n
14g-i, 18a-c
Comp. n  R R1 MNTC 
(µM)a 
TC50 
(µM)b 
IC50 (µM)c 
HRV 1B 
TId IC50 (µM)c 
HRV 14 
TId 
13g 3 H H 100.00 200.00 2.37 84.21 40.47 4.94 
13h  4 H H 50.00 100.00 0.54 183.82 12.70 7.87 
13i  5 H H 50.00 100.00 0.56 178.57 >50.00 (37%) - 
14g  3 H H 100.00 200.00 9.59 20.85 >100.00 (37%) - 
14h 4 H H 50.00 100.00 0.71 140.45 >50.00 (25%) - 
14i 5 H H 100.00 200.00 4.74 42.18 33.08 6.05 
18a 3 Cl H 100.00 200.00 1.79 111.73 25.00 8.00 
18b 3 Cl Cl 100.00 200.00 0.56 357.78 30.00 6.66 
18c 3 H Cl 50.00 100.00 0.48 206.18 1.36 73.26 
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5.3.1.3. Antiviral assays against selected RNA and DNA viruses  
 
To evaluate the selectivity of the new compounds as anti-HRV 
inhibitors, selected derivatives were evaluated against a large panel of 
RNA and DNA viruses. Among single-stranded, positive RNA viruses 
(ssRNA+), we considered two Picornaviruses (Coxsackie Virus type-
5, CVB-5 and Poliovirus type-1, Sabin strain, Sb-1), a Flavivirus 
(Yellow Fever Virus, YFV) and a Pestivirus (Bovine Viral Diarrhea 
Virus, BVDV). Among single-stranded, negative RNA viruses 
(ssRNA-) a Paramyxoviridae (Respiratory Syncytial Virus, RSV) and 
a Rhabdoviridae (Vesicular Stomatitis Virus, VSV) were selected as 
representatives. Among double-stranded RNA (dsRNA) viruses, a 
Reoviridae family member (Reo-1) was included. Finally, two 
representatives of DNA virus families were also included:	   Herpes 
Simplex Virus type-1, HSV-1 (Herpesviridae) and Vaccinia Virus, 
VV (Poxviridae). Pleconaril, ribavirin, 6-azauridine, acyclovir and 
mycophenolic acid were used as reference inhibitors. 
Cytotoxicity and antiviral activities of all the new synthesized 
and reference compounds are summarized in tables 5-7. 
All the tested compounds showed a low or no toxicity against 
the cellular lines utilized (MDBK, BHK-21, Vero 76). Many 
analogues showed TC50 values higher than the maximum tested 
concentration (100 µM).  
With the exception of (E)-8-chloro-3-styryl-2H-chromene (2e) 
and 3-phenethyl-2H-chromene (13a), the chromene and chroman 
derivatives were unable to interfere with the virus replication. (E)-8-
Chloro-3-styryl-2H-chromene (2e) showed a moderate activity against 
RSV (IC50 = 37 µM). The introduction of an additional halogen at the 
6 position (2f, 2h) or the replacement of the chlorine with a bromine 
atom (2i) abolished the activity. 
Furthermore, 3-(2-phenylethyl)-2H-chromene (13a) interfered 
with the replication of BVDV and YFV, both belonging to the 
Flaviviridae family. Although 13a exhibited a modest potency, this 
chromene displayed comparable efficacy than the reference inhibitor 
ribavirin against YFV (IC50 = 60 µM and 50 µM, respectively). 
Concerning its cytotoxicity, 13a showed no toxicity up to the highest 
concentration tested (100 µM) towards the cellular lines suitable for 
the replication of BVDV and YFV (MDBK and BHK21, 
respectively), while ribavirin presented a higher toxicity against 
MDBK (TC50 = 47 µM) than 13a. 
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2b: R1 = H, R2 = Br, R3 = H        2g: R1 = Br, R2 = Cl, R3 = H      2l: R1 = NO2, R2 = Br, R3 = H   
2c: R1 = H, R2 = NO2, R3 = H     2h: R1 = Cl, R2 = F, R3 = H      2m: R1 = Br, R2 = NO2, R3= H  
2d: R1 = Br, R2 = Br, R3 = H       2i:  R1 = Br, R2 = H, R3 = H      2n: R1 = NO2, R2 = H, R3 = H  
2e: R1 = Cl, R2 = H, R3 = H         2j: R1 = F, R2 = F, R3 = H         4n: R1 = H, R2 = H, R3 = NO2  
2f: R1 = Cl, R2 = Cl, R3 = H        2k: R1 = F, R2 = Br, R3 = H       5n: R1 = H, R2 = H, R3 = NO2 
 
Table 5. Cytotoxicity and antiviral activity of (E)-3-styryl-2H-chromenes 2b-n, 4n, and 
(Z)-3-styryl-2H-chromene 5n.                           
aConcentration of the compound (µΜ) that reduces the viability of MDBK cells by 50% compared to control, determined 
using the MTT method. 
bConcentration of the compound (µΜ) required to produce a 50% protection of MDBK cells by the effect of cytopathic 
BVDV, determined using the MTT method. 
cConcentration of the compound (µΜ) that reduces the viability of the monolayer of BHK cells by 50% compared to 
control, determined using the MTT method. 
O
R3
O
R3
2b-n, 4n 5n
R1
R2
R1
R2
Comp. MDBK BVDV BHK21 YFV Reo1 Vero76 HSV1 VV VSV CVB5 Sb1 RSV 
 TC50a IC50b TC50c IC50d IC50d TC50e IC50f IC50f IC50f IC50f IC50f IC50f 
2b >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
2c >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
2d >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
2e >100 >100 >100 >100 >100 80 >80 >80 >80 >80 >80 37 
2f >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
2g >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
2h >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
2i >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
2j >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
2k >100 >100 >100 >100 >100 90 >90 >90 >90 >90 >90 >90 
2l >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
2m >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
2n >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
4n >100 >100 >100 >100 >100 12 >12 >12 >12 >12 >12 >12 
5n >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
A - - - - - 60 - - - 0.004 3 - 
B - - - - - >100 0.3 - - - - - 
C - - - - - 20 - 0.8 - - -  
D - - >100 - 30 6 - - - - - 0.4 
E 47 15 >100 50 - - - - - - - - 
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dConcentration of the compound (µΜ) required to produce a 50% protection of BHK cells cytopathic effect induced by 
YFV, Reo-1, determined using the MTT method. 
eConcentration of the compound (µΜ) that reduces the viability of the cells VERO-76 by 50%, compared to the control, as 
determined by the MTT method. 
fConcentration of the compound (µM) required to produce a 50% protection of VERO-76 cells by the effect of cytopathic 
HSV-1, VV, VSV, CVB-5 Sb-1, RSV, determined using the MTT method. 
A = Pleconaril, B = Acyclovir, C = Mycophenolic acid, D = 6-Azauridine, E = Ribavirin. 
 
                 
 
 
Table 6. Cytotoxicity and antiviral activity of (E)-3-(2H-chromen-3-yl)-1-phenylprop-2-
en-1-one 2a, (E)-3-styryl-2H-chromene hromene 5a, 3-phenylethylchromans 6a and (E)-
3-(1-phenylpropen-2-yl)-2H-chromene 10. 
aConcentration of the compound (µΜ) that reduces the viability of MDBK cells by 50% compared to control, determined using 
the MTT method. 
bConcentration of the compound (µΜ) required to produce a 50% protection of MDBK cells by the effect of cytopathic 
BVDV, determined using the MTT method. 
cConcentration of the compound (µΜ) that reduces the viability of the monolayer of BHK cells by 50% compared to control, 
determined using the MTT method. 
dConcentration of the compound (µΜ) required to produce a 50% protection of BHK cells cytopathic effect induced by YFV, 
Reo-1, determined using the MTT method. 
eConcentration of the compound (µΜ) that reduces the viability of the cells VERO-76 by 50%, compared to the control, as 
determined by the MTT method. 
fConcentration of the compound (µM) required to produce a 50% protection of VERO-76 cells by the effect of cytopathic 
HSV-1, VV, VSV, CVB-5 Sb-1, RSV, determined using the MTT method. 
A = Pleconaril, B = Acyclovir, C = Mycophenolic acid, D = 6-Azauridine, E = Ribavirin  
 
 
O
O
O
2a
10
O
O
O
4a 5a
6a
Comp. MDBK BVDV BHK21 YFV Reo1 Vero76 HSV1 VV VSV CVB5 Sb1 RSV 
 TC50a IC50b TC50c IC50d IC50d TC50e IC50f IC50f IC50f IC50f IC50f IC50f 
2a >100 >100 39 >39 >39 80 >80 >80 >80 >80 >80 >80 
4a >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
5a >100 >100 >100 >100 >100 85 >85 >85 >85 >85 >85 >85 
6a >100 >100 >100 >100 >100 80 >80 >80 >80 >80 >80 >80 
10 >100 >100 >100 >100 >100 90 >90 >90 >90 >90 >90 >90 
A - - - - - 60 - - - 0.004 3 - 
B - - - - - >100 0.3 - - - - - 
C - - - - - 20 - 0.8 - - - - 
D - - >100 - 30 6 - - - - - 0.4 
E 47 15 >100 50 - - - - - - - - 
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                 13a: R1 = R2 = R3 = R4 =  H, 
                 13d: R1 = Cl, R2 = R3 = R4 = H 
                 13b: R1 = R3 = R4 = H, R2 = CF3 
                 13e: R1 = R2 = R4 = H, R3 =  CH3 
                 13c: R1 = CF3, R2 = R3 = R4 = H 
                 13f: R1 = R2 = R3 = H, R4 =  CH3 
 
Table 7. Cytotoxicity and antiviral activity of phenylalkyl-2H-chromenes 13a-f.                                              
aConcentration of the compound (µΜ) that reduces the viability of MDBK cells by 50% compared to control, determined using 
the MTT method. 
bConcentration of the compound (µΜ) required to produce a 50% protection of MDBK cells by the effect of cytopathic 
BVDV, determined using the MTT method. 
cConcentration of the compound (µΜ) that reduces the viability of the monolayer of BHK cells by 50% compared to control, 
determined using the MTT method. 
dConcentration of the compound (µΜ) required to produce a 50% protection of BHK cells cytopathic effect induced by YFV, 
Reo-1, determined using the MTT method. 
eConcentration of the compound (µΜ) that reduces the viability of the cells VERO-76 by 50%, compared to the control, as 
determined by the MTT method. 
fConcentration of the compound (µM) required to produce a 50% protection of VERO-76 cells by the effect of cytopathic 
HSV-1, VV, VSV, CVB-5 Sb-1, RSV, determined using the MTT method.  
A = Pleconaril, B = Acyclovir, C = Mycophenolic acid, D = 6-Azauridine, E = Ribavirin  
 
5.3.2. Experimental 
 
5.3.2.1. Chemistry 	  
Chemicals were purchased from Sigma-Aldrich and used 
without further purification. Melting points were determined on a 
Stanford Research Systems OptiMelt (MPA-100) apparatus and are 
uncorrected. NMR spectra were detected with a Bruker AM-400 
spectrometer, using TMS as internal standard. IR spectra were 
O
R3
R4 R1R2
Comp. MDBK BVDV BHK21 YFV Reo1 Vero76 HSV1 VV VSV CVB5 Sb1 RSV 
 TC50a IC50b TC50c IC50d IC50d TC50e IC50f IC50f IC50f IC50f IC50f IC50f 
13a >100 79 >100 60 >100 80 >80 >80 >80 >80 >80 >80 
13b 31 >31 >100 >100 >100 55 >55 >55 >55 >55 >55 >55 
13c 76 >76 80 >80 >80 75 >75 >75 >75 >75 >75 >75 
13d >100 >100 81 >81 >81 65 >65 >65 >65 >65 >65 >65 
13e >100 >100 >100 >100 >100 65 >65 >65 >65 >65 >65 >65 
13f >100 >100 >100 >100 >100 70 >70 >70 >70 >70 >70 >70 
A - - - - - 60 - - - 0.004 3 - 
B - - - - - >100 0.3 - - - - - 
C - - - - - 20 - 0.8 - - - - 
D - - >100 - 30 6 - - - - - 0.4 
E 47 15 >100 50 - - - - - - - - 
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recorded on a FT-IR PerkinElmer Spectrum 1000. All compounds 
were routinely checked by thin-layer chromatography (TLC) and 1H 
NMR. TLC was performed on silica gel or aluminium oxide 
fluorescent coated plates (Merck, Kieselgel or Aluminium oxide 60 
F254). Components were visualised by UV light. Elemental analyses 
(C, H, N, Cl, Br) of all new compounds were within ±0.4% of 
theoretical values. 
 
5.3.2.1.1. General procedure for the synthesis of the 2H-chromene-
3-carbaldehydes (1 a-n) methods A and B. 
 
Method A 
Acrolein (75 mmol) was added dropwise to a suspension of the 
appropriate 2-hydroxybenzaldehyde (50 mmol) and K2CO3 (79 mmol) 
in dry dioxane (115 mL). The mixture was refluxed for 4 h. After 
cooling, the solvent was removed under reduced pressure and the 
residue was distributed between CH2Cl2 and 2N NaOH. The organic 
phase was washed with brine, dried over anhydrous Na2SO4, filtered 
and evaporated to dryness. The residue was purified by column 
chromatography on silica gel eluting with a mixture of 
dichloromethane and light petroleum (1:1). 
 
Method B 
Acrolein (15 mmol) was added dropwise to a suspension of the 
appropriate 2-hydroxybenzaldehyde (10 mmol) and 1,4–diazabicyclo-
[2.2.2]-octane (DABCO) (8 mmol) in CHCl3 (7 mL) and water (7 mL) 
at room temperature. The mixture was stirred at room temperature and 
under nitrogen atmosphere for a week. After this period, the separated 
solid was filtered and washed with water. The organic layer was 
washed with 2N NaOH, 2N HCl, and brine, dried over Na2SO4, 
filtered and evaporated to dryness. The residue was purified as 
described in method A. 
 
5.3.2.1.1.1. 2H-Chromene-3-carbaldehyde (1a). Yield: 27% 
(method B), mp = 40-41 °C (lit 42-43 °C).7 The compound exhibited 
spectroscopic data identical to those previously reported.7 
 
5.3.2.1.1.2. 6-Bromo-2H-chromene-3-carbaldehyde (1b). Yield: 
44% (method A), 27% (method B), mp = 110-111 °C. IR (KBr): 2811, 
2708, 1665 cm-1. 1H NMR (CDCl3, 400MHz): δ (ppm) 9.59 (s, 1H, 
CHO), 7.37 (dd, 1H, H7, J7-8 = 8.4 Hz, J7-5 = 2.4 Hz), 7.33 (d, 1H, H5, 
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J7-5 = 2.4 Hz), 7.17 (s, 1H, H4), 6.78 – 6.75 (m, 1H, H8), 5.18 (s, 2H, 
H2). 
 
5.3.2.1.1.3. 6-Nitro-2H-chromene-3-carbaldehyde (1c). Yield: 1% 
(method A), 18% (method B), mp = 194-195 °C. IR (KBr): 2844, 
2741, 1673, 1505, 1338 cm-1. 1H NMR (CDCl3, 400MHz): δ (ppm) 
9.65 (s, 1H, CHO), 8.17 (dd, 1H, H7, J7-8 = 9.2 Hz, J7-5 = 2.8 Hz), 
8.13 (d, 1H, H5, J7-5 = 2.8 Hz), 7.81 (s, 1H, H4), 6.95 (d, 1H, H8, J7-8 
= 9.2 Hz), 5.38 (s, 2H, H2). 
 
5.3.2.1.1.4. 6,8-Dibromo-2H-chromene-3-carbaldehyde (1d). Yield: 
3% (method A), 30% (method B), mp = 143-144 °C. IR (KBr):  2848, 
2736, 1676 cm-1. 1H NMR (CDCl3, 400MHz): δ (ppm) 9.62 (s, 1H, 
CHO), 7.63 (d, 1H, H5, J7-5 = 2.4 Hz), 7.28 (d, 1H, H7, J7-5 = 2.4 Hz), 
7.14 (d, 1H, H4, J2-4 = 1.2 Hz), 5.14 (d, 2H, H2, J2-4 = 1.2 Hz). 
 
5.3.2.1.1.5. 8-Chloro-2H-chromene-3-carbaldehyde (1e). Yield: 6% 
(method A), 20% (method B), mp = 97-98 °C. IR (KBr): 2812, 2723, 
1668 cm-1. 1H NMR (CDCl3, 400MHz): δ (ppm) 9.61 (s, 1H, CHO), 
7.35 (dd, 1H, H5, J5-6 = 8.0 Hz, J7-5 = 1.6 Hz), 7.23 (d, 1H, H4,  J2-4 = 
1.2 Hz), 7.12 (dd, 1H, H7, J7-6 = 7.6 Hz, J7-5 = 1.6 Hz), 6.90 (dd, 1H, 
H6, J5-6 = 8.0 Hz, J7-6 = 7.6 Hz), 5.15 (d, 2H, H2, J2-4 = 1.2 Hz). 
 
5.3.2.1.1.6. 6,8-Dichloro-2H-chromene-3-carbaldehyde  (1f). Yield: 
1% (method A), 25% (method B), mp = 124-126 °C. IR (KBr): 2851, 
2723, 1678 cm-1. 1H NMR (CDCl3, 400MHz): δ (ppm) 9.62 (s, 1H, 
CHO), 7.34 (d, 1H, H7, J7-5 = 2.4 Hz), 7.16 (d, 1H, H4, J2-4 = 1.6 Hz), 
7.11 (d, 1H, H5, J7-5 = 2.4 Hz), 5.14 (d, 2H, H2, J2-4 = 1.6 Hz). 
 
5.3.2.1.1.7. 8-Bromo-6-chloro-2H-chromene-3-carbaldehyde (1g). 
Yield: 2% (method A), 40% (method B), mp = 151-153 °C. IR (KBr): 
2846, 2738 1677 cm-1. 1H NMR (CDCl3, 400MHz): δ (ppm) 9.62 (s, 
1H, CHO), 7.50 (d, 1H, J7-5 = 2.8 Hz), 7.15 (d, 1H, H5, J7-5 = 2.8 Hz), 
7.12 (s, 1H, H4), 5.15 (s, 2H, H2). 
 
5.3.2.1.1.8. 8-Chloro-6-fluoro-2H-chromene-3-carbaldehyde (1h). 
Yield: 13% (method A), 44% (method B), mp = 119-121 °C. IR 
(KBr):  2853, 2721, 1661 cm-1. 1H NMR (CDCl3, 400MHz): δ (ppm) 
9.63 (s, 1H, CHO), 7.17 (d, 1H, H4, J2-4 = 1.2 Hz), 7.12 (d, 1H, H7, 
J7-5 = 2.8 Hz), 6.87 (d, 1H, H5, J7-5 = 2.8 Hz), 5.11 (s, 2H, H2, J2-4 = 
1.2 Hz). 
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5.3.2.1.1.9. 8-Bromo-2H-chromene-3-carbaldehyde (1i). Yield: 
17% (method A), 20% (method B), mp = 110-101 °C. IR (KBr): 2811, 
2715, 1665 cm-1. 1H NMR (CDCl3, 400MHz): δ (ppm) 9.61 (s, 1H, 
CHO), 7.51 (dd, 1H, H5, J5-6 = 8.0 Hz, J7-5 = 1.2 Hz), 7.22 (d, 1H, H4, 
J2-4 = 1.2 Hz), 7.15 (dd, 1H, H7, J7-6 = 7.6 Hz, J7-5 = 1.2 Hz), 6.85 (dd, 
1H, H6, J5-6 = 8.0, Hz, J7-6 = 7.6 Hz), 5.11 (d, 2H, H2, J2-4 = 1.2 Hz). 
 
5.3.2.1.1.10. 6,8-Difluoro-2H-chromene-3-carbaldehyde  (1j). Yield: 
17% (method A), 31% (method B), mp = 91-92 °C. IR (KBr): 2853, 
2730, 1688 cm-1. 1H NMR (CDCl3, 400MHz): δ (ppm) 9.62 (s, 1H, 
CHO), 7.20 (d, 1H, H4, J2-4 = 1.2 Hz), 6.90 (s, 1H, H5), 6.76 (s, 1H, 
H7), 5.07 (s, 2H, H2, J2-4 = 1.2 Hz). 
 
5.3.2.1.1.11. 6-Bromo-8-fluoro-2H-chromene-3-carbaldehyde (1k). 
Yield: 4% (method A), 22% (method B), mp = 120-121 °C. IR (KBr): 
2841, 2730, 1684 cm-1. 1H NMR (CDCl3, 400MHz): δ (ppm) 9.61 (s, 
1H, CHO), 7.25 (dd, 1H, H5, J7-5 = 2.4 Hz), 7.18 – 7.14 (m, 2H, H4, 
H7), 5.10 (d, 2H, H2, J2-4 = 1.2 Hz). 
 
5.3.2.1.1.12. 6-Bromo-8-nitro-2H-chromene-3-carbaldehyde (1l). 
Yield: 6% (method B), mp = 222-223 °C. IR (KBr): 2848, 2739, 
1664, 1526, 1335 cm-1. 1H NMR (CDCl3, 400MHz): δ (ppm) 9.64 (s, 
1H, CHO), 8.00 (d, 1H, H5, J7-5 = 2.4 Hz), 7.54 (d, 1H, H7, J7-5 = 2.4 
Hz), 7.21 (d, 1H, H4, J2-4 = 1.2 Hz), 5.20 (d, 2H, H2, J2-4 = 1.2 Hz). 
 
5.3.2.1.1.13. 8-Bromo-6-nitro-2H-chromene-3-carbaldehyde (1m). 
Yield: 17% (method A), 5% (method B), mp = 227-228 °C. IR (KBr): 
2840, 2737, 1668, 1524, 1330 cm-1. 1H NMR (CDCl3, 400MHz): δ 
(ppm) 9.67 (s, 1H, CHO), 8.42 (d, 1H, H7, J7-5 = 2.4 Hz), 8.07 (d, 1H, 
H5, J7-5 = 2.4 Hz), 7.26 (d, 1H, H4, J2-4 = 1.2 Hz), 5.30 (s, 2H, H2, J2-4 
= 1.2 Hz). 
 
5.3.2.1.1.14. 8-Nitro-2H-chromene-3-carbaldehyde (1n). Yield: 4% 
(method A), 20% (method B), mp = 118 - 119 °C. IR (KBr): 2822, 
2720, 1683, 1519, 1337 cm-1. 1H NMR (CDCl3, 400MHz): δ (ppm) 
9.64 (s, 1H, CHO), 7.88 (dd, 1H, H5, J5-6 = 8.0 Hz, J7-5 = 1.6 Hz), 
7.43 (dd, 1H, H7, J7-6 = 7.6 Hz, J7-5 = 1.6 Hz), 7.28 (d, 1H, H4, J2-4 = 
1.2 Hz), 7.04 (dd, 1H, H6, J5-6 = 8.0 Hz, J7-6 = 7.6 Hz ), 5.20 (s, 2H, 
H2, J2-4 = 1.2 Hz). 
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5.3.2.1.2. General procedure for the synthesis of the  (E)-3-(2H-
chromen-3-yl)-1-phenylprop-2-en-1-one (2a) and  (E)-styryl-2H-
chromenes (2 b-n). 
 
A solution of diethyl (2-oxo-2-phenethyl)phosphonate or diethyl 
benzylphosphonate (11 mmol) in dry THF (30 mL) was added 
dropwise to a stirred suspension of NaH (11 mmol) in dry THF (15 
mL) under nitrogen. The mixture was stirred for 10 min at room 
temperature, then a solution of the appropriate 2H-chromene-3-
carbaldehyde (1 a-n) (10 mmol) in dry THF (15 mL) was added 
dropwise. After stirring for 20 h at room temperature, water was 
added to the mixture and THF was removed under reduced pressure. 
The solid was collected by filtration, washed with water, and 
chromatographed on silica gel, eluting with a mixture of 
dichloromethane and light petroleum (1:1). The product was further 
purified by crystallization from n-hexane. 
 
5.3.2.1.2.1. (E)-3-(2H-Chromen-3-yl)-1-phenylprop-2-en-1-one 
(2a). Yield: 72%, mp = 150-151 °C from n-hexane.  IR (KBr): 1651 
cm-1. 1H NMR (CD3OD, 400 MHz): δ (ppm) 8.04 – 8.01 (m, 2H, H2’, 
H6’), 7.65 – 7.52 (m, 4H, H3’, H4’, H5’, Hα), 7.22 – 7.16 (m, 2H, H5, 
H7), 7.10 (d, 1H, Hβ, Jα-β = 16.0 Hz), 7.00 (s, 1H, H4), 6.93 (t, 1H, 
H6, J7-6 = J5-6 = 7.2 Hz), 6.84 (d, 1H, H8, J7-8 = 8.0 Hz), 5.13 (s, 2H, 
H2). 13C NMR (CDCl3, 100 MHz): δ (ppm) 190.09, 154.66, 141.69, 
135.70, 132.80, 132.25, 131.03, 129.01, 128.65, 128.41, 128.13, 
121.96, 121.83, 120.63, 115.88, 65.28. 
 
5.3.2.1.2.2. (E)-6-Bromo-3-styryl-2H-chromene (2b). Yield: 22%, 
mp = 172-173 °C from n-hexane. IR (KBr): 1477 cm-1.1H NMR 
(CDCl3, 400 MHz): δ (ppm) 7.36 (d, 2H, H2’, H6’, J2’–3’ = 7.2 Hz), 
7.27 (t, 2H, H3’, H5’, J2’–3’ = J3’–4’ = 7.2 Hz), 7.25 (t, 1H, H4’, J3’–4’ = 
7.2 Hz), 7.10 (dd, 1H, H7, J7-8 = 8.4 Hz, J7–5 = 2.0 Hz), 7.05 (d, 1H, 
H5, J7–5 = 2.0 Hz), 6.76 (d, 1H, Hα, Jα-β = 16.8 Hz), 6.62 (d, 1H, H8, 
J7-8 = 8.4 Hz), 6.38 (d, 1H, Hβ, Jα-β = 16.8 Hz), 6.34 (s, 1H, H4), 5.01 
(s, 2H, H2). 
 
5.3.2.1.2.3. (E)-6-Nitro-3-styryl-2H-chromene (2c). Yield: 18%, mp 
= 176-177 °C from n-hexane. IR (KBr): 1488, 1336 cm-1.1H NMR 
(CDCl3, 400 MHz): δ (ppm) 8.00 (dd, 1H, H7, J7-8 = 8.8 Hz, J7-5 = 2.4 
Hz), 7.91 (d, 1H, H5, J7-5 = 2.4 Hz), 7.47–7.45 (m, 2H, H2’, H6’), 
7.39–7.35 (m, 2H, H3’, H5’), 7.31–7.27 (m, 1H, H4’), 6.88 (d, 1H, 
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H8, J7–8 = 8.8 Hz), 6.83 (d, 1H, Hα, Jα–β = 16.6 Hz), 6.52–6.47 (m, 
2H, H4, Hβ), 5.25 (s, 2H, H2). 
 
5.3.2.1.2.4. (E)-6,8-Dibromo-3-styryl-2H-chromene (2d). Yield: 
20%, mp = 145-146 °C from n-hexane. IR (KBr): 1465 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ (ppm) 7.43 (d, 2H, H2’, H6’, J2’–3’ = 7.6 Hz), 
7.41 (d, 1H, H5, J7-5 = 2.4 Hz), 7.35 (t, 2H, H3’, H5’, J2’–3’ = J3’–4’ = 
7.6 Hz), 7.27 (t, 1H, H4’, J3’–4’ = 7.6 Hz), 7.06 (d, 1H, H7, J7-5 = 2.4 
Hz), 6.81 (d, 1H, Hα, Jα-β = 16.4 Hz), 6.46 (d, 1H, Hβ, Jα-β = 16.8 Hz), 
6.37 (s, 1H, H4), 5.15 (s, 2H, H2). 
 
5.3.2.1.2.5. (E)-8-Chloro-3-styryl-2H-chromene (2e). Yield: 34%, 
mp = 130-132 °C from n-hexane. IR (KBr): 1444 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ (ppm) 7.44 (d, 2H, H2’, H6’, J2’–3’ = 7.2 Hz), 
7.34 (t, 2H, H3’, H5’, J2’–3’ = J3’–4’ = 7.2 Hz), 7.29–7.25 (m, 1H, H4’), 
7.16 (dd, 1H, H5, J5-6 = 8.0 Hz, J7-5 = 1.6 Hz), 6.93 (dd, 1H, H7, J7–6 = 
7.6 Hz, J7-5 = 1.6 Hz), 6.85 (d, 1H, Hα, Jα-β = 17.6 Hz), 6.81 (dd, 1H, 
H6, J5-6 = 8.0 Hz, J7-6 = 7.6 Hz), 6.49 (s, 1H, H4), 6.46 (d, 1H, Hβ, Jα–
β= 17.6 Hz), 5.21 (s, 2H, H2). 
 
5.3.2.1.2.6. (E)-6,8-Dichloro-3-styryl-2H-chromene (2f). Yield: 
19%, mp = 157-158 °C from n-hexane. IR (KBr): 1471 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ (ppm) 7.45 (d, 2H, H2’, H6’, J2’–3’ = 7.2 Hz), 
7.38 – 7.34 (m 2H, H3’, H5’), 7.30–7.26 (m, 1H, H4’), 7.15 (d, 1H, 
H7, J7–5 = 2.4 Hz), 6.91 (d, 1H, H5, J7-5 = 2.4 Hz), 6.84 (d, 1H, Hα, Jα-
β = 16.4 Hz), 6.49 (d, 1H, Hβ, Jα-β = 16.4 Hz), 6.41 (s, 1H, H4), 5.19 
(s, 2H, H2). 
 
5.3.2.1.2.7. (E)-8-Bromo-6-chloro-3-styryl-2H-chromene (2g). 
Yield: 23%, mp = 159-160 °C from n-hexane. IR (KBr): 1467 cm-1. 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.45 (dd, 2H, H2’, H6’, J2’–3’ = 
7.2 Hz, J2’-4’ = 1.6 Hz), 7.36 (t, 2H, H3’, H5’, J2’–3’ = J3’-4’ = 7.2 Hz), 
7.29 (m, 2H, H4’, H7), 6.95 (d, 1H, H5, J7-5 = 2.4 Hz), 6.84 (d, 1H, 
Hα, Jα-β = 16.4 Hz), 6.49 (d, 1H, Hβ, Jα-β = 16.4 Hz), 6.40 (s, 1H, H4), 
5.20 (s, 2H, H2). 
 
5.3.2.1.2.8. (E)-8-Chloro-6-fluoro-3-styryl-2H-chromene (2h). 
Yield: 24%, mp = 151-152 °C from n-hexane. IR (KBr): 1475 cm-1. 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.42 (d, 2H, H2’, H6’, J2’–3’ = 
7.6 Hz), 7.36–7.32 (m, 2H, H3’, H5’), 7.26 (s, 1H, H4’), 6.88 (m, 1H, 
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H7), 6.81 (d, 1H, Hα, Jα-β = 16.4 Hz), 6.64 (m, 1H, H5), 6.47 (d, 1H, 
Hβ, Jα-β = 16.4 Hz), 6.39 (s, 1H, H4), 5.13 (s, 2H, H2). 
 
5.3.2.1.2.9. (E)-8-Bromo-3-styryl-2H-chromene (2i). Yield: 27%, 
mp = 126-127 °C from n-hexane. IR (KBr): 1443 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ (ppm) 7.46–7.43 (m, 2H, H2’, H6’), 7.37–7.35 
(m, 2H, H3’, H5’), 7.31 (dd, 1H, H5 , J5-6 = 7.4 Hz, J7-5 = 1.6 Hz), 
7.29–7.24 (m, 1H, H4’), 7.05 (s, 1H, H4), 6.97 (dd, 1H, H7, J7–6 = 7.6 
Hz, J7-5 = 1.6 Hz), 6.86 (d, 1H, Hα, Jα-β = 16.4 Hz), 6.78–6.74 (m, 1H, 
H6), 6.48 (d, 1H, Hβ, Jα–β = 16.4 Hz), 5.21 (s, 2H, H2). 
 
5.3.2.1.2.10. (E)-6,8-Difluoro-3-styryl-2H-chromene (2j). Yield: 
20%, mp = 148-149 °C from n-hexane. IR (KBr): 1488 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ (ppm) 7.47–7.44 (m, 2H, H2’, H6’), 7.38 – 7.34 
(m, 2H, H3’, H5’), 7.30–7.26 (m, 1H, H4’), 6.84 (d, 1H, Hα, Jα–β = 
16.4 Hz), 6.72 – 6.66 (m, 1H, H5), 6.59–6.56 (m, 1H, H7), 6.51 (d, 
1H, Hβ, Jα-β = 16.4 Hz), 6.45 (s, 1H, H4), 5.12 (d, 2H, H2). 
 
5.3.2.1.2.11. (E)-6-Bromo-8-fluoro-3-styryl-2H-chromene (2k). 
Yield: 24%, mp = 162-163 °C from n-hexane. IR (KBr): 1481 cm-1. 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.45 – 7.43 (m, 2H, H2’, H6’), 
7.38–7.34 (m, 2H, H3’, H5’), 7.30–7.26 (m, 1H, H4’), 7.07 (m, 1H, 
H7), 6.95 (d, 1H, H5, J7-5 = 1.6 Hz), 6.83 (d, 1H, Hα, Jα-β = 16.8 Hz), 
6.49 (d, 1H, Hβ, Jα-β = 16.8 Hz), 6.43 (d, 1H, H4), 5.15 (s, 2H, H2). 
 
5.3.2.1.2.12. (E)-6-Bromo-8-nitro-3-styryl-2H-chromene (2l). 
Yield: 11%, mp = 180-181 °C from n-hexane. IR (KBr): 1515, 1336 
cm-1. 1H NMR (CDCl3, 400 MHz): δ (ppm) 7.81 (d, 1H, H5, J7-5 = 2.4 
Hz), 7.47–7.44 (m, 2H, H2’, H6’), 7.39–7.34 (m, 2H, H3’, H5’), 7.32 
(d, 1H, H7, J7-5 = 2.4 Hz), 7.30–7.28 (m, 1H, H4’), 6.84 (d, 1H, Hα, 
Jα-β = 16.4 Hz), 6.53 (d, 1H, Hβ, Jα-β = 16.4 Hz), 6.46 (s, 1H, H4), 
5.27 (s, 2H, H2). 
 
5.3.2.1.2.13. (E)-8-Bromo-6-nitro-3-styryl-2H-chromene (2m). 
Yield: 8%, mp = 172-173 °C from n-hexane. IR (KBr): 1511, 1338 
cm-1. 1H NMR (CDCl3, 400 MHz): δ (ppm) 8.16 (d, 1H, H7, J7-5 = 2.8 
Hz), 7.78 (d, 1H, H5, J7-5 = 2.8 Hz), 7-40-7.37 (m, 2H, H2’, H6’), 
7.31–7.27 (m, 2H, H3’, H5’), 7.25–7.21 (m, 1H, H4’), 6.78 (d, 1H, 
Hα, Jα-β = 16.0 Hz), 6.44 (d, 1H, Hβ, Jα-β = 16.0 Hz), 6.42 (s, 1H, H4), 
5.29 (s, 2H, H2). 
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5.3.2.1.2.14. (E)-8-Nitro-3-styryl-2H-chromene (2n). Yield: 7%, mp 
= 185-186 °C from n-hexane. IR (KBr): 1547, 1337 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ (ppm) 7.68 (dd, 1H, H5, J5-6 = 8.0 Hz, J7-5 = 1.6 
Hz), 7.46–7.43 (m, 2H, H2’, H6’), 7.38 – 7.33 (m, 2H, H3’, H5’), 
7.30–7.26 (m, 1H, H4’), 7.21 (dd, 1H, H7, J7-6 = 7.6 Hz, J7-5 = 1.6 
Hz), 6.93 (dd, 1H, H6, J7-6 = 7.6 Hz, J5-6 = 8.0 Hz), 6.84 (d, 1H, Hα, 
Jα-β = 16.4 Hz), 6.53 (d, 1H, H4), 6.50 (d, 1H, Hβ, Jα-β = 16.4 Hz), 
5.25 (s, 2H, H2). 
 
5.3.2.1.3. General procedure for the synthesis of the 
benzyltriphenylphosphonium bromides (3 b-m and 3o). 	  
Triphenylphosphine hydrobromide (20 mmol) was added to a 
solution of the appropriate benzyl alcohol (20 mmol) in dry CH3CN 
(47 mL). The obtained solution was refluxed for 5 h, while stirring. 
After this period, the mixture was cooled and Et2O was added. The 
white solid was filtered and used for the next reaction without further 
purification. 
 
5.3.2.1.3. (2-Trifluoromethylbenzyl)triphenylphosphonium 
bromide (3b). Yield: 73%, mp > 200 °C. 1H NMR (DMSO D6, 400 
MHz): δ (ppm) 7.96 - 7.92 (m, 1H, H3), 7.81-7.70 (m, 3H, H4, H5, 
H6), 7.68-7.54 (m, 15H, 3H2’ - H6’), 7.43-7.41 (m, 1H, H2), 5.17 (d, 
2H, CH2, JC- P  = 15.2 Hz). 
 
5.3.2.1.3.2. (3-Trifluoromethylbenzyl)triphenylphosphonium 
bromide (3c). Yield: 75%, mp > 200 °C. 1H NMR (DMSO D6, 400 
MHz): δ (ppm) 7.94-7.91 (m, 3H, H4, H5, H6), 7.79 - 7.51 (m, 15H, 
3H2’ - H6’), 7.43-7.41 (m, 1H, H2), 5.40 (d, 2H, CH2, JC- P  = 16.4 
Hz). 
 
5.3.2.1.3.3. (4-Trifluoromethylbenzyl)triphenylphosphonium  
bromide (3d). Yield: 58%, mp > 200 °C. 1H NMR (DMSO D6, 400 
MHz): δ (ppm) 7.94-7.91 (m, 4H, H2, H3, H5, H6), 7.77-7.71 (m, 
15H, 3H2’ -H6’), 5.40 (d, 2H, CH2, JC-P  = 16.4 Hz ). 
 
5.3.2.1.3.4. (2,4-Dichlorobenzyl)triphenylphosphonium bromide 
(3e). Yield: 45%, mp > 200 °C. 1H NMR (DMSO D6, 400 MHz): δ 
(ppm) 7.93 (m, 1H, H3), 7.78-755 (m, 15H, 3H2’- H6’), 7.40-7.37 (m, 
2H, H5, H6), 5.22 (d, CH2, JC–P = 14.5 Hz). 
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5.3.2.1.3.5. (3,5-Dichlorobenzyl)triphenylphosphonium bromide 
(3f). Yield: 55%, mp > 200 °C. 1H NMR (DMSO D6, 400 MHz): δ 
(ppm) 7.94 (s, 1H, H4) 7.81-7.72 (m, 15H, 3H2’ - H6’), 7.65–7.62 (m, 
2H, H2’, H6’), 5.35 (d, CH2, JC–P = 14.5 Hz). 
 
5.3.2.1.3.6. (2,6-Dichlorobenzyl)triphenylphosphonium bromide 
(3g). Yield: 80%, mp > 200 °C. 1H NMR (DMSO D6, 400 MHz): δ 
(ppm) 7.76-7.74 (m, 3H, H3, H4, H5), 7.73-7.64 (m, 15H, 3H2’ - 
H6’), 5.17 (d, CH2, JC–P = 14.4 Hz). 
 
5.3.2.1.3.7. (2-Chlorobenzyl)triphenylphosphonium bromide (3h). 
Yield: 84%, mp > 200 °C. 1H NMR (DMSO D6, 400 MHz): δ (ppm) 
7.93 (m, 3H, 3H4’), 7.78-7.65 (m, 12H, 3H2’, 3H3’, 3H5’, 3H6’), 
7.63–7.54 (m, 4H, H3, H4, H5, H6), 5.23 (d, CH2, JC–P = 14.8 Hz). 
 
5.3.2.1.3.8. (3-Chlorobenzyl)triphenylphosphonium bromide (3i). 
Yield: 68%, mp > 200 °C. 1H NMR (DMSO D6, 400 MHz): δ (ppm) 
7.9 –7.91 (m, 3H, 3H4’), 7.79-7.69 (m, 12H, 3H2’, 3H3’, 3H5’, 
3H6’), 7.39-7.29 (m, 3H, H4, H5, H6), 6.90 (s, 1H, H2), 5.26 (d, CH2, 
JC–P = 16.0 Hz). 
 
5.3.2.1.3.9. (4-Chlorobenzyl)triphenylphosphonium bromide (3j). 
Yield: 73%, mp > 200 °C. 1H NMR (DMSO D6, 400 MHz): δ (ppm) 
7.92–7.89 (m, 3H, 3H4’), 7.77-7.67 (m, 12H, 3H2’, 3H3’, 3H5’, 
3H6’), 7.41-7.33 (m, 3H, H4, H5, H6), 6.88 (s, 1H, H2), 5.28 (d, CH2, 
JC–P = 16.2 Hz). 
 
5.3.2.1.3.10. (2-Bromobenzyl)triphenylphosphonium bromide 
(3k). Yield: 86%, mp > 200 °C. 1H NMR (DMSO D6, 400 MHz): δ 
(ppm) 7.92 (s, 3H, 3H4’), 7.73-7.63 (m, 12H, 3H2’, 3H3’, 3H5’, 
3H6’), 7.56 (d, 1H, H3, J2-3 = 7.6 Hz),  7.31-7.19 (m, 3H, H4, H5, 
H6),  5.23 (d, CH2, JC–P = 14.8 Hz). 
 
5.3.2.1.3.11. (3-Bromobenzyl)triphenylphosphonium bromide (3l). 
Yield: 60%, mp > 200 °C. 1H NMR (DMSO D6, 400 MHz): δ (ppm) 
7.94–7.90 (m, 3H, 3H4’), 7.76-7.68 (m, 12H, 3H2’, 3H3’, 3H5’, 
3H6’), 7.51 (t, 1H, H5, J4-5 = J5-6 = 7.6 Hz), 7.31-7.19 (m, 3H, H4, 
H5, H6), 5.25 (d, CH2, JC–P = 15.6 Hz). 
 
5.3.2.1.3.12. (4-Bromobenzyl)triphenylphosphonium bromide 
(3m). Yield: 80%, mp > 200 °C. 1H NMR (DMSO D6, 400 MHz): δ 
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(ppm) 7.94–7.90 (m, 3H, 3H4’), 7.77-7.70 (m, 12H, 3H2’, 3H3’, 
3H5’, 3H6’), 7.46 (d, 2H, H3, H5, J2-3 = J5-6 = 8.0 Hz),  6.93 (d, 2H, 
H2, H6, J2-3 = J5-6 = 8.0 Hz), 4.92 (d, CH2, JC–P = 14.8 Hz). 
 
5.3.2.1.3.14. (2-Hydroxybenzyl)triphenylphosphonium bromide 
(3o). Yield: 80%, mp > 200 °C. 1H NMR (DMSO D6, 400 MHz): δ 
(ppm) 9.74 (s, 1H, OH), 7.91-7.87 (m, 4H, H3, H4, H5, H6), 7.74-
7.64 (m, 15H, 3H2’ - H6’), 4.92 (d, CH2, JC–P = 14.8 Hz). 
 
5.3.2.1.4. General procedure for the synthesis of the 3-styryl-2H-
chromenes (4a-n, 5a, 5e-f, 5i, 5l-n). 
 
tert-BuOK (40 mmol) was added to a solution of the appropriate 
benzyltriphenylphosphonium halide (3a-n) (20 mmol) in dry THF (86 
mL) at room temperature. After 10 minutes, a solution of 2H-
chromen-3-carbaldehyde (20 mmol) (1a) in dry THF (87 mL) was 
added dropwise. The mixture was stirred for 24 h at room 
temperature, under nitrogen. After this period, ice and water was 
added and the mixture was neutralized with 2N HCl.  The obtained 
suspension was extracted with CHCl3.  The organic layer was washed 
with brine, dried over anhydrous Na2SO4, filtered and evaporated to 
dryness. The obtained E/Z-mixtures (4/5a, 4/5e-f, 4/5i, 4/5l-n) were 
separated by column chromatography on silica gel eluting with CHCl3 
and light petroleum (1:3). The (Z) isomer was eluted at first. For 
compounds (4b-d, 4g-h, 4j-k) only the E isomers were purified by 
column chromatography on silica gel eluting with a mixture of 
dichloromethane and light petroleum (1:1). 
 
5.3.2.1.4.1. (E)-3-Styryl-2H-chromene (4a). Yield: 47%, mp = 122-
124 °C from n-hexane. IR (KBr): 1670 cm-1. 1H NMR (CDCl3, 400 
MHz): δ (ppm) 7.44 (d, 2H, H2’, H6’, J2’–3’ = 7.6 Hz), 7.34 (t, 2H, 
H3’, H5’, J2’–3’ = J3’–4’ = 7.6 Hz), 7.25 (t, 1H, H4’, J3’–4’ = 7.6 Hz), 
7.11 (dt, 1H, H7, J7–6 = J7–8 = 7.5 Hz,  J7-5 = 1.5 Hz), 7.03 (dd, 1H, 
H5, J5–6 = 7.5 Hz,  J7-5 = 1.5 Hz), 6.91–6.81 (m, 3H, H6, H8, Hβ), 
6.52 (s, 1H, H4), 6.44 (d, 1H, Hα, Jα–β = 16.5 Hz), 4.83 (d, 2H, H2). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 153.8, 137.0, 130.7, 129.1, 
128.8, 128.0, 127.9, 127.0, 126.6, 126.4, 124.0, 122.8, 121.5, 115.5, 
65.6. 
 
5.3.2.1.4.2. (Z)-3-Styryl-2H-chromene (5a). Resa: 0.60%. thick oil. 
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IR (KBr): 1600 cm-1. 1H-NMR (CDCl3, 400 MHz): δ (ppm) 7.32-7.22 
( m, 5H, H2’, H3’, H4’, H5’, H6’), 7.08 (dt, 1H, H7, J7-6  = J7-8  = 8.0 
Hz, J7-5 = 1.6 Hz ), 7.00 (dd, 1H, H5, J5-6 = 8.0 Hz, J7-5  = 1.6 Hz), 6.86 
(t, 1H, H6, J7-6 = J5-6 = 8.0 Hz), 6.75 (d, 1H, H8, J7-8 = 8.0 Hz ), 6.6 (d, 
1H, Hβ, Jα-β  = 12.0 Hz), 6.49 (s, 1H, H4), 6.23 (d, 1H, Hα, Jα-β  = 12.0 
Hz ), 5.08 (s, 2H, H2). 13C NMR (CDCl3, 100 MHz): δ (ppm): 153.77, 
138.25, 131.43, 130.96, 129.06, 128.66, 128.21, 128.16, 127.48, 
126.74, 125.56, 123.29, 121.55, 115.49, 67.00. 
 
5.3.2.1.4.3. (E)-3-[2-(Trifluoromethyl)styryl]-2H-chromene (4b). 
Yield: 24%, mp = 84–86 °C from n-hexane. IR (KBr): 1620 cm-1. 1H 
NMR (CDCl3, 400 MHz): δ (ppm) 7.87 (d, 1H, H3’, J3’-4’ = 7.6 Hz), 
7.70 (d, 1H, H6’, J6’-5’ = 8.0 Hz), 7.62 (t, 1H, H4’, J3’-4’ = J4’-5’ = 7.6 
Hz), 7.44 (dd, 1H, H5’, J6’-5’ = 8.0 Hz, J4’-5’ = 7.6 Hz), 7.15-7.09 (m, 
2H, H7, H5), 7.03 (d, Hβ,  Jα-β = 16.0 Hz), 6.88 (t, 1H, H6, J6-7 = J6-5 = 
7.6 Hz), 6.84-6.80 (m, 2H, H8, Hα), 6.71 (s, 1H, H4), 5.09 (s, 2H, 
H2). 13C NMR (CDCl3, 100 MHz): δ (ppm) 153.98, 136.02, 131.93, 
130.42, 130.37, 129.61, 127.36, 127.21 (q, J = 28 Hz), 127.20, 
126.69, 126.06 (q, J = 5.7 Hz), 125.66, 124.46 (q, J = 272 Hz), 
123.36, 122.49, 121.58, 115.67, 65.47. 
 
5.3.2.1.4.4. (E)-3-[3-(Trifluoromethyl)styryl]-2H-chromene (4c). 
Yield: 17%, mp = 103–105 °C from n-hexane. IR (KBr): 1596 cm-1. 
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.64 (s, 1H, H2’), 7.53 (d, 1H, 
H6’, J6’-5’ = 7.6 Hz), 7.46 (d, 1H, H4’, J4’-5’ = 7.6 Hz), 7.39 (t, 1H, H5’, 
J4’-5’ = J5’-6’ = 7.6 Hz), 7.11 (m, 1H, H7, J6-7 = J7-8 = 8.0 Hz, J5-7 = 1.2 
Hz), 7.03 (dd, 1H, H5, J5-6 = 7.6 Hz, J5-7 = 1.2 Hz), 6.88-6.80 (m, 3H, 
H6, H8, Hα), 6.52 (s, 1H, H4), 6.37 (d, 1H, Hβ, Jα-β = 16.4 Hz), 5.04 
(s, 2H, H2). 13C NMR (CDCl3, 100 MHz): δ (ppm) 153.87, 137.80, 
131.19 (q, J = 31.7 Hz), 130.13, 129.53, 129.41, 129.17, 128.31, 
127.16, 126.23, 125.31, 124.18 (q, J = 3.6 Hz), 124.14 (q, J = 271 
Hz), 122.99 (q, J = 3.7 Hz), 122.52, 121.62, 115.58, 65.47. 
 
5.3.2.1.4.5. (E)-3-[4-(Trifluoromethyl)styryl]-2H-chromene (4d). 
Yield: 26%, mp = 156–157 °C from n-hexane. IR (KBr): 1607 cm-1.  
1H NMR (CDCl3, 400 MHz): δ (ppm) 7.53 (m, 4H, H2’, H3’, H5’, 
H6’), 7.10–7.04 (m, 1H, H7, J6-7 = 7.2 Hz, J7-8 = 8.0 Hz, J5-7 = 0.8 Hz), 
7.03 (dd, 1H, H5, J5-6 = 6.4 Hz, J5-7 = 0.8 Hz), 6.88 (m, 2H, H6, Hα), 
6.83 (d, 1H, H8, J7-8 = 8.0 Hz),  6.56 (s, 1H, H4), 6.4 (d, 1H, Hβ, Jα-β = 
16.4 Hz), 5.07 (s, 2H, H2). 13C NMR (CDCl3, 100 MHz): δ (ppm) 
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153.91, 140.47, 130.14, 129.59, 129.44 (q, J = 32 Hz), 128.98, 
127.16, 126.46, 126.26, 125.69, 125.62 (q, J = 6.6 Hz), 124.86 (q, J = 
280 Hz), 122.48, 121.61, 115.58, 65.49. 
 
5.3.2.1.4.6. (E)-3-(2,4-Dichlorostyryl)-2H-chromene (4e). Yield: 
47%, mp = 129–135 °C from n-hexane. IR (KBr): 1595 cm-1.  1H 
NMR (CDCl3, 400 MHz): δ (ppm) 7.49 (d, 1H, H6’, J5’-6’ = 8.4 Hz), 
7.35 (d, 1H, H3’, J3’-5’ = 2.0 Hz), 7.19 (dd, 1H, H5’, J5’-6’ = 8.4 Hz, J3’-
5’ = 2.0 Hz), 7.11 (t, 1H, H7, J7-6 = 7.6  Hz), 7.01 (d, 1H, H5, J5-6 = 7.6 
Hz), 6.87 (d, 1H, H6, J5-6 = J7-6 = 7.6 Hz), 6.82 (d, 1H, H8, J7-8 = 7.6 
Hz),  6.77 (d, 1H, Hα, Jα-β = 16.4 Hz), 6.52 (s, 1H, H4), 6.69 (d, 1H, 
Hβ, Jα-β = 16.4 Hz), 5.07 (s, 2H, H2). 13C NMR (CDCl3, 100 MHz): δ 
(ppm) 153.95, 133.86, 133.78, 130.40, 129.65, 129.60, 129.39, 
128.71, 127.36, 127.16, 126.82, 125.58, 122.58, 122.47, 121.58, 
115.64, 65.47. 
 
5.3.2.1.4.7. (Z)-3-(2,4-Dichlorostyryl)-2H-chromene (5e). Yield: 
31%, thick oil. IR (KBr): 1609 cm-1. 1H NMR (CDCl3, 400 MHz): δ 
(ppm) 7.41 (d, 1H, H3’, J3’-5’ = 2.0 Hz), 7.19–7.07 (m, 3H, H5’, H6’, 
H7), 6.98 (d, 1H, H5, J5-6 = 7.6 Hz), 6.87 (t, 1H, H6, J5-6 = J7-6 = 7.6 
Hz), 6.74 (d, 1H, H8, J7-8 = 8.0 Hz),  6.50 (s, 1H, H4), 6.46 (d, 1H, 
Hβ, Jα-β = 12.0 Hz), 6.36 (d, 1H, Hβ, Jα-β = 12.0 Hz), 4.37 (s, 2H, H2). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 153.69, 135.26, 134.17, 
134.14, 131.42, 130.41, 130.32, 129.50, 129.13, 126.96, 126.81, 
126.31, 125.57, 122.91, 121.68, 115.55, 66.78. 
 
5.3.2.1.4.8. (E)-3-(3,5-Dichlorostyryl)-2H-chromene (4f). Yield: 
75%, mp = 131–134 °C from n-hexane. IR (KBr): 1597 cm-1.  1H 
NMR (CDCl3, 400 MHz): δ (ppm) 7.24 – 7.22 (m, 2H, H2’, H6’), 
7.18 (s, 1H, H4’), 711 (t, 1H,  H7,  J7-6  = J7-8 = 7.2 Hz), 7.01 (d, 1H, 
H5, J5-6 = 7.2 Hz), 6.87 (t, 1H, H6, J5-6 = J7-6 = 7.2 Hz), 6.82–6.76 (m, 
2H, H8, Hβ),  6.51 (s, 1H, H4), 6.21 (d, 1H, Hα, Jα-β = 16.4 Hz), 5.01 
(s, 2H, H2). 13C NMR (CDCl3, 100 MHz): δ (ppm) 153.89, 140.06, 
135.29, 129.82, 129.73, 129.19, 127.36, 127.26,125.96, 124.97, 
124.61, 122.37, 121.65, 115.62, 65.35. 
 
5.3.2.1.4.9. (Z)-3-(3,5-Dichlorostyryl)-2H-chromene (5f). Yield: 
6%, mp = 45–47 °C from n-hexane. IR (KBr): 1596 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ (ppm) 7.62 (s, 1H, H5’), 7.13–7.09 (m, 3H, H2’, 
H6’,  H7), 7.01 (d, 1H, H5, J5-6 = 8.0 Hz), 6.88 (t, 1H, H6, J7-6 = J5-6 = 
8.0 Hz), 6.77 (d, 1H, H8, J7-8 = 8.0 Hz), 6.53 (s, 1H, H4), 6.42 (d, 1H, 
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Hα, Jα-β = 12.0 Hz), 6.28 (d, 1H, Hβ, Jα-β  = 12.0 Hz), 4.41 (s, 2H, H2). 
13C NMR (CDCl3, 100 MHz): δ (ppm) 153.76, 141.18, 134.75, 
130.43, 130.69, 129.58, 128.57, 128.44, 127.41, 127.23, 126.99, 
126.93, 121.72, 115.60, 66.84. 
 
5.3.2.1.4.10. (E)-3-(2,6-Dichlorostyryl)-2H-chromene (4g). Yield: 
23%, mp = 107–108 °C from n-hexane. IR (KBr): 1597 cm-1.  1H 
NMR (CDCl3, 400 MHz): δ (ppm) 7.28 (d, 2H, H3’, H5’, J2’-3’ = 8.0 
Hz), 7.10 (t, 1H, H7, J7-6  = J7-8  = 7.6 Hz), 7.05–6.98 (m 2H, H4’, 
H5’), 6.91 – 6.81 (m, 3H, H6, H8, Hα), 6.49 (s, 1H, H4), 6.40 (d, 1H, 
Hβ, Jα-β = 16.8 Hz), 5.09 (s, 2H, H2). 13C NMR (CDCl3, 100 MHz): δ 
(ppm) 153.97, 134.83, 134.41, 134.16, 130.12, 129.61, 128.71, 
128.21, 127.25, 125.73, 122.47, 121.81, 121.58, 115.62, 65.30. 
 
5.3.2.1.4.11. (E)-3-(2-Chlorostyryl)-2H-chromene (4h). Yield: 30%, 
mp = 101–102 °C from n-hexane. IR (KBr): 1610 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ (ppm) 7.54 (d, 1H, H3’, J3’-4’ = 7.6 Hz), 7.32 (d, 
1H, H6’, J6’-5’ = 8.0 Hz), 7.18 (t, 1H, H4’, J3’-4’ = J4’-5’ = 7.6 Hz), 7.13 
(m, 2H, H7, H5’), 6.98 (d, 1H, H5, J5-6 = 6.8 Hz), 6.86-6.80 (m, 4H, 
H6, H8, Hα, Hβ), 6.46 (s, 1H, H4), 5.05 (s, 2H, H2). 13C NMR 
(CDCl3, 100 MHz): δ (ppm) 153.83, 134.90, 133.30, 130.56, 129.82, 
129.34, 128.85, 128.58, 127.02, 126.86, 126.07, 124.99, 123.63, 
122.50, 121.44, 115.52, 65.47. 
 
5.3.2.1.4.12. (E)-3-(3-Chlorostyryl)-2H-chromene (4i). Yield: 21%, 
mp = 61–63 °C from n-hexane. IR (KBr): 1681 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ (ppm) 7.36 (s, 1H, H2’), 7.18 (m, 3H, H6’, H5’, 
H4’), 7.08 (t, 1H, H7, J7-6 = J7-8 = 8.0 Hz), 7.03 (d, 1H, H5, J5-6 = 7.2 
Hz), 6.87–6.73 (m, 3H, H6, H8, Hβ), 6.45 (s, 1H, H4), 6.26 (d, 1H, 
Hα, Jα-β = 16.4 Hz), 5.00 (s, 2H, H2). 13C NMR (CDCl3, 100 MHz): δ 
(ppm) 153.85, 138.90, 134.74, 130.27, 129.96, 129.47, 127.94, 
127.70, 127.16, 126.38, 126.23, 125.03, 124.71, 122.61, 121.63, 
115.60, 65.50. 
 
5.3.2.1.4.13. (Z)-3-(3-Chlorostyryl)-2H-chromene (5i). Yield: 4%, 
thick oil. IR (KBr): 1681 cm-1. 1H NMR (CDCl3, 400 MHz): δ (ppm) 
7.53 (m, 3H, H2’, H4’, H5’), 7.09 (m, 2H, H7, H6’), 6.98 (d, 1H, H5, 
J5-6 = 7.6 Hz), 6.86 (t, 1H, H6, J5-6 = J7-6 = 7.6 Hz), 6.75 (d, 1H, H8, 
J7-8 = 8.0 Hz),  6.48 (m, 2H, H4, Hα), 6.4 (d, 1H, Hβ, Jα-β = 12.0 Hz), 
4.40 (s, 2H, H2). 13C NMR (CDCl3, 100 MHz): δ (ppm) 153.71, 
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140.01, 134.05, 130.68, 129.35, 129.30, 129.01, 128.59, 127.48, 
126.84, 126.72, 126.40, 123.02, 121.61, 115.51, 66.85. 
 
5.3.2.1.4.14. (E)-3-(4-Chlorostyryl)-2H-chromene (4j). Yield: 40%, 
mp = 166–167 °C from ethyl acetate (lit 167-168 °C).8 The compound 
exhibited spectroscopic data identical to those previously reported.8 
 
5.3.2.1.4.15. (E)-3-(2-Bromostyryl)-2H-chromene (4k). Yield: 11%, 
mp = 83–84 °C from n-hexane. IR (KBr): 1596 cm-1. 1H NMR 
(acetoneD, 400 MHz): δ (ppm) 7.77 (d, 1H, H3’, J3’-4’ = 7.6 Hz), 7.62 
(d, 1H, H6’, J5’-6’ = 7.6 Hz), 7.38 (t, 1H, H5’, J4’-5’ = J5’-6’ = 7.6 Hz), 
7.19 (t, 1H, H4’, J4’-5’ = J3’-4’ = 7.6 Hz),  7.14–7.11 (m, 2H, H7, H5), 
7.02 (d, 1H, Hα, Jα-β = 16.8 Hz), 6.91 – 6.80 (m, 3H, H6, H8, Hβ), 
6.72 (s, 1H, H4), 5.13 (s, 2H, H2). 13C NMR (CDCl3, 100 MHz): δ 
(ppm) 153.91, 136.69, 133.19, 130.65, 129.45, 129.14, 128.97, 
127.61, 127.09, 126.54, 126.40, 125.08, 124.18, 122.60, 121.56, 
115.62, 65.57. 
 
5.3.2.1.4.16. (E)-3-(3-Bromostyryl)-2H-chromene (4l). Yield: 24%, 
mp = 138–139 °C from n-hexane. IR (KBr): 1594 cm-1.  1H NMR 
(CDCl3, 400 MHz): δ (ppm) 7.55 (s, 1H, H2’), 7.35 – 7.29 (m, 2H, 
H4’, H6’), 7.16 (t, 1H, H5’, J4’-5’ = J5’-6’ = 8.0 Hz), 7.10 (t, 1H, H7, J7-
6 = J7-8 = 7.6 Hz), 7.01 (d, 1H, H5, J5-6 = 7.6 Hz), 6.87 (t, 1H, H6, , J5-6 
= J7-6 = 7.6 Hz ), 6.88–6.77 (m, 2H, H8, Hβ),  6.49 (s, 1H, H4), 6.29 
(d, 1H, Hα Jα-β = 16.4 Hz), 5.03 (s, 2H, H2). 13C NMR (CDCl3, 100 
MHz): δ (ppm) 153.79, 139.15, 130.53, 130.19, 130.16, 129.40, 
129.11, 127.93, 127.06, 126.22, 125.04, 124.98, 122.94, 122.53, 
121.55, 115.52, 65.44. 
 
5.3.2.1.4.17. (Z)-3-(3-Bromostyryl)-2H-chromene (5l). Yield: 5%, 
thick oil. IR (KBr): 1681 cm-1.  1H NMR (CDCl3, 400 MHz): δ (ppm) 
7.35 (s, 1H, H2’), 7.16–7.13  (m, 3H, H4’, H5’, H6’), 7.11 (t, 1H, H7, 
J7-6 = J7-8 = 7.6 Hz), 7.00 (d, 1H, H5, J5-6 = 7.6 Hz), 6.87 (t, 1H, H6, 
J5-6 = J7-6 = 7.6 Hz), 6.76 (d, 1H, H8, J7-8 = 7.6 Hz),  6.51–6.48 (m, 
2H, H4, Hα), 6.4 (d, 1H, Hβ, Jα-β = 11.6 Hz), 4.41 (s, 2H, H2). 13C 
NMR (CDCl3, 100 MHz): δ (ppm) 153.73, 140.34, 131.51, 130.69, 
130.42, 129.63, 129.41, 129.32, 128.94, 127.16, 126.86, 126.45, 
123.04, 122.27, 121.63, 115.53, 66.91. 
 
5.3.2.1.4.18. (E)-3-(4-Bromostyryl)-2H-chromene (4m). Yield: 
30%, mp = 185–186 °C from n-hexane. IR (KBr): 1609 cm-1. 1H 
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NMR (CDCl3, 400 MHz): δ (ppm) 7.45 (d, 2H, H3’, H5’, J2’-3’ = 8.4 
Hz), 7.29 (d, 2H, H2’, H6’, J2’-3’ = 8.4 Hz), 7.11 (t, 1H, H7, J7-6 = J7-8 
= 7.6 Hz), 7.03 (d, 1H, H5, J5-6 = 7.2 Hz), 6.90–6.81 (m, 3H, H6, H8, 
Hα),  6.52 (s, 1H, H4), 6.35 (d, 1H, Hβ, Jα-β = 16.4 Hz), 5.06 (s, 2H, 
H2). 13C NMR (CDCl3, 100 MHz): δ (ppm) 153.78, 135.93, 131.87, 
130.39, 129.33, 127.84, 127.28, 127.00, 126.62, 124.60, 122.64, 
121.58, 115.53, 65.49. 
 
5.3.2.1.4.19. (Z)-3-(4-Bromostyryl)-2H-chromene (5m). Yield: 
18%, mp = 76–77 °C from n-hexane. IR (KBr): 11591 cm-1.  1H NMR 
(CDCl3, 400 MHz): δ (ppm) 7.43 (d, 2H, H3’, H5’, J2’-3’ = 8.4 Hz), 
7.10–7.05 (m, 3H, H2’, H6’, H7), 6.97 (d, 1H, H5, J5-6 = 7.2 Hz), 6.88 
(t, 1H, H6, J7-6 = J5-6 = 7.2 Hz), 6.75 (d, 1H, H8, J7-8 = 8.0 Hz), 6.48 – 
6.44  (m, 2H, H4, Hα), 6.21 (d, 1H, Hβ, Jα-β = 12.0 Hz), 4.42 (s, 2H, 
H2). 13C NMR (CDCl3, 100 MHz): δ (ppm) 153.65, 136.96, 131.28, 
130.77, 130.22, 129.42, 129.24, 128.74, 126.79, 125.98, 123.03, 
121.60, 121.48, 115.51, 66.83. 
 
5.3.2.1.4.20. (E)-3-(4-Nitrostyryl)-2H-chromene (4n). Yield: 36%, 
mp = 174-175 °C from n-hexane. IR (KBr): 1504, 1332 cm-1. 1H 
NMR (CDCl3, 400 MHz): δ (ppm) 8.20 (d, 2H, H3’, H5’, J2’-3’ = 8.8 
Hz), 7.55 (d, 2H, H2’, H6’, J2’-3’ = 8.8 Hz), 7.17 – 7.13 (m, 1H, H7), 
7.00 (dd, 1H, H5, J5-6 = 7.6 Hz, J7-5 = 1.6 Hz), 6.97 (d, 1H, Hα, Jα-β = 
16.4 Hz), 6.92–6.88 (m, 1H, H6, J7-6 = J5-6 = 7.6 Hz, J6-8 = 1.2 Hz), 
6.84 (dd, 1H, H8, J7-8 = 7.6 Hz, J6-8 = 1.2 Hz), 6.63 (s, 1H, H4), 6.50 
(d, 1H, Hβ, Jα-β = 16.4 Hz), 5.09 (s, 2H, H2). 13C NMR (CDCl3, 100 
MHz): δ (ppm) 154.06, 146.87, 143.49, 130.95, 130.04, 129.89, 
127.41, 127.03, 126.74, 125.40, 124.20, 122.32, 121.74, 115.70, 
65.34. 
 
5.3.2.1.4.21. (Z)-3-(4-Nitrostyryl)-2H-chromene (5n). Yield: 8%, 
mp = 120-121 °C from n-hexane. IR (KBr): 1506, 1343 cm-1. 1H 
NMR (CDCl3, 400 MHz): δ (ppm) 8.17 (d, 2H, H3’, H5’, J2’-3’ = 8.8 
Hz), 7.40 (d, 2H, H2’, H6’, J2’-3’ = 8.8 Hz), 7.13–7.11 (m, 1H, H7), 
6.99 (dd, 1H, H5, J5-6 = 7.6 Hz, J7-5 = 1.6 Hz), 6.90–6.86 (m, 1H, H6, 
J7-6 = J5-6 = 7.6 Hz, J6-8 = 1.2 Hz), 6.76 (dd, 1H, H8, J7-8 = 7.6 Hz, J6-8 
= 1.2 Hz), 6.55-6.52 (m, 2H, H4, Hα), 6.36 (d, 1H, Hβ, Jα-β = 12.0 
Hz), 4.43 (s, 2H, H2). 13C NMR (CDCl3, 100 MHz): δ (ppm) 153.74, 
146.90, 144.85, 130.94, 129.76, 129.44, 128.24, 127.25, 127.09, 
124.17, 123.51, 122.75, 121.81, 115.66, 66.84.  
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5.3.2.1.5. General procedure for the synthesis of the 3-
phenethylchromans (6a-m). 
 
10% Pd/C (15.2 mmol) was added to a solution of the 
appropriate (E)-3-styryl-2H-chromene (4b-d, 4g-h,  4j-k) or to a 
mixture of E, Z isomers  (4/5a, 4/5e-f, 4/5i,  4/5l-m (10 mmol) in dry 
dioxane (80 mL). The suspension was hydrogenated at room 
temperature for 30 minutes, under 40 psi pressure. After this period, 
the catalyst was filtered off and the solvent was removed under 
reduced pressure. The residue was chromatographed on silica gel 
eluting with a mixture of CHCl3/light petroleum (1:1). The obtained 
solid was further purified by crystallization from n-hexane (6a-m). 
 
5.3.2.1.5.1. 3-Phenethylchroman (6a). Yield: 69%, mp = 42–43 °C 
from n-hexane. IR (KBr): 1607 cm-1. 1H NMR (CDCl3, 400 MHz): δ 
(ppm) 7.28 - 7.24 (m, 2H, H3’, H5’), 7.19-7.15 (m, 3H, H2’, H6’, 
H4’), 7.08-7.00 (m, 2H, H6, H5), 6.84 - 6.77 (m, 2H, H8, H7), 4.20 
(m, 1H, H2, Jgem = 10.8 Hz, J2-3 = 9.2 Hz), 3.76 (dd, 1H, H2, Jgem = 
10.8 Hz, J2-3 = 9.2 Hz), 2.88 (dd, 1H, H4, Jgem = 16.2 Hz, J3-4 = 5.2 
Hz), 2.78-2.66 (m, 2H, Hβ), 2.49 (m, 1H, H4), 2.07-1.97 (m, 1H, H3), 
1.75-1.56 (m, 2H, Hα). 13C NMR (CDCl3, 100 MHz): δ (ppm) 154.67, 
141.84, 129.88, 128.45, 128.32, 127.23, 125.96, 121.57, 120.25, 
116.44, 70.38, 33.50, 33.03, 31.67, 31.49. 
 
5.3.2.1.5.2. 3-[2-(Trifluoromethyl)phenethyl]chroman (6b). Yield: 
76%, mp = 42–44 °C from n-hexane. IR (KBr): 1608 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ (ppm) 7.58 (d, 1H, H3’, J3’-4’ = 7.6 Hz), 7.40 (t, 
1H, H5’, J4’-5’ = J5’-6’ = 7.6 Hz ), 7.27 (d, 1H, H6’, J5’-6’ = 7.6 Hz), 7.23 
(t, 1H. H4’, J4’-5’ = J5’-6’ = 7.6 Hz), 7.07–7.00 (m, 2H, H6, H5), 6.83-
6.78 (m, 2H, H8, H7), 4.20 (d, 1H, H2, Jgem = 10.8 Hz), 3.74 (d, 1H, 
H2, Jgem = 10.8 Hz), 2.93-2.78 (m, 3H, H4, 2Hβ), 2.48 (dd, 1H, H4, 
Jgem = 16 Hz, J3-4 = 9.6 Hz), 2.07 -2.0 (m, 1H, H3), 1.71-1.57 (m, 2H, 
2Hα).13C NMR (CDCl3, 100 MHz): δ (ppm) 154.69, 140.85, 131.85, 
130.93, 129.94, 128.39 (q, J = 29.5 Hz), 127.29, 126.10, 126.02 (q, J 
= 5.7 Hz), 124.76 (q, J = 272.2 Hz), 121.46, 120.34, 116.50, 70.21, 
33.91, 32.35, 31.41, 30.04. 
 
5.3.2.1.5.3. 3-[3-(Trifluoromethyl)phenethyl]chroman (6c). Yield: 
65%, mp = 43–45 °C from n-hexane. IR (KBr): 1610 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ (ppm) 7.44-7.43 (m, 2H, H2’, H5’), 7.40-7.36 
(m, 2H, H6’, H4’), 7.08 (t, 1H, H7, J7-8 = J7-6 = 7.2 Hz), 7.03 (d, 1H, 
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H5, J5-6 = 7.6 Hz), 6.85-6.79 (m, 2H, H6, H8), 4.21 (m, 1H, H2, Jgem = 
10.4 Hz, J2-3 = 2.8 Hz), 3.79 (m, 1H, H2, Jgem = 10.4 Hz, J2-3 = 2.8 
Hz), 2.90 (dd, 1H, H4, Jgem = 16.0 Hz, J3-4 = 4.8 Hz), 2.84-2.72 (m, 
2H, 2Hβ), 2.51 (dd, 1H, H4, Jgem = 16.0 Hz, J3-4 = 9.2 Hz), 2.07-1.98 
(m, 1H, H3), 1.78-1.66 (m, 2H, 2Hα). 13C NMR (CDCl3, 100 MHz): δ 
(ppm) 154.61, 142.79, 131.75, 130.84 (q, J = 31.7 Hz), 129.93, 
128.89, 127.34, 124.97 (q, J = 3.9 Hz), 124.21 (q, J = 271.7 Hz), 
122.92 (q, J = 3.4 Hz), 121.33, 120.40, 116.51, 70.17, 33.27, 32.93, 
31.81, 31.40. 
 
5.3.2.1.5.4. 3-[4-(Trifluoromethyl)phenethyl]chroman (6d). Yield: 
67%, mp = 43–45 °C from n-hexane. IR (KBr): 1617 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ (ppm) 7.51 (d, 2H, H3’, H5’, J2’-3’ = 8.0 Hz), 
7.27 (d, 2H, H2’, H6’, J2’-3’ = 8.0 Hz), 7.07 (t, 1H, H7, J7-8 = J7-6 = 7.6 
Hz), 7.02 (d, 1H, H5, J5-6 = 7.2 Hz), 6.85-6.79 (m, 2H, H6, H8), 4.21 
(m, 1H, H2, Jgem = 10.4 Hz, J2-3 = 3.2 Hz), 3.76 (d, 1H, H2, Jgem = 10.4 
Hz), 2.89 (dd, 1H, H4, Jgem = 16.0 Hz, J3-4 = 4.8 Hz), 2.81-2.69 (m, 
2H, Hβ), 2.48 (dd, 1H, H4, Jgem = 16.0 Hz, J3-4 = 9.2 Hz), 2.03-1.95 
(m, 1H, H3), 1.74 - 1.63 (m, 2H, Hα). 13C NMR (CDCl3, 100 MHz): δ 
(ppm) 154.62, 146.03, 129.95, 128.67, 128.39 (q, J = 32.2 Hz), 
127.35, 125.39 (q, J = 3.6 Hz), 124.45  (q, J = 270.1 Hz), 121.35, 
120.40, 116.51, 70.15, 33.14, 32.98, 31.68, 31.38. 
 
5.3.2.1.5.5. 3-(2,4-Dichlorophenethyl)chroman (6e). Yield: 84%, 
mp = 53–54 °C from n-hexane. IR (KBr): 1605 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ (ppm) 7.31 (d, 1H, H3’, J3’-5’ = 1.6 Hz), 7.16– 
6.99 (m, 4H, H5’, H6’, H5, H7), 6.83 – 6.77 (m, 2H, H6, H8), 4.20 (d, 
1H, H2, Jgem = 10.8 Hz), 3.75 (t, 1H, H2, Jgem = J2-3 = 9.2 Hz), 2.87 
(dd, 1H, H4, Jgem = 16.4 Hz, J3-4 = 4.8 Hz), 2.83 - 2.69 (m, 2H, Hβ), 
2.49 (m, 1H, H4, Jgem = 16.4 Hz, J3-4 = 9.2 Hz), 2.03-1.98 (m, 1H, 
H3), 1.68 - 1.55 (m, 2H, Hα). 13C NMR (CDCl3, 100 MHz): δ (ppm) 
154.68, 138.16, 134.58, 132.47, 131.01, 129.97, 129.39, 127.36, 
127.22, 121.43, 120.42, 116.56, 70.24, 32.01, 31.81, 31.48, 30.43. 
 
5.3.2.1.5.6. 3-(3,5-Dichlorophenethyl)chroman (6f). Yield: 75%, mp 
= 51–52 °C from n-hexane. IR (KBr): 1583 cm-1.  1H NMR (CDCl3, 
400 MHz): δ (ppm) 7.17 (s, 1H, H4’), 7.09-7.01 (m, 4H, H2’, H6’, 
H5, H7), 6.85–6.78 (m, 2H, H6, H8), 4.20 (d, 1H, H2, Jgem = 10.8 Hz), 
3.77 (d, 1H, H2, Jgem = 10.8 Hz, J2-3 = 8.8 Hz), 2.88 (dd, 1H, H4, Jgem 
= 16.0 Hz, J3-4 = 4.8 Hz), 2.72-2.60 (m, 2H, Hβ), 2.49 (m, 1H, H4, 
Jgem = 16.0 Hz, J3-4 = 8.8 Hz), 2.02-1.98 (m, 1H, H3), 1.73-1.55 (m, 
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2H, Hα). 13C NMR (CDCl3, 100 MHz): δ (ppm) 154.57, 145.23, 
134.91, 129.94, 127.39, 126.88, 126.31, 121.19, 120.45, 116.54, 
70.05, 32.91, 32.62, 31.70, 31.35. 
 
5.3.2.1.5.7. 3-(2,6-Dichlorophenethyl)chroman (6g). Yield: 91%, 
mp  = 51–52 °C from n-hexane. IR (KBr): 1609 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ (ppm) 7.22 (d, 2H, H3’, H5’, J3’-4’ = 8.0 Hz), 
7.07-6.97 (m, 3H, H5, H7, H4’), 6.83 – 6.78 (m, 2H, H6, H8), 4.27–
4.24 (m, 1H, H2, Jgem = 10.8 Hz, J2-3 = 9.2 Hz), 3.75 (t, 1H, H2, Jgem = 
J2-3 = 10.0 Hz ), 3.06-2.95 (m, 2H, Hβ),  2.90 (dd, 1H, H4, Jgem = 17.2 
Hz, J3-4 = 4.8 Hz), 2.49 (m, 1H, H4, Jgem = 16.0 Hz, J3-4 = 9.6 Hz), 
2.09–2.05 (m, 1H, H3), 1.65-1.53 (m, 2H, Hα). 13C NMR (CDCl3, 100 
MHz): δ (ppm) 154.58, 137.80, 135.10, 129.81, 128.14, 127.61, 
127.17, 121.47, 120.20, 116.39, 70.22, 32.30, 31.34, 30.16, 28.68. 
 
5.3.2.1.5.8. 3-(2-Chlorophenethyl)chroman (6h). Yield: 58%, mp = 
48–49 °C from n-hexane. IR (KBr): 1609 cm-1. 1H NMR (CDCl3, 400 
MHz): δ (ppm) 7.31 (d, 1H, H3’, J2’-3’ = 7.6 Hz), 7.19- 7.00 (m, 5H, 
H4’, H5’, H6’, H5, H7), 6.83 – 6.78 (m, 2H, H6, H8), 4.22 (m, 1H, 
H2, Jgem = 10.0 Hz, J2-3 = 9.0 Hz), 3.76 (t, 1H, H2, Jgem =  J2-3 = 10.0 
Hz), 2.92-277 (m, 3H, H4, 2Hβ), 2.50 (m, 1H, H4, Jgem = 16.0 Hz, J3-4 
= 9.6 Hz), 2.05-2.14 (m, 1H, H3), 1.71 - 1.59 (m, 2H, Hα). 13C NMR 
(CDCl3, 100 MHz): δ (ppm) 154.72, 139.55, 133.94, 130.30, 129.97, 
129.65, 127.55, 127.31, 126.95, 121.60, 120.35, 116.52, 70.39, 32.01, 
31.98, 31.53, 30.93. 
 
5.3.2.1.5.9. 3-(3-Chlorophenethyl)chroman (6i). Yield: 63%, mp = 
52–53 °C from n-hexane. IR (KBr): 1598 cm-1. 1H NMR (CDCl3, 400 
MHz): δ (ppm) 7.17–7.13 (m, 3H, H6’, H5, H7), 7.07– 6.98 (m, 3H, 
H4’, H5’, H2’), 6.82–6.77 (m, 2H, H6, H8), 4.17 (d, 1H, H2, Jgem = 
10.4 Hz), 3.72 (t, 1H, H2, Jgem = 10.8 Hz, J2-3 = 9.2 Hz), 2.88 (dd, 1H, 
H4, Jgem = 16.0 Hz, J3-4 = 4.4 Hz), 2.70-2.58 (m, 2H, Hβ), 2.49 (m, 
1H, H4, Jgem = 16.0 Hz, J3-4 = 9.2 Hz ), 1.98-1.96 (m, 1H, H3), 1.69-
1.57 (m, 2H, Hα). 13C NMR (CDCl3, 100 MHz): δ (ppm) 154.72, 
144.02, 134.32, 130.02, 129.81, 128.54, 127.40, 126.65, 126.29, 
121.48, 120.44, 116.59, 70.26, 33.27, 32.81, 31.75, 31.48. 
 
5.3.2.1.5.10. 3-(4-Chlorophenethyl)chroman (6j). Yield: 83%, mp  = 
41–42 °C from n-hexane. IR (KBr): 1581 cm-1. 1H NMR (CDCl3, 400 
MHz): δ (ppm) 7.20 (d, 2H, H3’, H5’, J2’-3’ = 8.4 Hz), 7.07–6.99 (m, 
4H, H2’, H6’, H5, H7), 6.82–6.77 (m, 2H, H6, H8), 4.17–4.14 (m, 1H, 
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H2), 3.76 (dd, 1H, H2, Jgem = 10.4 Hz, J2-3 = 9.2 Hz), 2.88 (dd, 1H, 
H4, Jgem = 16.4 Hz, J3-4 = 4.8 Hz), 2.70-2.58 (m, 2H, Hβ), 2.49 (m, 
1H, H4, Jgem = 16.4 Hz, J3-4 = 9.2 Hz ), 2.01-1.91 (m, 1H, H3), 1.68-
1.58 (m, 2H, Hα). 13C NMR (CDCl3, 100 MHz): δ (ppm) 154.53, 
140.21, 131.58, 129.84, 129.60, 128.46, 127.22, 121.34, 120.26, 
116.40, 70.12, 33.25, 32.29, 31.52, 31.32. 
 
5.3.2.1.5.11. 3-(2-Bromophenethyl)chroman (6k). Yield: 30%, mp = 
53–54 °C from n-hexane. IR (KBr): 1590 cm-1.  1H NMR (CDCl3, 400 
MHz): δ (ppm) 7.41 - 7.36 (m, 3H, H3’, H5’, H7’), 7.19-7.15 (m, 3H, 
H4’, H6’, H5), 7.12-7.08 (m, 2H, H6, H8), 4.20 (m, 1H, H2, Jgem = 
10.8 Hz, J2-3 = 9.2 Hz), 3.79 (dd, 1H, H2, Jgem = 10.8 Hz, J2-3 = 9.2 
Hz), 2.89 (dd, 1H, H4, Jgem = 16.2 Hz, J3-4 = 5.2 Hz), 2.81-2.69 (m, 
2H, Hβ), 2.51 (m, 1H, H4, Jgem = 16.0 Hz, J3-4 = 8.8 Hz ), 2.04-1.99 
(m, 1H, H3), 1.77-1.59 (m, 2H, Hα). 13C NMR (CDCl3, 100 MHz): δ 
(ppm) 154.66, 141.22, 132.94, 130.23, 129.93, 128.48, 128.35, 
127.77, 127.57, 127.28, 120.32, 116.48, 70.38, 33.50, 32.12, 31.99, 
31.50. 
 
5.3.2.1.5.12. 3-(3-Bromophenethyl)chroman (6l). Yield: 13%, mp = 
54–55 °C from n-hexane. IR (KBr): 1582 cm-1. 1H NMR (CDCl3, 400 
MHz): δ (ppm) 7.35-7.31 (m, 2H, H4’, H5’), 7.14-7.02 (m, 4H, H2’, 
H6’, H5, H7), 6.85–6.78 (m, 2H, H6, H8), 4.20 (m, 1H, H2, Jgem = 
10.4 Hz), 3.79 (t, 1H, H2, Jgem = J2-3 = 9.2 Hz), 2.89 (dd, 1H, H4, Jgem 
= 16.4 Hz, J3-4 = 4.8 Hz), 2.76-2.64 (m, 2H, Hβ), 2.50 (m, 1H, H4, 
Jgem = 16.0 Hz, J3-4 = 9.2 Hz), 2.04-2.02 (m, 1H, H3), 1.74-1.62 (m, 
2H, Hα). 13C NMR (CDCl3, 100 MHz): δ (ppm) 154.59, 144.20, 
131.37, 130.01, 129.91, 129.14, 128.46, 128.33, 127.31, 127.01, 
120.36, 116.48, 70.20, 33.22, 32.73, 31.66, 31.40. 
 
5.3.2.1.5.13. 3-(4-Bromophenethyl)chroman (6m). Yield: 30%, mp 
= 59–60 °C from n-hexane. IR (KBr): 1605 cm-1.  1H NMR (CDCl3, 
400 MHz): δ (ppm) 7.38 (d, 2H, H3’, H5’, J2’-3’ = 8.4 Hz), 7.09-7.01 
(m, 4H, H2’, H6’, H4’, H5, H7), 6.84–6.77 (m, 2H, H6, H8), 4.20 (d, 
1H, H2, Jgem = 10.4 Hz), 3.77 (t, 1H, H2, Jgem = 10.8 Hz, J2-3 = 9.2 
Hz), 2.89 (dd, 1H, H4, Jgem = 16.0 Hz, J3-4 = 4.8 Hz), 2.74 - 2.62 (m, 
2H, Hβ), 2.49 (m, 1H, H4, Jgem = 16.0 Hz, J3-4 = 8.8 Hz), 2.02–2.01 
(m, 1H, H3), 1.73-1.55 (m, 2H, Hα). 13C NMR (CDCl3, 100 MHz): δ 
(ppm) 154.59, 140.77, 131.50, 130.06, 129.87, 127.28, 121.37, 
120.32, 119.70, 116.46, 70.21, 33.26, 32.47, 31.63, 31.41. 
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5.3.2.1.6. 1-(2H-Chromen-3-yl)ethanone (7). 
 
3-buten-2-one (40 mmol) was added dropwise to a suspension 
of 2-hydroxybenzaldehyde (20 mmol) and 1,4–diazabicyclo-[2.2.2]-
octane (DABCO) (20 mmol) in CHCl3 (14 mL) and H2O (14 mL) at 
room temperature. The mixture was stirred at room temperature and 
under nitrogen atmosphere for a week. After this period, the separated 
solid was filtered and washed with water. The organic layer was 
washed with 2N NaOH, 2N HCl and brine, dried over anhydrous 
Na2SO4, filtered and evaporated to dryness. The obtained solid was 
purified by column chromatography on silica gel eluting with a 
mixture of chloroform/light petroleum (1:1). Yield: 46%. mp = 44–45 
°C IR (KBr): 1637 cm-1. 1H-NMR (CDCl3, 400 MHz): δ (ppm) 7.30 
(d, 1H, H4, J2-4 = 1.6 Hz ), 7.27-7.23 (m, 1H, H5), 7.16 (m, 1H, H7, 
J7-8 = 8.0 Hz, J7-6 = 7.6 Hz, J7-5 = 1.6 Hz), 6.93 (7, 1H, H6, J5-6 = J7-6 = 
7.6 Hz), 6.85 (d, 1H, H8, J7-8 = 8.0 Hz ), 5.00 (s, 2H, H2, J2-4 = 1.6 
Hz), 2.40 (s, 3H, CH3). 13C NMR (CDCl3, 100 MHz): δ (ppm) 194.65, 
154.43, 132.72, 131.29, 129.56, 128.10, 120.65, 119.63, 115.13, 
63.10, 23.80. 
 
5.3.2.1.7. 1-(2H-Chromen-3-yl)ethanol (8).  
 
A solution of NaBH4 (10 mmol) in 2N NaOH (5 mL) is added, 
in a single portion, to a stirred solution of 3-acetyl-2H-chromene in 
dry EtOH (50 mL).  After stirring at room temperature for 2 hours, the 
solvent was evaporated to dryness under vacuum and the residue was 
taken up with H2O and extracted with Et2O. The organic phase was 
washed with brine,	  dried over anhydrous sodium sulfate, filtered and 
evaporated to dryness. The white oil was used for the next reaction 
without further purification. Yield: 89%, oil. 1H-NMR (CDCl3, 400 
MHz): δ (ppm) 7.08 (m, 1H, H7, J7-8 = J7-6 = 8.0 Hz, J5-7 = 1.6 Hz), 
6.96 (dd, 1H, H5, J6-5 = 7.6 Hz, J5-7 = 1.6 Hz) , 6.85 (m, 1H, H6,  J6-5 
= 7.6 Hz, J7-6 = 8.0 Hz, J6-8 = 1.2 Hz), 6.78 (dd, 1H, H8 J7-8 = 8.0 Hz, 
J6-8 = 1.2 Hz), 6.32 (s, 1H, H4), 4.76 (s, 2H, H2), 4.36 (q, 1H, CH, 
JCH–CH3 = 6.4 Hz), 2.12 (s, 1H, OH), 1.34 (d, 3H, CH3, JCH-CH3 = 6.4 
Hz). 13C NMR (CDCl3, 100 MHz): δ (ppm) 153.55, 137.48, 128.98, 
126.75, 122.49, 121.49, 118.46, 115.54, 68.62, 65.51, 21.30. 
 
5.3.2.1.8.           [1-(2H-Chromen-3-yl)ethyl]triphenylphosphonium  
bromide (9). 
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Triphenylphosphine hydrobromide (10 mmol) was added at 
room temperature to a solution of the 1-(2H-chromen-3-yl)ethanol (8) 
(10 mmol) in dry CH3CN (24 mL). The reaction mixture was refluxed 
for 5 h. After cooling to room temperature, Et2O was added. The 
white precipitate was filtered and used for the next reaction without 
further purification. Yield: 45%. Mp > 200 °C 1H-NMR (CD3OD, 400 
MHz): δ (ppm) 7.96-7.88 (m, 3H, 3H4’), 7.81-7.7 (m, 6H, 3H3’, 
3H5’), 7.61-7.54 (m, 6H, 3H2’, 3H6’), 7.17-7.13 (m, 1H, H5), 6.89 - 
6.84 (m, 1H, H7), 6.80-6.75 (m, 1H, H6), 6.24 (m, 1H, H8), 4.91-4.83 
(m, 1H, H4), 4.44-4.26 (m, 2H, H2), 3.32-3.30 (m, 1H, CH), 1.75 -
169 (m, 3H, CH3). 
 
5.3.2.1.9. (E)-3-(1-Phenylprop-1-en-2-yl)-2Hchromene (10). 
 
tert-BuOK (10 mmol) was added to a suspension of [1-(2H-
chromen-3-yl)ethyl]triphenylphosphonium bromide (9) (10 mmol) in 
dry THF (43 mL) at room temperature. After 30 minutes, a solution 
of benzaldehyde (10 mmol) in dry THF (45 mL) was added dropwise. 
The mixture was stirred for 24 h at room temperature under nitrogen. 
After this period, ice and water was added and the mixture was 
neutralized with 2N HCl. The obtained suspension was extracted with 
CHCl3 and the organic layer was washed with brine, dried over 
anhydrous Na2SO4, filtered and evaporated to dryness. The obtained 
solid was chromatographed on silica gel eluting with a mixture of 
CHCl3/light petroleum (1:1), and further purified by crystallization 
from n-hexane. Yield: 24%, mp = 56–57 °C from n-hexane. 1H-NMR 
(CDCl3, 400 MHz): δ (ppm) 7.36-7.33 (m, 2H, H2’, H6’), 7.29-7.21 
(m, 3H, H3’, H5’, H4’), 7.11 (m, 1H, H7, J7-6 = J7-8 = 8.0 Hz, J7-5 = 
1.6 Hz), 7.04 (dd, 1H, H5, J5-6 = 8.0 Hz, J7-5 = 1.6 Hz), 6.88 (t, 1H, 
H6, J7-6 = J5-6 = 8.0 Hz), 6.83 (d, 1H, H8, J7-8 = 8.0 Hz) 6.61 (s, 1H, 
H4), 6.45 (s, 1H, Hβ), 5.10 (s, 2H, H2), 2.19 (s, 3H, CH3). 13C NMR 
(CDCl3, 100 MHz): δ (ppm): 153.54, 137.71, 133.44, 133.24, 129.40, 
128.96, 128.17, 127.13, 126.79, 126.47, 122.91, 121.46, 120.41, 
115.35, 66.48, 14.88. 
 
5.3.2.1.10. General procedure for the synthesis of the 1-
bromomethylphenylalkyl-2-ones (12a-i).  
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Oxalyl chloride (23 mmol) was added dropwise to a solution of 
the appropriate phenylalkyl acid (11 a-i) (10 mmol) in dry CH2Cl2 
(18.5 mL) cooled at 0 °C. After complete addition, the mixture was 
stirred at room temperature for 3 h. After this period, the mixture was 
evaporated to dryness and the obtained phenylalkyl acyl chloride was 
used for the next reaction without further purification. 2N 
trimethylsilyldiazomethane in dry Et2O (27.3 mL) was added 
dropwise to a solution of the appropriate phenylalkyl acyl chloride (10 
mmol) in dry CH3CN (13.5 mL) cooled at 0 °C. After stirring at 0 °C 
for 2 h, 48% aqueous HBr (15.3 mL) was added dropwise to the 
mixture cooled at 0°C. After complete addition, the mixture was 
stirred at room temperature overnight, then diluted with water and 
extracted with ethyl acetate. The organic layer was washed with brine 
and NaHCO3 solution, then dried over Na2SO4, filtered and 
evaporated to dryness. The residue was purified by column 
chromatography on silica gel eluting with a mixture of ethyl 
acetate/light petroleum (1:2). 
 
5.3.2.1.10.1. 1-Bromo-4-phenylbutan-2-one (12a). Yield: 72%, mp 
= 43–44 °C. IR (KBr): 1718 cm-1. 1H-NMR (CDCl3, 400 MHz): δ 
(ppm) 7.32-7.27 (m, 2H, H3’, H5’), 7.22-7.17 (m, 3H, H2’, H4’, H6’), 
3.84 (s, 2H, 2H1), 2.98-2.94 (m, 4H, 2H3, 2H4). 13C NMR (CDCl3, 
100 MHz): δ (ppm): 200.63, 136.23, 130.29, 128.96, 128.60, 40.82, 
33.85, 27.10. 
 
5.3.2.1.10.2. 1-Bromo-4-[2-(trifluoromethyl)phenyl]butan-2-one 
(12b). Yield: 69%, mp = 42–43 °C IR (KBr): 1718 cm-1. 1H-NMR 
(CDCl3, 400 MHz): δ (ppm) 7.60 (d, 1H, H3’, J3’-4’ = 7.6 Hz), 7.46 (t, 
1H, H5’, J4’-5’ = J5’-6’ = 7.6 Hz), 7.34-7.27 (m, 2H, H4’, H6’), 3.90 (s, 
2H, 2H1), 3.10 (t, 2H, 2H3, J3-4 = 7.6 Hz), 2.97 (m, 2H, 2H4, J3–4 = 
7.6 Hz, J4–6’ = 1.6 Hz). 13C NMR (CDCl3, 100 MHz): δ 199.34, 
138.06, 130.98, 130.04, 127.30 (q, J = 29.5 Hz), 125.45, 124.50 (q, J 
= 5.7 Hz), 123.50 (q, J = 272.0 Hz), 40.21, 33.02, 25.59. 
 
5.3.2.1.10.3. 1-Bromo-4-[4-(trifluoromethyl)phenyl]butan-2-one 
(12c). Yield: 88%, mp = 43–44 °C. IR (KBr): 1717 cm-1. 1H-NMR 
(CDCl3, 400 MHz): δ (ppm) 7.53 (d, 2H, H3’, H5’, J2’-3’ = 8.0 Hz), 
7.30 (d, 2H, H2’, H6’ J2’-3’ = 8.0 Hz), 3.86 (s, 2H, 2H1), 3.01-2.99 (m, 
4H, 2H3, 2H4). 13C NMR (CDCl3, 100 MHz): δ (ppm): 200.70, 
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144.80, 128.87, 128.68 (q, J = 32.1 Hz), 125.55 (q, J = 3.8 Hz), 
124.44 (q, J = 270.2 Hz), 40.81, 34.30, 29.55. 
 
5.3.2.1.10.4. 1-Bromo-4-(4-chlorophenyl)butan-2-one (12d). Yield: 
82%, mp = 47–48 °C. IR (KBr): 1719 cm-1. 1H-NMR (CDCl3, 400 
MHz): δ (ppm) 7.26-7.24 (m, 2H, H3’, H5’), 7.13-7.11 (m, 2H, H2’, 
H6’), 3.84 (s, 2H, 2H1), 2.99-2.89 (m, 4H, 2H3, 2H4). 13C NMR 
(CDCl3, 100 MHz): δ (ppm): 200.86, 138.75, 132.13, 129.68, 128.66, 
41.10, 34.03, 29.10. 
 
5.3.2.1.10.5. 1-Bromo-3-methyl-4-phenylbutan-2-one (12e). Yield: 
75%, mp = 48–49 °C. IR (KBr): 1713 cm-1. 1H-NMR (CDCl3, 400 
MHz): δ (ppm) 7.24 (t, 2H, H3’, H5’, J2’-3’ = J3’-4’ = 7.6 Hz), 7.16 (t, 
1H, H4’, J4’-5’ = J3’-4’ = 7.6 Hz), 7.10 (d, 2H, H2’, H6’, J2’-3’ = 7.6 Hz), 
3.77-3.68 (m, 2H, 2H1), 3.14-3.07 (m, 1H, H4), 2.95-2.90 (m, 1H, 
H3), 2.61-2.56 (m, 1H, H4), 1.09 (d, 3H, CH3, JCH3-H = 6.8 Hz). 13C 
NMR (CDCl3, 100 MHz): δ (ppm) 204.95, 139.01, 128.89, 128.63, 
126.60, 45.68, 39.73, 34.31, 16.94. 
 
5.3.2.1.10.6. 1-Bromo-4-methyl-4-phenylbutan-2-one (12f). Yield: 
76%, mp = 46–47 °C. IR (KBr): 1718 cm-1. 1H-NMR (CDCl3, 400 
MHz): δ (ppm) 7.26 (m, 2H, H3’, H5’, J2’-3’ = J3’-4’ = 7.6 Hz J3’-5’ = 
1.6 Hz), 7.19-7.14 (m, 3H, H2’, H4’, H6’), 3.70 (m, 2H, 2H1), 3.32-
3.27 (m, 1H, H4), 2.93-2.79 (m, 2H, 2H3), 1.25 (d, 3H, CH3, JCH3–H = 
6.8 Hz). 13C NMR (CDCl3, 100 MHz): δ  (ppm) 200.50, 145.44, 
128.55, 126.66, 126.45, 47.93, 35.46, 34.95, 21.79. 
 
5.3.2.1.10.7. 1-Bromo-5-phenylpentan-2-one (12g). Yield: 30%, mp 
= 51–50 °C. IR (KBr): 1715 cm-1. 1H-NMR (CDCl3, 400 MHz): δ 
(ppm) 7.30–7.26 (m, 2H, H3’, H5’), 7.10–7.14 (m, 3H, H2’, H6’, 
H4’), 3.83 (s 2H, 2H1), 2.66–2.61 (m, 4H, 2H3, 2H5), 1.98–1.91 (m, 
2H, 2H4). 13C NMR (CDCl3, 100 MHz) : δ (ppm) 201.74, 141.19, 
128.46, 126.08, 125.97, 51.46, 35.11, 34.24, 25.23. 
 
5.3.2.1.10.8. 1-Bromo-6-phenylhexan-2-one (12h). Yield: 58%, mp 
= 48–49 °C. IR (KBr): 1715 cm-1. 1H-NMR (CDCl3, 400 MHz): δ 
(ppm) 7.20–7.18 (m, 2H, H3’, H5’), 7.12–7.08 (m, 3H, H2’, H6’, 
H4’), 3.73 (s, 2H, 2H’), 2.54–2.45 (m, 4H, 2H3, 2H6), 1.57–1.48 (m, 
4H, 2H4, 2H5). 13C NMR (CDCl3, 100 MHz): δ  (ppm) 201.25, 
141.93, 128.63, 125.69, 48.23, 39.28, 35.47, 30.55, 23.27. 
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5.3.2.1.10.9. 1-Bromo-7-phenylheptan-2-one (12i). Yield: 47%, mp 
= 47–48 °C. IR (KBr): 1717 cm-1. 1H-NMR (CDCl3, 400 MHz): δ 
(ppm) 7.23-7.17 (m, 2H, H3’, H5’), 7.15–7.13 (m, 3H, H2’, H6’, 
H4’), 3.82 (s, 2H, 2H1), 2.61–2.57 (m, 4H, 2H3, 2H7), 1.66–1.57 (m, 
4H, 2H4, 2H6), 1.36–1.28 (m, 2H, 2H5). 13C NMR (CDCl3, 100 
MHz): δ  (ppm) 201.95, 142.35, 128.34, 128.24, 125.66, 39.61, 35.64, 
34.35, 31.09, 28.54, 23.61. 
 
5.3.2.1.11. General procedure for the synthesis of the phenylalkyl-
2H-chromenes (13a-i).  
 
Method A 
A solution of EtONa prepared from Na (20 mmol) in dry EtOH 
(27 mL) was added dropwise to a solution of (2-
hydroxybenzyl)triphenylphosphonium bromide (3o) (10 mmol) in dry 
EtOH (30 mL) at room temperature. After stirring for 30 minutes, a 
solution of the appropriate bromomethyl-phenylketone (12a, d) (5 
mmol) in dry EtOH (23 mL) was added dropwise. The mixture was 
stirred at room temperature overnight, water was added and EtOH was 
removed under reduced pressure. The remaining mixture was 
extracted with CH2Cl2. The organic layer was washed with brine, 
dried over anhydrous Na2SO4, filtered and evaporated to dryness. The 
solid products was chromatographed on silica gel eluting with a 
mixture of CHCl3/light petroleum (1:1) and further purified by 
crystallization from n-hexane. 
 
Method B 
tert-BuOK (10 mmol) was added to a solution of (2-
hydroxybenzyl)triphenylphosphonium bromide (3o) (10 mmol) in dry 
THF (43 mL) at room temperature. After 10 minutes, a solution of the 
appropriate bromomethylphenylketone (12b-c, 12e-i) (10 mmol) in 
dry THF (44 mL) was added dropwise. After 2 h, a new portion of 
tert-BuOK (10 mmol) was added and the mixture was stirred for 24 h 
at room temperature under nitrogen. After this period, ice and water 
were added and the mixture was neutralized and extracted with 
CHCl3. The organic layer was washed with brine, dried over 
anhydrous Na2SO4, filtered and evaporated to dryness. The solid 
products was chromatographed on silica gel eluting with a mixture of 
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CHCl3/light petroleum (1:1) and further purified by crystallization by 
n-hexane. 
 
5.3.2.1.11.1. 3-Phenethyl-2H-chromene (13a). Yield: (Method A) 
22%, mp = 39–40 °C from n-hexane. IR (KBr): 1604 cm-1. 1H-NMR 
(CDCl3, 400 MHz): δ (ppm) 7.29-7.16 (m, 2H, H3’, H5’), 7.21-7.17 
(m, 3H, H2’, H6’, H4’), 7.06 (m, 1H, H7, J7-6 = J7-8 = 7.4 Hz, J5-7 = 
1.6 Hz), 7.03 (m, 1H, H5, J5-6 = 7.4 Hz, J5-7 = 1.6 Hz), 6.90 (t, 1H, H6, 
J5-6 = J6-7 = 7.4 Hz,), 6.83 (m, 1H, H8), 6.15 (m, 1H, H4), 4.66 (s, 2H, 
H2), 2.80 (t, 2H, Hβ, Jα-β = 7.6 Hz), 2.36 (t, 2H, Hα, Jα-β = 7.6 Hz). 13C 
NMR (CDCl3, 100 MHz): δ (ppm) 152.98, 141.24, 134.44, 128.48, 
128.31, 128.25, 126.14, 126.03, 122.87, 121.31, 119.22, 115.29, 
68.31, 33.52, 29.71. 
 
5.3.2.1.11.2. 3-(2-Trifluoromethyl)phenethyl-2H-chromene (13b). 
Yield: (Method B) 37%, mp = 58–59 °C from n-hexane. IR (KBr): 
1607 cm-1. 1H-NMR (CDCl3, 400 MHz): δ (ppm) 7.59 (d, 1H, H3’, 
J3’-4’ = 8.0 Hz), 7.41 (t, 1H, H5’, J6’-5’ = J5’-4’ = 8.0 Hz) 7.28-7.21 (m, 
2H, H4’, H6’), 7.03 (m, 1H, H7, J7-6 = J7-8 = 7.6 Hz, J7-5 = 1.6 Hz), 
6.89 (dd, 1H, H5, J5-6 = 7.6 Hz, J7-5 = 1.6 Hz), 6.80 (m, 1H, H6, J5-6 = 
J7-6 = 7.6 Hz, J6-8 = 1.2 Hz), 6.76 (dd, 1H, H8, J7-8 = 7.6 Hz, J6-8 = 1.2 
Hz), 6.15 (s, 1H, H4), 4.66 (s, 2H, H2),  2.94 (t, 2H, Hβ, Jα-β = 8.0 
Hz), 2.36 (t, 2H, Hα, Jα-β = 8.0 Hz). 13C NMR (CDCl3, 100 MHz): δ 
(ppm) 153.20, 140.02, 133.97, 131.89 (q, J = 1.1 Hz), 131.07, 128.44 
(q, J = 29.6 Hz), 128.43. 126.34, 126.19, 126.12 (q, J = 5.7 Hz), 
124.77 (q, J = 272 Hz), 122.81, 121.40, 119.51, 115.40, 68.16, 35.09, 
30.51. 
 
5.3.2.1.11.3. 3-(4-Trifluoromethyl)phenethyl-2H-chromene (13c). 
Yield: (Method B) 39%, mp = 59–61 °C from n-hexane. IR (KBr): 
1615 cm-1. 1H-NMR (CDCl3, 400 MHz): δ (ppm) 7.52 (d, 2H, H3’, 
H5’, J2’-3’ = 8.0 Hz), 7.27 (d, 2H, H2’, H6’, J2’-3’ = 8.0 Hz), 7.04 (m, 
1H, H7, J7-6 = 7.6 Hz, J7-8 = 8.0 Hz, J7-5 = 1.6 Hz), 6.89 (dd, 1H, H5, 
J5-6 = 7.6 Hz, J7-5 = 1.6 Hz), 6.83 (t, 1H, H6, J5-6 = J7-6 = 7.6 Hz), 6.77 
(d, 1H, H8, J7-8 = 8.0 Hz,), 6.14 (s, 1H, H4), 4.65 (s, 2H, H2), 2.84 (t, 
2H, Hβ, Jα-β = 8.0 Hz), 2.36 (t, 2H, Hα, Jα-β = 8.0 Hz). 13C NMR 
(CDCl3, 100 MHz): δ (ppm) 152.98, 145.33, 133.74, 128.68, 128.58 
(q, J = 21.7 Hz),  128.47, 126.15, 125.42 (q, J = 3.7 Hz), 124.39 (q, J 
= 270.1 Hz), 122.72, 121.45, 119.55, 115.39, 114.94, 68.22, 34.57, 
33.20. 
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5.3.2.1.11.4. 3-(4-Chlorophenethyl)-2H-chromene (13d). Yield: 
(Method A) 5%, mp = 46–48 °C from n-hexane. IR (KBr): 1731 cm-1. 
1H-NMR (CDCl3, 400 MHz): δ (ppm) 7.24–7.20 (m, 2H, H3’, H5’), 
7.11–7.08 (2H, H2’, H6’), 7.06 (m, 1H, H7, J7-6 = 7.6 Hz, J7-8 = 8.0 
Hz, J7-5 = 1.6 Hz), 6.91 (dd, 1H, H5, J5-6 = 7.6 Hz, J7-5 = 1.6 Hz), 6.84 
(m, 1H, H6, J5-6 = J7-6 = 7.6 Hz), 6.77 (d, 1H, H8, J7-8 = 8.0 Hz), 6.15 
(s, 1H, H4), 4.66 (s, 2H, H2), 2.80 (t, 2H, Hβ, Jα-β = 8.0 Hz), 2,36 (t, 
2H, Hα, Jα-β = 8 Hz). 13C NMR (CDCl3, 100 MHz): δ (ppm) 152.93, 
139.60, 133.92, 131.91 129.67, 128.58, 128.36, 126.07, 122.73, 
121.37, 119.49, 115.32, 68.26, 34.89, 32.83. 
 
5.3.2.1.11.5. 3-(2-phenylpropyl)-2H-chromene (13e). Yield: 
(Method B) 58%, mp = 63–64 °C from n-hexane. IR (KBr): 1604 cm-
1. 1H-NMR (CDCl3, 400 MHz): δ (ppm) 7.49 (m, 2H, H3’, H5’ ), 
7.39–7.36 (m, 3H, H2’, H6’, H4’), 7.24–7.21 (m, 1H, H7, J7-6 = J7-8 = 
8.0 Hz, J7-5 = 1.6 Hz), 7.10 (dd, 1H, H5, J5-6 = 7.2 Hz, J7-5 = 1.6 Hz), 
7.03 (m, 1H, H6, J5-6 = 7.2 Hz, J7-6 = 8.0 Hz), 6.99 (d, 1H, H8, J7-8 = 
8.0 Hz), 6.31 (s, 1H, H4), 4.76 (dd, 2H, H2), 3.16-3.07 (m, 1H, Hβ), 
2,63-2.49 (m, 2H, Hα), 1.50 (d, 3H, CH3, JCH3-β = 6.8 Hz). 13C NMR 
(CDCl3, 100 MHz): δ (ppm) 152.89, 146.32, 133.35, 128.40, 128.13, 
126.70, 126.21, 125.91, 122.84, 121.17, 120.61, 115.20, 68.22, 42.58, 
37.99, 21.73. 
 
5.3.2.1.11.6. 3-(1-phenylpropan-yl)-2H-chromene (13f). Yield: 
(Method B) 38%, mp = 65–68 °C from n-hexane. IR (KBr): 1604 cm-
1. 1H-NMR (CDCl3, 400 MHz): δ (ppm) 7.23 (t, 2H, H3’, H5’, J2’-3’ = 
8.0 Hz), 7.16-7.10 (m, 3H, H2’, H6’, H4’), 7.01–6.98 (m, 1H, H7, J7-6 
= J7-8 = 8.0 Hz, J7-5 = 1.6 Hz), 6.89 (dd, 1H, H5, J5-6 = 7.6 Hz, J7-5 = 
1.6 Hz), 6.81 (m, 1H, H6, J5-6 = 7.6 Hz, J7-6 = 8.0 Hz), 6.76 (d, 1H, 
H8, J7-8 = 8.0 Hz), 6.11 (s, 1H, H4), 4.68–4.66 (m, 2H, H2 ), 2,84-
2.79 (m, 1H, Hβ), 2,57-2.52 (m, 1H, Hα), 2.47-2.38 (m, 1H, CH), 1.05 
(d, 3H, CH3, JCH3-H = 7.2 Hz). 13C NMR (CDCl3, 100 MHz): δ (ppm) 
153.18, 140.01, 138.97, 129.00, 128.24, 128.18, 126.15, 126.08,  
123.09, 121.29, 118.18, 115.27, 67.21, 41.37, 39.41, 18.04. 
 
5.3.2.1.11.7. 3-(3-Phenylpropyl)-2H-chromene (13g). Yield: 
(Method B) 43%, mp = 43–45 °C from n-hexane. IR (KBr): 1604 cm-
1. 1H-NMR (CDCl3, 400 MHz): 7.23–7.22 (m, 2H, H3’, H5’),  7.17–
7.12 (m, 3H, H2’, H6’, H4’), 7.05 (m, 1H, H7, J7-8 = J7-6 = 8.0 Hz, J7-5 
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= 1.6 Hz), 6.87 (dd, 1H, H5, J5-6 = 8.0 Hz, J7-5 = 1.6 Hz ), 6.79 (m, 1H, 
H6, J7-6 = J5-6 = 8.0 Hz, J6-8 =1.2 Hz), 6.74 (dd, 1H, H8, J7-8 = 8.0 Hz, 
J6-8 = 1.2 Hz), 6.10 (s, 1H, H4), 4.6 (s, 1H, H2), 2.59 (t, 2H, 2Hα, Jα-β 
= 7.2 Hz), 2.02 (t, 1H, 2Hγ, Jβ-γ = 8.0 Hz), 1.80–1.73 (m, 2H, 2Hβ). 
13C NMR (CDCl3, 100 MHz) : δ (ppm) 153.16, 142.02, 134.97, 
128.62, 128.58, 128.35, 126.14, 126.10, 123.12, 121.47, 119.04, 
115.48, 68.51, 35.59, 32.81, 28.60. 
 
5.3.2.1.11.8. 3-(4-Phenylbutyl)-2H-chromene (13h). Yield: (Method 
B) 42%, mp = 45–46 °C from n-hexane. IR (KBr): 1604 cm-1. 1H-
NMR (CDCl3, 400 MHz): 7.29–7.45 (m, 2H, H3’, H5’), 7.19–7.15 
(m, 3H, H2’, H6’, H4’), 7.04–6.99 (m, 1H, H7, J7-6 = J7-8 = 7.6 Hz, J7-5 
= 2.0 Hz ), 6.90 (dd, 1H, H5, J5-6 = 7.6 Hz, J7-5 = 2.0 Hz ), 6.84–6.80 
(m, 1H, H6, J5-6  = J7-6 = 7.6 Hz, J6-8 = 1.2 Hz), 6.74 (dd, 1H, H8, J7-8 = 
7.6 Hz, J6-8 = 1.2 Hz), 6.10 (s, 1H, H4), 4.6 (s, 1H, H2), 2,63 (t, 2H, 
2Hα, Jα-β = 7.2 Hz), 2.08 (t, 2H, 2Hδ, Jγ-δ = 7.6 Hz), 1.68–1.62 (m, 2H, 
2Hγ), 1.56-1.49 (m, 2H, 2Hβ). 13C NMR (CDCl3, 100 MHz) : δ (ppm) 
152.88, 142.26, 135.01, 128.38, 128.31, 128.07, 125.87, 125.75, 
122.94, 121.25, 118.69, 115.22, 68.32, 35.69, 33.07, 30.99, 26.36. 
 
5.3.2.1.11.9. 3-(5-Phenylpentyl)-2H-chromene (13i). Yield: (Method 
B) 55%, mp = 45–46 °C from n-hexane. IR (KBr): 1604 cm-1. 1H-
NMR (CDCl3, 400 MHz): δ (ppm) 7.27-7.23 (m, 2H, H3’, H5’), 7.16-
7.14 (m, 3H, H2’, H6’, H4’), 7.04–6.99 (m, 1H, H7, J7-6 = J7-8 = 8.0 
Hz, J7-5 = 1.6 Hz), 6.88 (dd, 1H, H5, J5-6 = 8.0 Hz, J7-5 = 1.6 Hz), 6.81 
(t, 1H, H6, J5-6 = J7-6 = 8.0 Hz), 6.75 (d, 1H, H8, J7-8 = 8.0 Hz), 6.10 
(s, 1H, H4), 4.63 (s, 2H, H2), 2.59 (t, 2H, 2Hα, Jα-β = 7.6 Hz), 2.03 (t, 
2H, 2Hδ, Jδ-ε = 7.6 Hz), 1.67–1.59 (m, 2H, 2Hε), 1.53–1.46 (m, 2H, 
2Hβ), 1.42–1.33 (m, 2H, 2Hγ). 13C NMR (CDCl3, 100 MHz): δ (ppm) 
153.87, 142.52, 135.19, 128.35, 128.25, 128.03, 125.86, 125.45, 
122.96, 121.23, 118.56, 115.21, 68.32, 35.82, 33.11, 31.23, 28.88, 
26.68. 
 
5.3.2.1.12. General procedure for the synthesis of 3-
phenylalkylchromans (14g-i, 18a-c). 
 
A solution of the appropriate phenylalkyl-2H-chromene (13g-i) 
or the appropriate mixture of (Z)-3-[(E)-3-phenylallylidene]chroman, 
(E)-3-(3-phenyl)prop-1-en-1-yl)-2H-chromene, and 3-cinnamyl-2H-
chromene (15, 16, 17a; 15, 16, 17b or 15, 16, 17c)4 (10 mmol) in dry 
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dioxane (80 mL) was hydrogenated over 10% Pd/C (15.2 mmol) at 
room temperature for 30 minutes, under 40 psi pressure. After this 
period, the catalyst was filtered off and the solvent was removed 
under reduced pressure. The residue was chromatographed on silica 
gel eluting with a mixture of chloroform/light petroleum (1:1). The 
product was further purified by crystallization from n-hexane. 
 
5.3.2.1.12.1. 3-(3-Phenylpropyl)chroman (14g). Yield: 34%, mp = 
41–42 °C from n-hexane. IR (KBr): 1606 cm-1. 1H-NMR (CDCl3, 400 
MHz): δ (ppm) 7.28–7.24 (m, 2H, H3’, H5’), 7.18-7.15 (m, 3H, H2’, 
H6’, H4’), 7.07–7.03 (t, 1H, H7, J7-6 = J7-8 = 8.0 Hz), 6.99 (d, 1H, H5, 
J5-6 = 7.6 Hz), 6.82 (dd, 1H, H6, J5-6 = 7.2 Hz, J6-8 = 1.2 Hz), 6.78 (d, 
1H, H8, J7-8 = 8.0 Hz, J6-8 = 1.2 Hz),  4.19–4.15 (m, 1H, H2 ), 3.72–
3.67 (m, 1H, H2), 2.82 (dd, 1H, H4, Jgem = 16 Hz, J3-4 = 4.0 Hz ), 
2.64-2.58 (m, 2H, 2Hγ), 2.45–2.38 (m, 1H, H4, Jgem = 16 Hz, J3-4 = 
9.6 Hz ), 2.03–1.97 (m, 1H, H3), 1.77–1.66 (m, 2H, 2Hα), 1.42–1.20 
(m, 2H, 2Hβ). 13C NMR (CDCl3, 100 MHz): δ (ppm) 154.65, 142.14, 
129.83, 128.34, 128.32, 127.16, 125.79, 121.67, 120.18, 116.39, 
70.49, 35.95, 32.03, 31.48, 31.36, 28.58. 
 
5.3.2.1.12.2. 3-(4-Phenylbutyl)chroman (14h). Yield: 86%, mp = 
43–44 °C from n-hexane. IR (KBr): 1607 cm-1. 1H-NMR (CDCl3, 400 
MHz): δ (ppm) 7.26–7.23 (m, 2H, H3’, H5’), 7.16-7.13 (m, 3H, H2’, 
H6’, H4’), 7.04 (t, 1H, H7, J7-6 = J7-8 = 7.6 Hz), 6.97 (d, 1H, H5, J5-6 = 
7.2 Hz), 6.81–6.77 (m, 2H, H6, H8), 4.16–4.12 (m, 1H, H2), 3.69–
3.65 (m, 1H, H2), 2.78 (dd, 1H, H4, Jgem = 16.0 Hz, J3-4 = 4.8 Hz ), 
2.59 (t, 2H, 2Hδ, Jγ-δ = 7.2 Hz ) 2.41–2.35 (m, 1H, H2, Jgem = 16.0 
Hz), 1.99–1.88 (m, 1H, H3), 1.65–1.58 (m, 2H, CH3, 2Hγ), 1.46-1.22 
(m, 4H, 2Hα, 2Hβ) . 13C NMR (CDCl3, 100 MHz): δ (ppm) 154.61, 
142.38, 129.81, 128.32, 128.24, 127.10, 125.65, 121.68, 120.11, 
116.34, 70.48, 35.77, 31.98, 31.55, 31.48, 31.46, 26.31. 
 
5.3.2.1.12.3. 3-(5-Phenylpentyl)chroman (14i). Yield: 81%, mp = 
42–43 °C from n-hexane. IR (KBr): 1607 cm-1. 1H-NMR (CDCl3, 400 
MHz): δ (ppm) 7.26–7.23 (m, 2H, H3’, H5’), 7.15-7.13 (m, 3H, H2’, 
H6’, H4’), 7.04 (t, 1H, H7, J7-6 = J7-8 = 8.0 Hz), 6.98 (d, 1H, H5, J5-6 = 
7.2 Hz), 6.82–6.77 (m, 2H, H6, H8), 4.17–4.13 (m, 1H, H2), 3.69–
3.65 (m, 1H, H2), 2.79 (dd, 1H, H4, Jgem = 16.4 Hz, J3-4 = 4.8 Hz), 
2.58 (t, 2H, Hδ, Jγ-δ = 7.6 Hz), 2,41-2.35 (m, 1H, H4, Jgem = 16.4 Hz, 
J3-4 = 9.6 Hz), 1.96–1.91 (m, 1H, H3), 1.65–1.57 (m, 2H, 2Hγ), 1.46–
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1.18 (m, 6H, 2Hε, 2Hα, 2Hβ). 13C NMR (CDCl3, 100 MHz): δ (ppm) 
154.62, 142.56, 129.81, 128.32, 128.20, 127.00, 125.59,  121.72, 
120.10, 116.33, 70.52, 32.00, 31.66, 31.49, 31.35, 29.33, 26.57.  
 
5.3.2.1.12.4. 6-chloro-3-(3-phenylpropyl)chroman (18a). Yield: 
79%, mp = 42–43 °C from n-hexane. IR (KBr): 1484 cm-1. 1H-NMR 
(CDCl3, 400 MHz): δ (ppm) 7.29–7.26 (m, 2H, H3’, H5’), 7.20-7.16 
(m, 3H, H2’, H6’, H4’), 7.00 (dd, 1H, H7, J7-6 = 8.4 Hz, J7-5 = 2.4 Hz), 
6.97 (d, 1H, H5, J7-5 = 2.4 Hz), 6.70 (d, 1H, H8, J7-8 = 8.4 Hz), 4.18–
4.15 (m, 1H, H2), 3.71–3.67 (m, 1H, H2), 2.80 (dd, 1H, H2, Jgem = 
16.0 Hz, J3-4 = 4.0 Hz), 2,61 (t, 2H, 2Hγ, Jβ-γ = 7.6 Hz ), 2.42-2.36 (m, 
1H, H4, Jgem = 16.0 Hz, J3-4 = 9.2 Hz ), 2.03–1.95 (m, 1H, H3), 1.76–
1.68 (m, 2H, 2Hα), 1.45-1.30 (m, 2H, 2Hβ). 13C NMR (CDCl3, 100 
MHz): δ (ppm) 153.29, 142.05, 129.36, 128.37, 127.14, 127.13, 
125.87, 124.83, 123.29, 117.70, 70.57, 35.94, 31.75, 31.34, 31.19, 
28.55. 
 
5.3.2.1.12.5. 6-chloro-3-[3-(4-chlorophenyl)propyl]chroman (18b). 
Yield: 85%, mp = 41–42 °C from n-hexane. IR (KBr): 1484 cm-1. 1H-
NMR (CDCl3, 400 MHz): δ (ppm) 7.20 (d, 2H, H3’, H5’, J2’-3’ = 8.0 
Hz), 6.96 (m, 1H, H7, J7-8 = 8.8 Hz, J7-5 = 2.4 Hz), 6.92 (d, 1H, H5, J7-
5 = 2.4 Hz), 6.67 (d, 1H, H8, J7-8 = 8.8 Hz), 4.12–4.09 (m, 1H, H2), 
3.65–3.60 (d, 1H, H2), 2.71 (s, 1H, H4, Jgem = 16.4 Hz, J3-4 = 4.8 Hz), 
2.54 (t, 2H, Hγ, Jβ-γ = 7.6 Hz), 2,34-2.28 (m, 1H, H4, Jgem = 16.4 Hz, 
J3-4 = 9.6 Hz), 1.91–1.87 (m, 1H, H3), 1.70 (m, 2H, Hα), 1.37–1.19 
(m, 2H, 2Hβ). 13C NMR (CDCl3, 100 MHz): δ (ppm) 153.19, 140.41, 
131.44, 129.64, 128.28, 128.36, 127.05, 124.69,  123.15, 117.64, 
70.34, 35.16, 31.58, 31.18, 30.98, 28.34. 
 
5.3.2.1.12.6. 3-[3-(4-chlorophenyl)propyl]chroman (18c). Yield: 
16%, mp = 42–43 °C from n-hexane. IR (KBr): 1489 cm-1. 1H-NMR 
(CDCl3, 400 MHz): δ  (ppm) 7.23 (d, 2H, H3’, H5’, J2’-3’ = 8.4 Hz), 
7.10-7.04 (m, 3H, H2’, H6’, H7), 7.00 (d, 1H, H5, J5-6 = 7.2 Hz), 
6.84–6.77 (m, 2H, H6, H8), 4.19–4.16 (m, 1H, H2), 3.74–3.69 (d, 1H, 
H2), 2.83 (dd, 1H, H4, Jgem = 16.0 Hz, J3-4 = 4.4 Hz), 2.59 (t, 2H, Hγ, 
Jβ-γ = 8.0 Hz), 2,46-2.39 (m, 1H, H4, Jgem = 16.0 Hz, J3-4 = 9.6 Hz), 
2,04–1.95 (m, 1H, H3), 1.76–1.63 (m, 2H, 2Hα), 1,44–1.27 (m, 2H, 
2Hβ). 13C NMR (CDCl3, 100 MHz): δ (ppm) 154.62, 140.56, 131.54, 
129.86, 129.71, 128.44, 127.21, 121.58,  120.24, 116.41, 70.43, 35.28, 
32.03, 31.47, 31.23, 28.51. 
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5.3.2.2.1. Anti-HRV assays  
 
The cytotoxicity and anti-HRV activity assays were performed 
by Prof. Cinzia Conti, Department of Public Health Sciences, Section 
of Microbiology, Sapienza University of Rome. The new compounds 
were evaluated following the experimental protocol previously 
described.4 
 
5.3.2.2.2. Antiviral assays against selected RNA and DNA viruses  
 
Tests of cytotoxicity and antiviral activity in vitro were 
performed by Dr. Roberta Loddo at the Department of Biomedical 
Sciences and Technologies, Section of General Microbiology and 
Virology & Microbial Biotechnologies, University of Cagliari. 
 
5.3.2.2.2.1 Cells and viruses 
 
Cell lines were purchased from American Type Culture 
Collection (ATCC). The absence of mycoplasma contamination was 
checked periodically by the Hoechst staining method. Cell lines 
supporting the multiplication of RNA and DNA viruses were the 
following: Madin Darby Bovine Kidney (MDBK) [ATCC CCL 22 
(NBL-1) Bos Taurus]; Baby Hamster Kidney (BHK-21) [ATCC CCL 
10 (C-13) Mesocricetus auratus] and Monkey kidney (Vero 76) 
[ATCC CRL 1587 Cercopithecus Aethiops]. Viruses were purchased 
from American Type Culture Collection (ATCC) except Yellow Fever 
Virus (YFV). Viruses representative of positive-sense single strand 
RNA (ssRNA+) group used were: (ii) Flaviviridae family: YFV [strain 
17-D vaccine (Stamaril Pasteur J07B01)] and Bovine Viral Diarrhea 
Virus (BVDV) [strain NADL (ATCC VR-534)] (iii) Picornaviridae 
family: Human Coxsackievirus type B5 (CVB-5) strain Ohio-1 
(ATCC VR-29) and Human Poliovirus type-1 Sabin (Sb-1) [strain 
Chat (ATCC VR-1562)]. Virus representative of a negative-sense 
single-strand RNA (ssRNA-) group used were: Vesicular Stomatitis 
Virus (VSV) [strain Indiana Lab (ATCC VR-158)] and Human 
Respiratory Syncytial Virus (RSV) [strain A2 (ATCC VR-1540)]. A 
virus representative of a double strand RNA (dsRNA) group used 
was: Reovirus type-1 [strain 3651 (SV-12, simian virus 12) (ATCC 
VR-214)]. Viruses representatives of DNA group used were: (i) 
Poxviridae family: Vaccinia Virus (VV) [strain Elstree-Lister Vaccine 
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(ATCC VR-1549)]; (ii) Herpesviridae family: Human Herpesvirus 1 
(HSV-1) [strain KOS (ATCC VR-1493)]. As reference inhibitors were 
used: Pleconaril for picornaviruses, Ribavirin for ssRNA+ and dsRNA 
viruses; 6-Azauridine, Ribavirin and Mycophenolic acid for the 
ssRNA- viruses; Mycophenolic acid and Acyclovir for DNA viruses. 
 
5.3.2.2.2.2. Cytotoxicity assays 
 
MDBK and BHK cells were seeded at an initial density of 6x105 
and 1x106 cells/mL in 96-well plates, respectively, in culture medium 
[Minimum Essential Medium with Earle’s salts (MEM-E) with L-
glutamine, supplemented with 10% horse serum and 1 mM sodium 
pyruvate (for MDBK cells) or with 10% fetal bovine serum (FBS) (for 
BHK cells), 0.025 g/L kanamycin]. Cell cultures were then incubated 
at 37 °C in a humidified, 5% CO2 atmosphere in the absence or 
presence of serial dilutions of test compounds. Cell viability was 
determined after 48–96 h at 37 °C by the MTT method. Vero-76 cells 
were seeded at an initial density of 4x105 cells/mL in 24-well plates, 
in culture medium [Dulbecco’s Modified Eagle Medium (DMEM) 
with L-glutamine, supplemented with fetal bovine serum (FBS), 0.025 
g/L kanamycin]. Cell cultures were then incubated at 37 °C in a 
humidified, 5% CO2 atmosphere in the absence or presence of serial 
dilutions of test compounds. Cell viability was determined after 48–96 
h at 37 °C by the crystal violet staining method. 
 
5.3.2.2.2.3. Antiviral assays 
 
Compounds activity against YFV and Reo-1 was based on 
inhibition of virus-induced cytopathogenicity in BHK-21 cells acutely 
infected with a m.o.i. of 0.01. Compounds activity against BVDV was 
based on inhibition of virus-induced cytopathogenicity in MDBK cells 
acutely infected with a m.o.i. of 0.01. Briefly, BHK and MDBK cells 
were seeded in 96-well plates at a density of 5x104 and 3x104 
cells/well, respectively, and were allowed to form confluent 
monolayers by incubating overnight in growth medium at 37 °C in a 
humidified CO2 (5%) atmosphere. Cell monolayers were then infected 
with 50 µL of a proper virus dilution in maintenance medium (MEM-
E with L-glutamine, supplemented with 0.5% inactivated FBS, 1 mM 
sodium pyruvate and 0.025 g/L kanamycin) to give a m.o.i of 0.01. 
After 1 h, 50 µL of maintenance medium, without or with serial 
dilutions of test compounds, were added. After a 3–4 days incubation 
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at 37 °C, cell viability was determined by the MTT method. 
Compounds activity against CVB-5, Sb-1, VSV, VV, HSV-1 and 
RSV was determined by plaque reduction assays in infected Vero 76 
cell monolayers. To this end, Vero 76 cells were seeded in 24-well 
plates at a density of 2x105 cells/well and were allowed to form 
confluent monolayers by incubating overnight in growth medium 
[Dulbecco’s Modified Eagle Medium (DMEM) with L-glutamine and 
4500 mg/L D-glucose, supplemented with 10% FBS and 0.025 g/L 
Kanamycin] at 37 °C in a humidified CO2 (5%) atmosphere. Then, 
monolayers were infected for 2 h with 250 µL of proper virus 
dilutions to give 50–100 PFU/well. Following removal of unadsorbed 
virus, 500 µL of maintenance medium (DMEM medium with L-
glutamine and 4500 mg/L D-glucose supplemented with 1% 
inactivated FBS and 0.75% methyl-cellulose), without or with serial 
dilutions of test compounds, were added. Cultures were incubated at 
37 °C for 2 (Sb-1 and VSV), 3 (CVB-5, VV and HSV-1) or 5 days 
(RSV) and then fixed with PBS containing 50% ethanol and 0.8% 
crystal violet, washed and air-dried. Plaques were then counted and 
IC50 (50% effective concentration) was calculated by linear regression 
technique. The cytotoxicity of test compounds was determined in 
parallel on the same 24-well plate used for the IC50 determination. 
Linear regression analysis: viral and cell growth at each drug 
concentration was expressed as percentage of untreated controls and 
concentrations resulting in 50% (IC50 and TC50) growth inhibition 
were determined by linear regression analysis. 
 
References 
 
1. Loiodice, F.; Longo, A.; Bianco, P.; Tortorella, V. Tetrahedron: Asymmetry 
1995, 6, 1001. 
2. Silva, V. L. M.; Silva, A. M. S.; Pinto, D. C. G. A.; Cavaliero, J. A. S.; Patanay, 
T. Synlett 2004, 2717. 
3. Gangjee A, Yang J, Ihnat MA, Kamat S. Bioorg Med Chem. 2003, 11, 5155–
5170. 
4. Conti C., Proietti Monaco L., Desideri N., Bioorg & Med. Chem. 2011, 19, 
7357. 
5. Scudiero, D. A.; Shoemaker, R. H.; Paull, K.D.; Monks, A.; Tierney, S.; 
Nofziger, T. H.; Currens, M. J.; Seniff, D.; Boyd, M. R. Cancer Res. 1988, 48, 
4827. 
6. Desideri N., Conti C., Sestili I., Tomao P., Stein M.L, Orsi N., Antiviral Chem. 
Chemother. 1992, 3, 195. 
7. Alami, M.; Peyrat, J. F.; Belachmi, L.; Brion, J. D. Eur. J. Org. Chem. 2001, 14, 
4207. 
8. Conti, C.; Desideri, N.  Bioorg. Med. Chem. 2010, 18, 6480. 
127	  	  
5.4. Conclusions 
 
New series of 3-arylalkyl 4H-chromen-4-ones, chromans and 
2H-chromenes have been synthesized and tested in vitro against HRV 
1B and 14, two representative serotypes for HRV group B and A, 
respectively.  
 
By anti-HRV data we can draw the following structure-activity 
relationships: 
• electron-withdrawing substituents, in particular a chlorine 
atom at the 6 and/or 4’ position, have the best impact on the 
activity; 
• the oxidation of chromene ring causes decrease in activity, 
while the reduction of the ring maintains or improves the 
potency; 
• the branching of the chain between the two rings usually 
leads to an increase in cytotoxity and reduction or loss of 
anti-HRV activity. Compounds containing an unsaturated 
chain with four carbon atoms are usually less powerful than 
the analogues with shorter or saturated chains. The 
substitution with a saturated or monounsaturated chain from 
two to five carbon atoms leads to analogues endowed with 
potency in the submicromolar range, in particular against 
serotype 1B. 
• The bioisosteric replacement of phenyl ring with a pyridine 
ring produce analogues active at the micromolar or 
submicromolar concentrations. 
 
Several 2H-chromene and chroman derivatives displayed a wide 
spectrum of anti-HRV activity. The efficacy in the micromolar or 
submicromolar range coupled with the low cytotoxicity resulted in 
compounds with high therapeutic index. The antiviral evaluation 
against a large panel of RNA and DNA viruses demonstrated the 
selectivity of the new compounds as anti-HRV inhibitors.  
Mechanism of action studies of selected derivatives suggest that 
these compounds act as capsid-binders and interfere with early stages 
of  virus replication. However, while (E)-3-styryl-2H-chromene was 
able to interfere also with virus binding to cellular receptor, both (E)-
6-chloro-3-(3-phenylprop-1-en-1-yl)-2H-chromene and (E)-2-[2-(2H-
chromen-3-yl)vinyl]pyridine did not appear to affect the absorption of 
virus suggesting an interference during the uncoating process. 
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CHAPTER 2 
FLAVONOID ANALOGUES AS POTENT AND SELECTIVE 
MAO-B INHIBITORS 
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1. INTRODUCTION 
 
Monoamine oxidase (MAO, EC 1.4.3.4) is a flavoenzyme that 
catalyzes the deamination of a broad spectrum of biogenic and 
xenobiotic amines. Two isoforms of MAOs have been identified and 
designated as MAO-A and MAO-B. The MAO isozymes are products 
of separate genes and they share approximately 70% amino acid 
sequence identity.1 Studies on X-ray crystallographic structures of 
human MAO-A and MAO-B indicate that 6 of the 16 amino acid 
residues comprising the active sites differ between the two enzymes.2,3 
For these reasons, MAO-A and MAO-B have different substrate and 
inhibitor specificities. MAO-A preferentially metabolizes the 
neurotransmitters, serotonin, epinephrine and norepinephrine, and it is 
selectively inhibited by clorgyline. MAO-B are predominantly 
involved in the metabolism of benzylamine and β−phenylethylamine, 
and it is selectively inhibited by selegiline and rasagiline. Dopamine 
and tyramine are considered to be a substrate for both isozymes.4 
Although in humans both isozymes are expressed in most peripheral 
tissues and organs, MAO-A is preponderant in placenta, lung and 
small intestine, while MAO-B is the only isoform in platelets and 
lymphocytes. In brain MAO-B (present in glial cells) predominates 
over MAO-A.1 These properties determine the therapeutic potential of 
MAO inhibitors. MAO-A inhibitors have therapeutic utility for the 
treatment of depression5 whereas MAO-B inhibitors are used with L-
DOPA and/or dopamine agonists in the symptomatic treatment of 
Parkinson’s disease6,7, and are potential drugs in the therapy of 
Alzheimer’s disease (AD).8,9 However, the first generation of non 
selective and irreversible MAO inhibitors was characterized by 
adverse side-effects such as serious hypertensive crisis following the 
ingestion of dietary tyramine. The efforts devoted to the discovery of 
safer inhibitors led to the new generation of MAO inhibitors 
characterized by the selectivity against MAO isoforms and in some 
cases by the reversibility of action.  Various structural classes of 
potent MAO inhibitors, including hydrazide, amide, thiazole, 
imidazole, oxazolidinone, oxadiazolone, diacylurea derivatives, etc. 
have been identified.10-23 Figure 1 shows the chemical structures of 
some representative MAO inhibitors used in research or clinical 
practice. 
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Figure 1. Some representative structures of non selective and 
selective MAO inhibitors 
 
As the ideal drug candidate has not been achieved, researchers 
continued to explore this field. 
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2.1. Homoisoflavonoids: natural scaffolds with potent 
and selective monoamine oxidase-B inhibition 
properties. 
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The aim of the present study was the identification of novel 
potent MAO inhibitors that could serve as potential lead molecules for 
drug discovery. 
Homoisoflavonoids constitute a small class of natural products 
prevalently isolated from the bulbs, rhizomes or roots of several 
genera of Hyacinthaceae and Caesalpinioideae. These compounds are 
structurally related to the more widespread flavonoids and, according 
to their structural features, can be classified into three types: 3-
benzylidenechroman-4-ones, 3-benzyl-4H-chromen-4-ones and 3-
benzylchroman-4-ones. Several natural and synthetic 
homoisoflavonoids, like the related flavonoids, were found to possess 
various biological properties such as antifungal,1 antiviral,2-4 
antimutagenic,5,6 antiproliferative,7 antioxidant,8,9 anti-allergic and 
anti-histaminic,10 anti-inflammatory11 and protein tyrosine kinase 
(PTK) inhibitor activities.12 However, no data are available on the 
inhibitory activity of homoisoflavonoids on MAOs. 
Recently, several substituted chalcones and flavanones were 
reported as potent and selective inhibitors of the B-isoform of human 
MAO (hMAO).13,14 The structural relationship of homoisoflavonoids 
to chalcones and flavanones prompted us to investigate their 
inhibitory activity against the A and B isoforms of hMAO. Initially, 
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we tested the synthetic (E)-3-benzylidenechroman-4-ones 1a-g, 3-
benzyl-4-chromones 2a-g and 3-benzylchroman-4-ones 3a-e, 
previously studied as anti-picornavirals.2-4 Because all the (E)-3-
benzylidenechroman-4-ones 1a-g, which may be regarded as rigid 
analogues of chalcones, were potent and selective inhibitors of the B 
isoform of hMAO, we planned the synthesis of a larger panel of (E)-3-
benzylidenechroman-4-ones to further investigate the structure-
activity relationships. The MAO recognition of the most active 
compounds, 1h and 1l, was investigated by docking experiments 
performed using available Protein Data Bank (PDB) structures as 
receptor models. 
 
2.1.1. Chemistry 
 
The (E)-3-benzylidenechroman-4-ones 1a-w were synthesized 
by acid-catalyzed condensation of the appropriate chroman-4-one with 
substituted benzaldehydes (scheme 1).  
In general, the target compounds were prepared in good yield 
using 85% phosphoric acid as the acid catalyst and heating the 
mixture at 80 °C for 6 h. Under these conditions, the reaction of 
chroman-4-one with N-(4-formylphenyl)acetamide gave a mixture of 
amide 1k and the corresponding amine 1j, which were easily 
separated by column chromatography. Starting from substituted 
chroman-4-ones or 2-substituted benzaldehydes, treatment with 85% 
phosphoric acid provided the corresponding chromanones (1d, 1e, 1g, 
1i and 1s-v) in very low yields. To obtain these compounds more 
efficiently, the condensations were carried out in dry ethyl alcohol 
saturated with dry hydrogen chloride. A single stereoisomer was 
obtained with both procedures. The 1H NMR spectra allow the E 
configuration of the double bound to be assigned on the basis of the 
chemical shift of the olefinic proton, ranging from 7.6 ppm to 7.9 
ppm. 
(E)-5,7-Dihydroxy-3-(4-hydroxybenzylidene) chroman-4-one 
(1h) was synthesized by saponification of the corresponding 
tribenzoate following published procedures.15 
The reduction of (E)-3-(4-hydroxy-3-nitrobenzylidene) chroman-4-
one (1q) with tin chloride in ethyl alcohol and concentrated hydrogen 
chloride provided the corresponding amino derivative (1r). 
The (E)-3-benzylidenechroman-4-ones 1a-g were converted into 
the corresponding 3-benzyl-4-chromones 2a-g or 3-benzylchroman-4-
ones 3a-e according to procedures described previously.2 
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Scheme1. Reagents and conditions: (i) 85% H3PO4, 80° C, 6h; (ii) dry EtOH sat. 
HCl, r.t., 48h. 
 
2.1.2. Biochemistry 
 
The potential effects of the tested compounds on hMAO activity 
were investigated by measuring their effects on the production of 
hydrogen peroxide (H2O2) from p-tyramine, using the Amplex Red 
MAO assay kit (Molecular Probes, Inc., Eugene, Oregon, USA) and 
microsomal MAO isoforms prepared from insect cells (BTI-TN-5B1-
4) infected with recombinant baculovirus containing cDNA inserts for 
hMAO-A or hMAO-B (Sigma-Aldrich Química S.A., Alcobendas, 
Spain). In this study hMAO activity was evaluated using the above 
method following the general procedure described previously by us.16 
The tested drugs (new compounds and reference inhibitors) 
themselves were unable to react directly with the Amplex Red reagent, 
which indicates that these compounds do not interfere with the 
measurements. On the other hand, in our experiments and under our 
experimental conditions, the control activity of hMAO-A and hMAO-
B (using p-tyramine as a common substrate for both isoforms) was 
165 ± 2 pmol of p-tyramine oxidized to p-
hydroxyphenylacetaldehyde/min (n = 20).  
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The results of hMAO-A and hMAO-B inhibition studies are 
expressed as IC50 and reported in tables 1 and 2 together with the 
hMAO-B selectivity indexes (SI = IC50 MAO-A/IC50 MAO-B).  
 
Table 1. IC50 and SI values for the inhibitory effects of (E)-3-benzylidenechroman-
4-ones 1a-w and reference inhibitors on the enzymatic activity of human 
recombinant MAO isoforms expressed in baculovirus infected BTI insect cells. 
Comp. R R1 R2 R3 R4 R5 MAO-A  (IC50) 
MAO-B 
(IC50) 
SIc 
1a H H H H H H ** 479.70 ± 19.37 nM > 208
# 
1b H H H H OH H ** 55.37 ± 2.18 nM > 1806
# 
1c H H H H Cl H ** 154.23 ± 6.93 nM > 648
# 
1d H Cl H H Cl H ** 31.82 ± 1.19 nM > 3143
# 
1e  Cl H H H Cl H ** 13.03 ± 0.79 nM > 7675
# 
1f H H H H OCH3 H ** 
58.90 ± 
2.09 nM > 1698
# 
1g OCH3 H H H OCH3 H ** 
1.57 ± 
0.03 µM > 64
# 
1h OH H H H OH H 
11.46 ± 
0.43µMa 
8.61 ± 
0.12 nM 1331 
1i H Cl H H H H ** 
331.11± 
9.63 nM > 302
# 
1j H H H H NH2 H ** 
879.18 ± 
45.31 nM > 114
# 
1k H H H H NHCOCH3 H 
2.10 ± 
0.11µMb 
1.06 ± 
0.04 µM 2.0 
1l H H H H N(CH3)2 H ** 
8.51 ± 
0.32 nM > 11751
# 
1m H H H OCH3 OH H *** 
104.34 ± 
2.61 nM > 958
# 
1n H H H OH OCH3 H ** 
476.51± 
21.60 nM > 210
# 
1o H H H OH OH H 4.74± 0.21µMa 
140.52 ± 
4.71 nM 34 
1p H H H COOH OH H ** **  
1q H H H NO2 OH H ** 
490.84 ± 
12.73 nM > 204
# 
1r H H H NH2 OH H 
1.44± 
0.51µMa 
483.88 ± 
16.21 nM 3.0 
1s H H OH H OCH3 H *** 
1.33 ± 
0.07 µM > 75
# 
1t H H OCH3 H OCH3 H ** 
247.51 ± 
6.31 nM > 404
# 
1u H H OCH3 OCH3 H H ** 
1.92 ± 
0.08 µM > 52
# 
1v H H OCH3 OCH3 OCH3 H ** 
1.31 ± 
0.04 µM > 76
# 
1w H H H OCH3 OCH3 OCH3 ** 
20.69 ± 
0.37 µM > 4.8
# 
A       4.46±      0.32nMa 
61.35 ± 
1.13 µM 0.000073 
B       67.25 ± 1.02 µMa 
19.60 ± 
0.86 nM 3431 
C       6.56± 0.76 µM 
7.54 ± 
0.36 µM 0.87 
D       361± 19.37µM * < 0.36 
All IC50 values shown in this table are the mean ± S.E.M. from five experiments. Level of statistical 
significance: aP < 0.01 or bP < 0.05 versus the corresponding IC50 values obtained against MAO-B, as 
determined by ANOVA/Dunnett´s. c  SI: hMAO-B selectivity index = IC50 (hMAO-A)/IC50 (hMAO-B). 
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* inactive at 1 mM (highest concentration tested). ** Inactive at 100 µM (highest concentration tested). 
*** 100 µM inhibits the corresponding MAO activity by approximately 40-50%. At higher 
concentration the compounds precipitate. # Values obtained under the assumption that the corresponding 
IC50 against MAO-B is the highest concentration tested (100 µM).  
A: Clorgyline, B: Selegiline, C: Iproniazid, D: Moclobemide 
 
In table 1 are presented the data obtained for the (E)-3-
benzylidenechroman-4-ones 1a-w. Most of these homoisoflavonoids 
selectively inhibited the enzymatic activity of hMAO-B in the 
nanomolar or micromolar range. Derivatives 1h, 1k, 1o and 1r were 
also able to inhibit hMAO-A in the micromolar range. Among these 
analogues, 1k and 1r were essentially non selective (SI = 2 and 3, 
respectively) whereas 1h and 1o exhibited hMAO-B selectivity to 
different extents (SI = 1331 and 34, respectively). Only the acid 1p 
was found to be completely inactive towards both isoforms up to the 
highest concentration tested (100 µM). (E)-3-[4-
(Dimethylamino)benzylidene]chroman-4-one (1l) was the most potent 
and selective hMAO-B inhibitor identified in this study exhibiting an 
IC50 value of 8.51 nM and SI > 11751. In comparison with the 
reference inhibitor selegiline, compound 1l showed higher hMAO-B 
affinity and selectivity. The replacement of the dimethylamino group 
with the amino group resulted in compound 1j, about one hundred 
fold less potent and selective as a hMAO-B inhibitor (IC50 = 879.18 
nM, SI > 114) than 1l. Interestingly, acetylation of the amino group 
(compound 1k) produced a further decrease of hMAO-B inhibitory 
activity and a dramatic reduction of selectivity (IC50 = 1.06 µM, SI = 
2). (E)-5,7-Dihydroxy-3-(4-hydroxybenzylidene)chroman-4-one (1h) 
showed an affinity for hMAO-B (IC50 = 8.61 nM) comparable to 1l.  
Although 1h was able to inhibit both hMAO isoforms, it still 
exhibited an excellent hMAO-B selectivity (SI = 1331). Although less 
active than 1h and 1l, (E)-5,7-dichloro-3-(4-
chlorobenzylidene)chroman-4-one (1e) showed hMAO-B affinity and 
selectivity (IC50 = 13.03 nM, SI > 7675) better than those of the 
reference compound, selegiline.  
The results for inhibitory effects and selectivity of the 3-benzyl-
4H-chromen-4-ones 2a-g and 3-benzylchroman-4-ones 3a-e on 
hMAO isoforms are reported in table 2.  
Several of these compounds (2e, 2f, 3a and 3c-e) showed 
selective hMAO-B inhibitory activities, whereas the 3-benzyl-4-
chromones 2a-d and 2g and the 3-benzylchroman-4-one 3b were 
essentially inactive towards both isoforms up to the highest 
concentration tested (100 µM). Disappointly, the endocyclic migration 
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of the double bond produces a loss of the inhibitory activity 
(compounds 2a-d, 2g) or a marked reduction in potency (compounds 
2e and 2f) with respect to the corresponding (E)-3-
benzylidenechroman-4-ones 1a-g. 
 
Table 2. IC50 and SI values for the inhibitory effects of 3-benzyl-4H-chromen-4-
ones 2a-g and 3-benzylchroman-4-ones 3a-e and reference inhibitors on the 
enzymatic activity of human recombinant MAO isoforms expressed in 
baculovirus infected BTI insect cells. 
Comp. R R1 R2 R3 R4 R5 MAO-A (IC50) 
MAO-B 
(IC50) 
SIb 
2a H H H H H H ** **  
2b H H H H OH H ** ***  
2c H H H H Cl H ** **  
2d H Cl H H Cl H ** ***  
2e Cl H H H Cl H *** 438.60 ± 27.48 nM > 228
# 
2f H H H H OCH3 H ** 
21.59 ± 
1.06 µM > 4.6
# 
2g OCH3 H H H OCH3 H ** ***  
3a H H H H H H ** 58.53 ± 2.24 µM > 1.7
# 
3b H H H H OH H ** ***  
3c H H H H Cl H ** 7.37 ± 0.31 µM > 14
# 
3d H Cl H H Cl H ** 3.07 ± 0.11 µM > 33
# 
3e Cl H H H Cl H ** 4.59 ± 0.19 µM > 22
# 
A       4.46 ± 0.32 nM a 
61.35 ± 
1.13 µM 0.000073 
B       67.25 ± 1.02 µM a 
19.60 ± 
0.86 nM 3431 
C       6.56± 0.76 µM 
7.54 ± 
0.36 µM 0.87 
D       361± 19.37 µM * < 0.36 
All IC50 values shown in this table are the mean ± S.E.M. from five experiments. Level of statistical 
significance: aP < 0.01 versus the corresponding IC50 values obtained against MAO-B, as determined 
by ANOVA/Dunnett´s. b SI: hMAO-B selectivity index = IC50 (hMAO-A)/IC50 (hMAO-B). * inactive 
at 1 mM (highest concentration tested). ** Inactive at 100 µM (highest concentration tested).*** 100 
µM inhibits the corresponding MAO activity by approximately 40-50%. At higher concentration the 
compounds precipitate.  # Values obtained under the assumption that the corresponding IC50 against 
MAO-B is the highest concentration tested (100 µM). 
A: Clorgyline, B: Selegiline, C: Iproniazid, D: Moclobemide 
 
The reduction of the double bond results in compounds 3a-e, 
generally more potent and selective than the corresponding 3-benzyl-
4H-chromen-4-ones 2a-g. The only exception was 5,7-dichloro-3-(4-
chlorobenzyl)-4H-chromen-4-one (2e) that exhibited  submicromolar 
potency towards hMAO-B, whereas the corresponding 3-
benzylchroman-4-one (3e) was about tenfold less active and less 
selective. However, all the 3-benzylchroman-4-ones 3a-e were less 
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potent hMAO-B inhibitors than the corresponding (E)-3-
benzylidenechroman-4-ones 1a-e. 
Table 3 shows the results of the reversibility and irreversibility 
tests for the most effective compounds 1h and 1l. hMAO-A and 
hMAO-B inhibition was irreversible in presence of 1h as shown by 
the lack of enzyme activity restoration after repeated washing. Similar 
results were obtained for compound 1l and selegiline against hMAO-
B. On the contrary, significant recovery of hMAO-A activity was 
observed after repeated washing of moclobemide, indicating that this 
drug is a reversible inhibitor of hMAO-A. 
 
Table 3. Reversibility and irreversibility of hMAO-B inhibition of 
derivatives 1h and 1la 
 % hMAO-A inhibition 
Compound Before washing After repeated washing 
1h (50 µM) 68.26 ± 4.34 61.76 ± 4.98 
Moclobemide (500 µM) 85.98 ± 4.03 11.45 ± 0.58b 
 % hMAO-B inhibition 
Compound Before washing After repeated washing 
1h (10 nM) 48.66 ± 6.39  36.22 ± 4.26 
1l  (10 nM) 56.34 ± 5.37 58.67 ± 6.60 
Selegiline (20 nM) 53.28 ± 2.59 56.34 ± 2.01 
aEach value is the mean ± S.E.M. from five experiments (n = 5). bLevel of statistical 
significance: P < 0.01 versus the corresponding % MAO-A or MAO-B inhibition before 
washing, as determined by ANOVA/Dunnett´s. 
 
2.1.3. Docking studies 
 
Docking studies were carried out to evaluate the binding modes 
of this class of homoisoflavonoids with respect to both isoforms of 
human MAO. Crystallographic structures were selected from the PDB 
to build our theoretical receptors models (Experimental section). 
Taking into account the experimental hMAO inhibition data, 
compounds 1h and 1l were chosen for our molecular modeling 
investigation. Although the irreversible inhibitors usually form a 
covalent bond with a residue on the enzyme, they may also act by 
other mechanisms.17 The so-called tight-binding inhibitors, owing to 
the very low dissociation constant, may show kinetics similar to 
covalent irreversible inhibitors. In some cases, the inhibitors may 
rapidly bind to the enzyme in a low-affinity enzyme-inhibitor (EI) 
complex and then undergoes a slower rearrangement to a very tightly 
bound EI* complex. For instance, R-(-)-deprenyl, an irreversible 
142	  	  
MAO inhibitor, forms a non-covalent complex with MAO as an initial 
and reversible step. Afterwards, the interaction of R-(-)-deprenyl with 
MAO leads to a reduction of the enzyme-bound FAD, and 
concomitant oxidation of the inhibitor. This oxidized inhibitor is able 
to form a covalent bond at the N-5-position of FAD.18 The initial non-
covalent binding to MAO has been also described for other MAO 
inhibitors (e.g.: clorgyline derivatives).19 Moreover, we have already 
docked non-covalent ligands13,14, 20  showing an irreversible profile 
similar to 1h and 1l.  
Both homoisoflavonoids were submitted to a conformational 
search revealing, not surprisingly, only two conformers within 10 
kcal/mol from the global minimum energy. Using the AutoDock-Vina 
method,21 the most populated structures of 1h and 1l were submitted 
to flexible docking simulation with respect to both hMAO-A and 
hMAO–B receptor models (Experimental section). The theoretical 
complexes were evaluated taking into account two interaction energy 
descriptors. Best interaction energy (IE) is the AutoDock-Vina lowest 
ligand-target interaction energy. ΔGbind is the Boltzmann averaged 
binding free energy computed with the entire complex ensemble 
generated by the docking program. In both cases, good qualitative 
agreements with experimental inhibition data have been obtained 
(table 4).  
 
Table 4. Comparison between experimental IC50 data and 
theoretical binding affinities of 1h and 1l with respect to 
hMAO-A and –B. 
hMAO-A hMAO-B 
 1h 1l 1h 1l 
IC50 a 11460.00 >100000.00 8.61 8.51 
ΔGbind b -6.30 -1.88 -9.10 -9.35 
Best IEc -7.00 -3.00 -9.50 -10.40 
a experimental inhibition data (nM); b free energy of binding (kcal/mol); c best 
interaction energy (kcal/mol) 
 
The most stable binding modes of both homoisoflavonoids in 
the hMAO-A and -B active sites were graphically inspected (figure 2). 
Docking simulations generated several low energy binding 
modes of 1h and 1l within both hMAO isoforms. These poses 
revealed the ability of these ligands to alternatively recognize the 
FAD with both benzyl and chromone rings (see Supporting 
Information). Interestingly, the hMAO-A best poses of the 1h and 1l 
chromone rings were located toward the enzymatic cofactor (figure 
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2a). Most of the ligand-enzyme interactions appeared to be identical. 
The main difference between 1h and 1l hMAO-A recognition was due 
to the presence of a phenol OH in the former compound that 
established a hydrogen bond with FAD N5 atom. Moreover 1h, 
attracted by the FAD, resulted in exclusive contact with Tyr69; 
conversely 1l was involved in attractive hydrophobic contacts with 
Asn181 and Tyr444. The effects of these different interactions on 
binding energy are highlighted in table 4.  
 
   
Figure 2. Most representative binding modes of 1h (green) and 1l (white) into a) hMAO-A  and b) 
hMAO-B catalytic sites. Common 1h and 1l interacting residues are reported in magenta carbon 
atoms sticks. Exclusive 1h or 1l interacting residues are displayed according to the corresponding 
ligands. The FAD cofactor is depicted using the spacefill representation. The rest of the enzyme is 
shown in yellow, transparent cartoon. Yellow dotted lines indicate hydrogen bonds.  
 
The best poses of these compounds in the hMAO-B binding site were 
different from the A isoform. These configurations displayed the 
chromone ring far from the FAD cofactor. In both 1h and 1l hMAO-B 
complexes the interaction pattern was similar: one hydrogen bond 
between the carbonyl oxygen of the ligands and Tyr326-OH and 
several almost identical hydrophobic contacts. The slightly better 
interaction of 1l can be addressed to its more hydrophobic nature than 
1h. Actually the chromone ring was surrounded by a large lipophilic 
cage (Phe103, Pro104, Trp119, Leu164, Leu167, Phe168, Leu171, 
Ile199 and Ile316) where 1h, due to its hydrophilic substituents, was 
disfavoured. Finally, the hMAO-B selectivity of both compounds can 
be referred to: a) the larger set of residues interacting with hMAO-B; 
b) the different hydrogen bond contribution, stronger in hMAO-B 
(Tyr326-OH--O=1h/1l) than in hMAO-A (FAD-N5--HO-1h).  
 
2.1.4. Conclusion 
 
In the current study we have synthesized and evaluated a series 
of (E)-3-benzylidenechroman-4-ones 1a-w, 3-benzyl-4H-chromen-4-
ones 2a-g and 3-benzylchroman-4-ones 3a-e as inhibitors of h-MAO 
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isoforms A and B. In general, the active compounds showed potent 
and selective activity towards the B isoform. In particular, several (E)-
3-benzylidenechroman-4-ones exhibited potencies in the nanomolar 
range. Two derivatives, 1h and 1l, were the most potent and selective 
hMAO-B inhibitors with higher potency than the reference inhibitor 
selegiline and, in the latter case, even higher selectivity. Molecular 
docking studies suggest that stronger enzyme-inhibitor hydrogen 
bonds and hydrophobic contacts in the hMAO-B active site can 
explain the selectivity of both inhibitors for this isoform. 
 
2.1.5. Experimental section 
 
2.1.5.1. Chemistry 
 
Chemicals were purchased from Sigma-Aldrich and used 
without further purification. Melting points were determined on a 
Stenford Research Systems OptiMelt (MPA-100) apparatus and are 
uncorrected. 1H NMR and 13C NMR spectra were recorded in 
DMSO-d6, unless indicated otherwise, on a Bruker AM-400 
spectrometer, using TMS as internal standard. IR spectra were 
recorded in KBr disks on an FT-IR PerkinElmer Spectrum 1000. All 
compounds were routinely checked by thin-layer chromatography 
(TLC), 1H NMR and 13C NMR. TLC was performed on silica gel or 
aluminium oxide fluorescent coated plates (Merck, Kieselgel or 
Aluminium oxide 60 F254). Components were visualised by UV light. 
Compound purity was determined by elemental analysis and was 
confirmed to be ≥ 95% for all compounds. (E)-3-
Benzylidenechroman-4-ones (1a-g), 3-benzyl-4-chromones (2a-g) and 
3-benzylchroman-4-ones (3a-e) were prepared as previously described 
by us.2 (E)-5,7-Dihydroxy-3-(4-hydroxybenzylidene)chroman-4-one 
(1h) was obtained by saponification of the corresponding tribenzoate 
as previously reported.25 
 
2.1.5.1.1. General Procedure for the Synthesis of (E)-3-
Benzylidenechroman-4-ones 1l-q and 1w. 
 
A mixture of the appropriate chroman-4-one (0.01 mol) and 
substituted benzaldehyde (0.01 mol) in 85% phosphoric acid (20 mL) 
was heated at 80 °C for 6h. After cooling, the mixture was diluted 
with ice-water (and made alkaline for the preparation of compound 
1l). The solid was filtered off, washed with water and crystallized. 
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2.1.5.1.1.1. (E)-3-(4-(Dimethylamino)benzylidene) chroman-4-one 
(1l). Yield: 77%, mp = 151-153 °C (lit 150-153 °C)7 from EtOH. The 
compound exhibited spectroscopic data identical to those previously 
reported.7 
 
2.1.5.1.1.2. (E)-3-(4-Hydroxy-3-methoxybenzylidene) chroman-4-
one (1m). Yield: 71%, mp = 130-131 °C (lit 126-129 °C)22 from ethyl 
alcohol. IR (KBr): 3200, 1655 cm-1. 1H NMR: δ (ppm) 9.75 (bs, 1H, 
OH), 7.88 (dd, 1H, H5, J5-6 = 8.0 Hz, J5-7 = 1.6 Hz), 7.71 (t, 1H, =CH, 
Jall= 1.8 Hz), 7.58 (ddd, 1H, H7, J6-7 = 7.2 Hz, J7-8 = 8.4 Hz, J5-7 = 1.6 
Hz), 7.12 (ddd, 1H, H6, J6-7 = 7.2 Hz, J5-6 = 8.0 Hz, J6-8 = 1.0 Hz), 
7.07 (d, 1H, H2’, J2’-6’ = 1.7 Hz), 7.05 (dd, 1H, H8, J7-8 = 8.4 Hz, J6-8 
= 1.0 Hz), 6.93 (dd, 1H, H6’, J2’-6’ = 1.7 Hz), 6.90 (d, 1H, H5’, J5’-6’ = 
8.4 Hz), 5.47 (d, 2H, H2, Jall= 1.7 Hz), 3.84 (s, 3H, OCH3). 13C NMR: 
δ (ppm) 180.9, 160.4, 148.8, 147.6, 137.2, 135.8, 127.7, 127.1, 125.2, 
124.4, 121.8, 121.6, 117.7, 115.6, 114.8, 67.5, 55.6. 
 
2.1.5.1.1.3. (E)-3-(3-Hydroxy-4-methoxybenzylidene)chroman-4-
one (1n). Yield: 78%, mp = 192-193 °C from EtOH. IR (KBr): 3150, 
1650 cm-1. 1H NMR: δ (ppm) 9.34 (bs, 1H, OH), 7.88 (dd, 1H, H5, J5-6 
= 7.9 Hz, J5-7 = 1.8 Hz), 7.64 (t, 1H, =CH, Jall = 1.8 Hz), 7.58 (ddd, 
1H, H7, J6-7 = 7.2 Hz, J7-8 = 8.4 Hz, J5-7 = 1.8 Hz), 7.13 (ddd, 1H, H6, 
J6-7 = 7.2 Hz, J5-6 = 7.9 Hz, J6-8 = 1.0 Hz), 7.07-7.03 (m, 2H, H8, H5’), 
6.94-6.91 (m, 2H, H2’, H6’), 5.43 (d, 2H, H2, Jall = 1.8 Hz), 3.85 (s, 
3H, OCH3). 13C NMR: δ (ppm) 180.9, 160.4, 149.4, 146.5, 136.8, 
135.9, 128.3, 127.1, 126.5, 122.9, 121.8, 121.5, 117.7, 117.2, 112.0, 
67.4, 55.6. 
 
2.1.5.1.1.4. (E)-3-(3,4-Dihydroxybenzylidene)chroman -4-one (1o). 
Yield: 54% , mp = 227-230 °C (lit 224-225 °C)22 from EtOH. IR 
(KBr): 3400, 1640 cm-1. 1H NMR: δ (ppm) 9.50 (bs, 2H, 2OH), 7.87 
(dd, 1H, H5, J5-6 = 7.8 Hz, J5-7 = 1.7 Hz), 7.61 (t, 1H, =CH, Jall= 1.8 
Hz), 7.58 (ddd, 1H, H7, J6-7 = 7.4 Hz, J7-8 = 8.4 Hz, J5-7 = 1.7 Hz), 7.12 
(ddd, 1H, H6, J6-7 = 7.4 Hz, J5-6 = 7.8 Hz, J6-8 = 1.0 Hz), 7.05 (dd, 1H, 
H8, J7-8 = 8.4 Hz, J6-8 = 1.0 Hz), 6.89-6.80 (m, 3H, H2’, H5’, H6’), 
5.43 (d, 2H, H2, Jall = 1.8 Hz). 13C NMR: δ (ppm) 180.9, 160.3, 147.8, 
145.3, 137.2, 135.8, 127.3, 127.1, 125.2, 123.4, 121.7, 121.6, 117.7, 
115.8, 67.5. 
 
2.1.5.1.1.5.    (E)-2-Hydroxy-5-[(4-oxochroman-3-ylidene)methyl] 
146	  	  
benzoic acid (1p). Yield: 74%, mp = 234-238 °C from EtOH. IR 
(KBr): 3500-2300, 1650, 1600 cm-1. 1H NMR: δ (ppm) 11.87 (bs, 1H, 
COOH), 7.87-7.80 (m, 2H, H5, H2’), 7.69 (bs, 1H, =CH), 7.63-7.54 
(m, 2H, H6’, H7), 7.12-7.01 (m, 3H, H5’, H6, H8), 5.40 (d, 2H, H2, 
Jall = 1.4 Hz). 13C NMR: δ (ppm) 180.9, 171.2, 162.0, 160.5, 137.4, 
136.0, 135.6, 132.7, 129.4, 127.1, 125.0, 121.8, 121.4, 117.8, 117.7, 
113.5, 67.2. 
 
2.1.5.1.1.6. (E)-3-(4-Hydroxy-3-nitrobenzylidene)chroman-4-one 
(1q). Yield: 77%, mp = 203-205 °C from EtOAc. IR (KBr): 3240, 
1655, 1530, 1300 cm-1. 1H NMR: δ (ppm) 11.65 (bs, 1H, OH), 7.94 (d, 
1H, H2’, J2’-6’ = 2.2 Hz), 7.88 (dd, 1H, H5, J5-6 = 7.9 Hz, J5-7 = 1.8 Hz), 
7.70 (bs, 1H, =CH), 7.64 (dd, 1H, H6’, J2’-6’ = 2.2 Hz, J5’-6’ = 8.7 Hz), 
7.60 (ddd, 1H, H7, J6-7 = 7.3 Hz, J7-8 = 8.4 Hz, J5-7 = 1.8 Hz), 7.23 (d, 
1H, H5’, J5’-6’ = 8.7 Hz), 7.13 (ddd, 1H, H6, J6-7 = 7.3 Hz, J5-6 = 7.9 
Hz, J6-8 = 0.9 Hz), 7.05 (dd, 1H, H8, J7-8 = 8.4 Hz, J6-8 = 0.9 Hz), 5.44 
(d, 2H, H2, Jall = 1.8 Hz).13C NMR: δ (ppm) 180.5, 160.5, 152.8, 
137.2, 136.5, 135.1, 134.4, 130.2, 127.2, 127.1, 124.9, 121.9, 121.3, 
119.3, 117.8, 67.2. 
 
2.1.5.1.1.7. (E)-3-(3,4,5-Trimethoxybenzylidene)chroman-4-one 
(1w). Yield: 63%, mp = 105-106 °C (lit 108-109 °C)23 from 
EtOAc/petroleum ether. IR (KBr): 1660 cm-1. 1H NMR: δ (ppm) 7.90 
(dd, 1H, H5, J5-6 = 7.8 Hz, J5-7 = 1.8 Hz), 7.73 (bs, 1H, =CH), 7.60 
(ddd, 1H, H7, J7-8 = 8.4 Hz, J6-7 = 7.2 Hz, J5-7 = 1.8 Hz), 7.14 
(ddd,1H, H6, J6-7 = 7.2 Hz, J5-6 = 7.8 Hz, J6-8 = 1.0 Hz), 7.06 (dd, 1H, 
H8, J7-8 = 8.4 Hz,  J6-8 = 1.0 Hz), 6.77 (s, 2H, H2’, H6’), 5.50 (d, 2H, 
H2 Jall= 1.8 Hz), 3.84 (s, 6H, 2OCH3), 3.74 (s, 3H, OCH3). 13C NMR: 
δ (ppm) 181.0, 160.6, 152.8, 138.9, 136.9, 136.2, 130.0, 129.2, 127.2, 
121.9, 121.5, 117.8, 108.0, 67.4, 60.1, 56.0. 
 
2.1.5.1.2. Synthesis of (E)-3-(4-Aminobenzylidene) chroman-4-one 
(1j) and (E)-N-(4-[(4-Oxochroman-3-ylidene)methyl]phenyl) 
acetamide (1k).  
 
A mixture of chroman-4-one (0.01 mol) and 4-
aminobenzaldehyde (0.01 mol) in 85% H3PO4 (20 mL) was heated at 
80 °C for 6h. After cooling, the mixture was diluted with ice-water 
and alkalinized with 2N NaOH. The solid was filtered off and washed 
with water. The obtained mixture of (E)-3-(4-aminobenzylidene) 
chroman-4-one (1j) and (E)-N-(4-[(4-oxochroman-3-
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ylidene)methyl]phenyl)acetamide (1k) was separated by column 
chromatography on silica gel eluting with AcOEt/ petroleum ether 
(1:1). 
 
2.1.5.1.2.1. (E)-3-(4-Aminobenzylidene)chroman-4-one (1j). Yield: 
30%, mp = 164-66 °C from EtOAc/petroleum ether. IR (KBr): 3430, 
3340, 1650 cm-1. 1H NMR: δ (ppm) 7.85 (dd, 1H, H5, J5-6 = 7.8 Hz, J5-
7 = 1.8 Hz), 7.62 (bs, 1H, = CH), 7.55 (ddd, 1H, H7, J6-7 = 7.2 Hz, J7-8 
= 8.4 Hz, J5-7 = 1.8 Hz), 7.21 (d, 2H, H2’, H6’, J2’-3’ = 8.6 Hz), 7.10 
(ddd, 1H, H6, J6-7 = 7.2 Hz, J5-6 = 8.2 Hz, J6-8 = 1.0 Hz), 7.03 (dd, 1H, 
H8, J7-8 = 8.4 Hz, J6-8 = 1.0 Hz), 6.66 (d, 2H, H3’, H5’, J2’-3’ = 8.6 
Hz), 5.95 (bs, 2H, NH2), 5.43 (d, 2H, H2, Jall= 1.8 Hz). 13C NMR: δ 
(ppm) 180.6, 160.2, 151.2, 137.8, 135.4, 133.0, 127.0, 124.6, 121.8, 
121.6, 121.0, 117.6, 113.5, 67.8. 
 
2.1.5.1.2.2. (E)-N-(4-[(4-Oxochroman-3-ylidene) methyl]phenyl) 
acetamide (1k). Yield: 25%, mp = 175-176 °C from 
EtOAc/petroleum ether. IR (KBr): 3300, 1664, 1660 cm-1. 1H NMR: δ 
(ppm) 10.23 (s, 1H, NH), 7.88 (dd, 1H, H5, J5-6 = 7.8 Hz, J5-7 = 1.6 
Hz), 7.74-7.70 (m, 3H, H2’, H6’, =CH), 7.59 (ddd, 1H, H7, J6-7 = 7.1 
Hz, J7-8 = 8.4 Hz, J5-7 = 1.6 Hz), 7.44 (d, 2H, H3’, H5’, J2’-3’ = 8.6 
Hz), 7.13 (ddd, 1H, H6, J6-7 = 7.1 Hz, J5-6 = 7.8 Hz, J6-8 = 0.7 Hz), 
7.06 (dd, 1H, H8, J7-8 = 8.4 Hz, J6-8 = 0.7 Hz), 5.45 (d, 2H, H2, Jall= 
1.6 Hz), 2.09 (s, 3H, CH3). 13C NMR: δ (ppm) 181.0, 168.7, 160.5, 
140.8, 136.3, 136.0, 131.5, 129.1, 128.3, 127.2, 121.9, 121.5, 118.7, 
117.8, 67.5, 24.1. 
 
2.1.5.1.3. General Procedure for the Synthesis of (E)-3-
Benzylidenechroman-4-ones 1i and 1s-v.  
 
A mixture of the appropriate chroman-4-one (0.01 mol) with 
substituted benzaldehyde (0.01 mol) in dry EtOH saturated with HCl 
(40 mL) was stirred at room temperature for 48h. After this time, the 
mixture was diluted with ice-water, the solid filtered off and washed 
with water. The product was purified by column chromatography on 
silica gel or by crystallization.  
 
2.1.5.1.3.1. (E)-3-Benzylidene-6-chlorochroman-4-one (1i). Yield: 
86%, mp = 158-159 °C (lit 148-150 °C)24  from EtOAc. IR (KBr): 
1660 cm-1. 1H NMR (CDCl3): δ (ppm) 7.98 (d, 1H, H5, J5-7 = 2.6 Hz), 
7.90 (bs, 1H, =CH), 7.49-7.37 (m, 4H, H7, H3’-H5’), 7.33-7.30 (m, 
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2H, H2’, H6’), 6.93 (d, 1H, H8, J7-8 = 8.8 Hz), 5.35 (d, 2H, H2, Jall = 
1.8 Hz). 13C NMR (DMSO d6): δ (ppm) 180.2, 159.2, 137.3, 135.7, 
133.5, 130.3, 129.8, 128.8, 126.0, 125.9, 124.8, 122.4, 120.3, 67.5. 
 
2.1.5.1.3.2. (E)-3-(2-Hydroxy-4-methoxybenzylidene) chroman-4-
one (1s). Purified by column chromatography eluting with 
AcOEt/petroleum ether (1:5). Yield: 56%, mp = 158-160 °C from 
EtOH. IR (KBr): 3124, 1655 cm-1. 1H NMR: δ (ppm) 10.34 (bs, 1H, 
OH), 7.89-7.86 (m, 2H, =CH, H5), 7.57 (ddd, 1H, H7, J6-7 = 7.2 Hz, 
J7-8 = 8.4 Hz, J5-7 = 1.8 Hz), 7.12 (ddd, 1H, H6, J6-7 = 7.2 Hz, J5-6 = 7.9 
Hz, J6-8 = 1.0 Hz), 7.08 (d, 1H, H6’, J5’-6’ = 8.2 Hz), 7.04 (dd, 1H, H8, 
J7-8 = 8.4 Hz, J6-8 = 1.0 Hz), 6.53-6.49 (m, 2H, H3’, H5’), 5.33 (d, 2H, 
H2, Jall = 1.8 Hz), 3.77 (s, 3H, OCH3). 13C NMR: δ (ppm) 181.2, 
162.2, 160.5, 158.6, 135.8, 132.8, 131.7, 127.3, 127.1, 121.8, 121.7, 
117.8, 114.0, 105.4, 101.1, 67.9, 55.2. 
 
2.1.5.1.3.3. (E)-3-(2,4-Dimethoxybenzylidene) chroman-4-one (1t). 
Yield: 64%, mp = 123-125 °C (lit 133-135 °C)7 from MeOH. The 
compound exhibited spectroscopic data identical to those previously 
reported.7 
 
2.1.5.1.3.4. (E)-3-(2,3-Dimethoxybenzylidene) chroman-4-one (1u). 
Yield: 53%, mp = 108-109 °C EtOAc/petroleum ether. IR (KBr): 
1673 cm-1. 1H NMR: δ d(ppm) 7.90 (dd, 1H, H5, J5-6 = 7.8 Hz, J5-7 = 
1.7 Hz), 7.82 (bs, 1H, =CH), 7.61 (ddd, 1H, H7, J7-8 = 8.9 Hz, J6-7 = 
7.2 Hz, J5-7 = 1.7 Hz), 7.22-7.12 (m, 3H, H6, H5’, H6’), 7.05 (d, 1H, 
H8, J7-8 = 8.3 Hz), 6.83 (dd, 1H, H4’, J4’-5’ = 6.9 Hz, J4’-6’ = 2.2 Hz), 
5.29 (d, 2H, H2 Jall= 1.8 Hz), 3.86 (s, 3H, OCH3), 3.74 (s, 3H, OCH3). 
13C NMR: δ (ppm) 181.2, 160.8, 152.5, 147.6, 136.3, 132.2, 131.3, 
127.6, 127.3, 124.1, 122.0, 121.8, 121.5, 118.0, 114.8, 67.6, 60.6, 
55.8. 
 
2.1.5.1.3.5. (E)-3-(2,3,4-Trimethoxybenzylidene) chroman-4-one 
(1v). Yield: 43% , mp = 116-118 °C (lit viscous oil)23 from acetone. 
IR (KBr): 1668 cm-1. 1H NMR: δ (ppm) 7.89 (dd, 1H, H5, J5-6 = 7.8 
Hz, J5-7 = 1.8 Hz), 7.79 (bs, 1H, =CH), 7.60 (ddd, 1H, H7, J7-8 = 8.9 
Hz, J6-7 = 7.2 Hz, J5-7 = 1.8 Hz), 7.13 (ddd, 1H, H6, J6-7 = 7.2 Hz, J5-6 
= 7.8 Hz, J6-8 = 1.0 Hz), 7.05 (dd, 1H, H8, J7-8 = 8.9 Hz, J6-8 = 1.0 
Hz), 6.98 (s, 1H, H6’, J2’-6’ = 8.7 Hz), 6.92 (s, 1H, H5’, J2’-6’ = 8.7 
Hz), 5.33 (d, 2H, H2, Jall= 1.8 Hz), 3.88 (s, 3H, OCH3), 3.83 (s, 3H, 
OCH3), 3.80 (s, 3H, OCH3). 13C NMR: δ (ppm) 181.1, 160.6, 155.3, 
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152.7, 141.7, 136.0, 132.0, 129.5, 127.2, 125.6, 121.9, 121.6, 120.3, 
117.8, 107.7, 67.7, 61.3, 60.5, 56.0. 
 
2.1.5.1.4. Synthesis of (E)-3-(3-Amino-4-hydroxybenzylidene) 
chroman-4-one (1r).  
 
Tin (II) chloride (0.03 mol) in EtOH (15 mL) was added to a 
suspension of (E)-3-(4-hydroxy-3-nitrobenzylidene) chroman-4-one 
(1q) (0.005 mol) in EtOH (35 mL) and concentrated HCl (75 mL). 
The mixture was refluxed for 2 h under stirring. After cooling, the 
mixture was neutralized with 2N NaOH and the solid was filtered off. 
The product was purified by column chromatography on silica gel 
(AcOEt/ petroleum ether 1:1). Yield: 46%, mp = 192-195 °C from 
EtOAc/petroleum ether. IR (KBr): 3460, 3380, 1655 cm-1. 1H NMR: δ 
(ppm) 9.80 (bs, 1H, OH), 7.86 (d, 1H, H5, J5-6 = 7.6 Hz), 7.59-7.55 
(m, 2H, = CH, H7), 7.12 (t, 1H, H6, J5-6 = J6-7 =  7.6 Hz), 7.04 (d, 1H, 
H8, J7-8 = 8.3 Hz), 6.78-6.75 (m, 2H, H2’, H6’), 6.61 (d, 1H, H5’, J5’-
6’ = 7.9 Hz), 5.43 (d, 2H, H2, Jall= 1.5 Hz), 4.76 (bs, 2H, NH2). 13C 
NMR: δ (ppm) 181.0, 160.4, 146.5, 137.9, 137.0, 135.7, 127.1, 126.8, 
125.3, 121.8, 121.7, 120.9, 117.7, 115.9, 114.3, 67.7. 
 
2.1.6. Pharmacological Studies. Determination of hMAO Isoform 
Activity.  
 
The effects of the test compounds on hMAO isoform enzymatic 
activity were evaluated by a fluorimetric method following the 
experimental protocol previously described.25 
 
2.1.6.1. Reversibility and Irreversibility Experiments.  
 
To evaluate whether some of the tested compounds (1h and 11) 
are reversible or irreversible hMAO-B inhibitors, an effective 
centrifugation-ultrafiltration method (so-called repeated washing) was 
used.13 
 
2.1.6.2. Molecular Modeling.  
 
Compounds 1h and 1l were built by means of the Maestro 
GUI.26 Conformational properties of both molecules have been 
investigated by means of 1000 steps of Monte Carlo (MC) search as 
implemented in Macromodel ver. 7.2.27 Each conformer was energy 
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minimized using the AMBER* 28 force field in united atoms notation. 
Water solvent effects have been taken into account by means of the 
implicit model GB/SA.29 The global minimum energy structures of 1h 
and 1l were considered for the next docking simulations. 
Crystallographic structures, deposited into the Protein Data Bank 
(PDB)30 with codes 2Z5X31 and 2V60,32 were considered, after 
graphical manipulation (fixing missing atoms and/or bond order, 
adding non-aliphatic H atoms), as receptor model of hMAO-A and 
hMAO-B, respectively. The co-crystallized ligands, harmine and 7-(3-
chlorobenzyloxy)-4-carboxaldehyde-coumarin respectively for 2Z5X 
and 2V60, were removed, FAD double bonds were fixed and 
hydrogen atoms were added onto both proteins and cofactors.  
According to the Autodock-Vina21 docking methodology, a regular 
box of 15,625 Å3, centered on the FAD N5, was considered as the 
active site in both hMAO-A and B receptor models. The global 
minimum energy conformers of 1h and 1l were submitted to flexible 
docking simulations. The estimation of the ΔGbind was carried out 
according to the following equation: 
 
 
 
ΔGbind = Boltzmann averaged binding free energy, c = configuration of the ligand-
target complex, n = maximum number of configurations, IEc = AutoDock-Vina 
interaction energy of the configuration c, Pc = Boltzman population at 300 °K for 
configuration c. 
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Supporting Information 
 
SI1. Elemental analyses of derivatives 1a-w. 
 
SI2. Elemental analyses of derivatives 2a-g and 3a-e. 
 
 
 
 
 
 
 
 
 
 
 
Comp C H Cl N 
 Calc  % Found % Calc % Found % Calc % Found % Calc % Found % 
1a 81.34 81.49 5.12 5.13     
1b 76.18 76.28 4.79 4.81     
1c 70.99 71.07 4.10 4.12 13.10 13.05   
1d 62.97 62.86 3.30 3.31 23.24 23.28   
1e 56.59 56.41 2.67 2.65 31.32 31.36   
1f 76.68 76.53 5.30 5.33     
1g 69.93 69.77 5.56 5.54     
1h 67.60 67.42 4.25 4.26     
1i 70.99 70.81 4.10 4.11 13.10 13.07   
1j 76.48 76.24 5.21 5.22   5.57 5.55 
1k 73.71 73.56 5.15 5.14   4.78 4.79 
1l 77.40 77.23 6.13 6.11   5.01 5.03 
1m 72.33 72.58 5.00 5.01     
1n 72.33 72.56 5.00 5.00     
1o 71.64 71.53 4.51 4.52     
1p 68.92 68.70 4.08 4.10     
1q 64.65 64.80 3.73 3.74   4.71 4.69 
1r 71.90 71.81 4.90 4.89   5.24 5.26 
1s 72.33 72.27 5.00 5.01     
1t 72.96 73.24 5.44 5.45     
1u 72.96 72.83 5.44 5.47     
1v 69.93 69.82 5.56 5.57     
1w 69.93 70.04 5.56 5.55     
Comp C H Cl 
 Calc % Found % Calc % Found % Calc % Found % 
2a 81.34 81.63 5.12 5.11   
2b 76.18 76.07 4.79 4.78   
2c 70.99 70.78 4.10 4.08 13.10 13.14 
2d 62.97 63.09 3.30 3.29 23.24 23.13 
2e 56.59 56.48 2.67 2.68 31.32 31.37 
2f 76.68 76.61 5.30 5.29   
2g 69.93 69.82 5.56 5.57   
3a 80.65 80.43 5.92 5.93   
3b 75.57 75.68 5.55 5.54   
3c 70.46 70.65 4.80 4.79 13.00 13.02 
3d 62.56 62.75 3.94 3.93 23.08 23.11 
3e 56.25 56.34 3.25 3.26 31.13 31.06 
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Molecular modeling details of derivatives 1h and 1l. 
 
 
Figure SI1: most stable complexes of compounds 1h (a-c) and 1l (d-f) 
into the hMAO-A active site and related interaction energies (I.E.) and 
Boltzman population (B.P.). The inhibitors are depicted in polytube, 
FAD cofactor in spacefill and enzyme residues in wireframe. Atoms are 
coloured following the CPK notation. I.E. 
 
 
 
Figure SI2: most stable complexes of compounds 1h (a-c) and 1l (d-f) 
into the hMAO-B active site and related interaction energies (I.E.) and 
Boltzman population (B.P.). The inhibitors are depicted in polytube, 
FAD cofactor in spacefill and enzyme residues in wireframe. Atoms are 
coloured following the CPK notation.	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2.2. 1,5-Diphenylpenta-2,4-dien-1-ones as potent and 
selective monoamine oxidase-B inhibitors. 
 
Nicoletta Desideria, Rossella Fioravantia, Luca Proietti Monacoa, 
Mariangela Biavaa, Matilde Yáñezb, Francesco Ortusoc, Stefano 
Alcaroc.  
Eur. J. Med. Chem. 59 (2013), 91-100. 
 
a Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza - 
Università di Roma, P.le Aldo Moro, 5, 00185 Rome, Italy 
b Departamento de Farmacología and Instituto de Farmacia 
Industrial, Facultad de Farmacia, Universidad de Santiago de 
Compostela, Campus Universitario Sur, E-15782 Santiago de 
Compostela (La Coruña), Spain 
c Dipartimento di Scienze della Salute, Università “Magna Græcia” 
di Catanzaro, Campus Universitario “S. Venuta”, Viale Europa, 
88100 Catanzaro, Italy. 
 
Recently, we reported new series of MAO inhibitors related to 
natural compounds as flavones, thioflavones and flavanones1, 
homoisoflavones2, and chalcones3, the biogenetic precursors of 
flavonoids. The potent and selective hMAO-B inhibitory activity of 
several synthetic chalcones3 and of 1,4-diphenyl-2-butene4, prompted 
us to designed and tested against hMAO-A and hMAO-B isoforms a 
series of structurally related (2E,4E)-1-(2-hydroxyphenyl)-5-
phenylpenta-2,4-dien-1-ones (3a-r) and (2Z,4E)-3-hydroxy-1-(2-
hydroxyphenyl)-5-phenylpenta-2,4-dien-1-one (6a-j). 
 
2.2.1. Results and discussion 
 
2.2.1.1. Chemistry 
 
  (2E,4E)-1-(2-Hydroxyphenyl)-5-phenylpenta-2,4-dien-1-ones 
(3a-r) were synthesized by base-catalysed reaction of the appropriate 
2-hydroxyacetophenone (1a-g) and substituted cinnamaldehyde (2a-
f). The condensation was performed in hydro-alcoholic sodium 
hydroxide or in methanol using barium hydroxide octahydrate as base 
(scheme 1). The deprotection of hydroxyl groups to obtain the 
compounds 3h, 3n, 3o, 3p and 3q was achieved during the work up of 
the reaction mixture.  
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(2Z,4E)-3-Hydroxy-1-(2-hydroxyphenyl)-5-phenylpenta-2,4-
dien-1-ones (6a-j) were prepared according to the two step procedure 
shown in scheme 2. The appropriate 2-hydroxyacetophenone (1a-e) 
was first converted into the corresponding 2-acetylphenyl (E)-
cinnamate (5a-j) by treatment with substituted cinnamic acid (4a-g) in 
the presence of phosphoryl chloride, in dry pyridine. In the second 
step, the Baker–Venkataraman rearrangement of the formed ester (5a-
j) into desired 6a-j was achieved in the presence of potassium 
carbonate, in dry acetone.  
The hydroxy-analogues 6k and 6l were achieved by treatment with 
boron tribromide of a solution of the corresponding methoxy 
derivatives 6e and 6f in dry dichloromethane (scheme 3).  
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2.2.1.2. Biochemistry 
 
The inhibitory potencies of the compounds on hMAO activity 
were investigated by measuring their effects on the production of 
hydrogen peroxide from p-tyramine using the Amplex Red MAO 
assay kit and microsomal MAO isoforms prepared from insect cells 
(BTI-TN-5B1-4) infected with recombinant baculovirus containing 
cDNA inserts for hMAO-A or hMAO-B. The hMAO activity was 
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evaluated by measuring the fluorescence generated by resorufin using 
the general procedure described previously by us5. 
The hMAO-A and hMAO-B inhibition data and the selectivity 
indexes (SI = IC50 hMAO-A /IC50 hMAO-B) of the (2E,4E)-1-(2-
hydroxyphenyl)-5-phenylpenta-2,4-dien-1-ones (3a-r) and (2Z,4E)-3-
hydroxy-1-(2-hydroxyphenyl)-5-phenylpenta-2,4-dien-1-ones (6a-l) 
are reported in table 1 and 2, respectively, together with the results 
obtained for the reference inhibitors (clorgyline, selegiline, isatin, 
iproniazid and moclobemide). 
Generally, the new tested compounds selectively inhibited the 
enzymatic activity of hMAO-B in the nanomolar or low micromolar 
range. The most interesting compound of the entire series of inhibitors 
was (2E,4E)-5-(4-chlorophenyl)-1-(2-hydroxy-4-
methoxyphenyl)penta-2,4-dien-1-one 3g, showing potent hMAO-B 
activity and high selectivity (IC50 = 4.51 nM, SI > 22173). Within the 
series of (2E,4E)-1-(2-hydroxyphenyl)-5-phenylpenta-2,4-dien-1-ones 
(3a-r), in addition to the affinity for hMAO-B, some derivatives (3f, 
3h, 3n, 3o, 3p and 3q) are also able to inhibit hMAO-A in the 
micromolar range. These compounds demonstrate a different extent of 
hMAO-B selectivity, showing SIs ranging from 1.5 to 1354. With the 
exception of 3f, these analogues bear at least another hydroxyl group 
in the aromatic rings in addition to the hydroxyl group in position 2. 
The same behavior was observed for related chalcones and 
homoisoflavones previously studied by us2,3. It is noteworthy that the 
replacement of the methoxyl group in the potent hMAO-B inhibitor 
3g with the hydroxyl group in the same position resulted in compound 
3h, able to inhibit both hMAO isoforms. Although about 2-fold less 
potent than 3g as hMAO-B inhibitor, 3h remain potent in the 
nanomolar range and endowed with an excellent selectivity (IC50 = 
11.35 nM, SI = 1354).  In this series of penta-2,4-dien-1-ones (3a-r), 
only the trimethoxy analogue 3m was essentially inactive against both 
isoforms up to the highest concentration tested (100 µM). The 
replacement of one or two methoxyl groups in 3m with hydroxyl 
groups results in compounds (3o, 3p and 3q) with affinity toward both 
hMAO isoforms. On the contrary, the removal of one or two methoxyl 
groups (compounds 3l and 3k, respectively) restored only the MAO-B 
affinity in the micromolar range. The replacement of the 3-methoxyl 
group in 3l with the hydroxyl group to obtain compound 3n, 
confirmed the ability of poli-hydroxy substituted analogues to inhibit 
both isoforms. 
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Table 1. hMAO Inhibitory activities and selectivity indexes of (2E,4E)-1-(2-
hydroxyphenyl)-5-phenylpenta-2,4-dien-1-ones (3a-r), (E)-1-(5-fluoro-2-
hydroxyphenyl)-3-phenylprop-2-en-1-one (7) and reference inhibitors. 
aAll IC50 values shown in this table are the mean ± S.E.M. from five experiments. Level of statistical significance: b P < 
0.01 or c P < 0.05 versus the corresponding IC50 values obtained against MAO-B, as determined by ANOVA/Dunnett´s. d 
SI: hMAO-B selectivity index = IC50(hMAO-A)/IC50(hMAO-B). e Inactive at 100 µM (highest concentration tested). f 100 
µM inhibits the corresponding MAO activity by approximately 40-50%. At higher concentration the compounds 
precipitate. g Inactive at 1 mM (highest concentration tested). h Values obtained under the assumption that the 
corresponding IC50 against MAO-A is the highest concentration tested (100 µM). iValues obtained under the assumption 
that the corresponding IC50 against MAO-B is the highest concentration tested (1 mM).  
A: Clorgyline, B: Selegiline, C: Isatin, D: Iproniazid, E: Moclobemide. 
 
 
Comp. R R1 R2 R3 R4 MAO-A (IC50)a MAO-B (IC50)a SId 
3a H H H H H e 105.51 ± 5.68 nM > 948h 
3b H Cl H H H e 54.77 ± 2.63 nM > 1826h 
3c H Cl H OCH3 H e 153.14 ± 6.21 nM > 653h 
3d H Cl H NO2 H e 1.08 ± 0.08 µM > 93h 
3e H Cl H Cl H e 1.46 ± 0.13 µM >68h 
3f H H H Cl H 37.73 ± 1.57 µMb 860.46 ± 43.18 nM 44 
3g OCH3 H H Cl H e 4.51 ± 0.28 nM > 22173h 
3h OH H H Cl H 15.37 ± 1.18 µMb 11.35 ± 0.73 nM 1354 
3i H F H H H e 75.84 ± 7.66 nM > 1319h 
3j H F H OCH3 H e 725.92 ± 31.56 nM > 138h 
3k H H H OCH3 H f 1.81 ± 0.15 µM > 55h 
3l H H H OCH3 OCH3 f 14.61 ± 2.18 µM > 6.8h 
3m H H OCH3 OCH3 OCH3 f e  
3n H H H OH OCH3 1.56 ± 0.19 µMb 501.66 ± 49.19 nM 3.1 
3o H H OCH3 OH OCH3 1.03 ± 0.25 µMb 486.35 ± 43.36 nM 2.1 
3p H H OH OCH3 OCH3 25.16 ± 1.96 µMb 1.45 ± 0.16 µM 17 
3q H H OH OH OCH3 1.43 ± 0.22 µMc 969.44 ± 87.45 nM 1.5 
3r H H H NO2 H e 160.32 ± 12.48 nM > 624h 
7 H F H H H f 667.89 ± 59.32 nM > 150h 
A      4.46 ± 0.32 nMb 61.35 ± 1.13 µM 0.000073 
B       67.25±1.02 µMb 19.60 ± 0.86 nM 3431 
C      f 21.07 ± 1.47 µM > 4.7 h 
    D      6.56 ± 0.76 µM 7.54 ± 0.36 µM 0.87 
E      361.38±19.3 µM g < 0.36i 
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Table 2. hMAO Inhibitory activities and selectivity indexes of (2Z,4E)-3-hydroxy-
1-(2-hydroxyphenyl)-5-phenylpenta-2,4 dien-1-ones (6a-l) and reference 
inhibitors. 
 
 
 
6a-l 
 
 
a All IC50 values shown in this table are the mean ± S.E.M. from five experiments. Level of statistical 
significance: b P < 0.01 or c P < 0.05 versus the corresponding IC50 values obtained against MAO-B, 
as determined by ANOVA/Dunnett´s. d SI: hMAO-B selectivity index = IC50(hMAO-A)/IC50(hMAO-
B). e Inactive at 100 µM (highest concentration tested). f 100 µM inhibits the corresponding MAO 
activity by approximately 40-50%. At higher concentration the compounds precipitate. gInactive at 1 
mM (highest concentration tested). h Values obtained under the assumption that the corresponding 
IC50 against MAO-A is the highest concentration tested (100 µM). iValues obtained under the 
assumption that the corresponding IC50 against MAO-B is the highest concentration tested (1 mM).  
A: Clorgyline, B: Selegiline, C: Isatin, D: Iproniazid, E: Moclobemide. 
 
The introduction of a hydroxyl group in position 3 of the chain 
results in the (2Z,4E)-3-hydroxy-1-(2-hydroxyphenyl)-5-phenylpenta-
2,4-dien-1-ones (6a-l). This structural modification produced a loss of 
the inhibitory activity or a marked reduction in potency with respect to 
unsubstituted (2E,4E)-1-(2-hydroxyphenyl)-5-phenylpenta-2,4-dien-1-
Compd R R1 R2 R3 R4 MAO-A (IC50)a MAO-B (IC50)a SId 
6a H H H H H e 1.16 ± 0.03 µM > 86h 
6b H Cl H Cl H e e  
6c H H H Cl H e f  
6d H F H H H e 50.44 ± 4.61 nM > 1983h 
6e H H H OCH3 H e f  
6f H H H OCH3 OCH3 e e  
6g H H OCH3 OCH3 OCH3 f e  
6h H H OCH3 OH OCH3 3.76 ± 0.42 µMb 1.68 ± 0.21 µM 2.2 
6i H H H NO2 H e 2.67 ± 0.28 µM > 37h 
6j H H H CH3 H e 3.77 ± 0.19 µM > 27h 
6k H H H OH H 1.52 ± 0.04 µMb 26.46 ± 1.97 nM 57 
6l H H H OH OH 431.07 ± 52.45 nMc 654.32 ± 61.05nMb 0.66 
A      4.46 ± 0.32 nMb 61.35 ± 1.13 µM 0.000073 
B      67.25 ± 1.02 µMb 19.60 ± 0.86 nM 3431 
C      f 21.07 ± 1.47 µM > 4.7 h 
D      6.56 ± 0.76 µM 7.54 ± 0.36 µM 0.87 
E      361.38 ± 19.3 µM g < 0.36i 
161	  	  
ones (3a-r) (table 2). The only exception was represented by (2Z,4E)-
1-(5-fluoro-2-hydroxyphenyl)-3-hydroxy-5-phenylpenta-2,4-dien-1-
one (6d) that showed a potent hMAO-B inhibitory activity slightly 
higher than the corresponding (2E,4E)-1-(5-fluoro-2-hydroxyphenyl)-
5-phenylpenta-2,4-dien-1-one (3i) (IC50 = 50.44 nM and 75.84 nM, 
respectively) and better selectivity (SI > 1983 and > 1319, 
respectively). Also in this series of inhibitors, the compounds 
substituted with more than one hydroxyl group in the aromatic rings 
(6h, 6k and 6l) are able to inhibit both hMAO isoforms. In particular, 
6l was the only hMAO-A inhibitor of both series active in the 
submicromolar range. Moreover, its potency toward B isoform was 
slightly higher than the potency toward A isoform, resulting in an 
essentially nonselective compound. 
To evaluate whether the most potent hMAO-B inhibitors (3b, 3g, 
3h, 6d, 6k) are reversible or irreversible hMAO-B inhibitors, the so-
called repeated washing method was used3. The results obtained using 
selegiline (irreversible inhibitor) and isatin (reversible inhibitor) as 
reference compounds are reported in table 3. 
 
Table 3. Reversibility and irreversibility of hMAO-B inhibition of 
derivatives 3b, 3g, 3h, 6d and 6k. 
% MAO-B inhibition 
Comp	   Before 
washing 
After repeated washinga 
3b (100 nM) 58.10 ± 0.10 60.30 ± 2.53 
3g (10 nM) 61.34 ± 2.38 37.51 ± 1.13 
3h (10 nM) 51. 52 ± 3.18 42.02 ± 0.70 
6d (100 nM) 62.35 ± 0.45 68.80 ± 3.33 
6k (100 nM) 66.70 ± 1.52 68.55 ± 4.39 
isatin (30 µM) 64.31 ± 2.08 31.22 ± 0.91 
selegiline (20 nM) 53.08 ± 1.64 54.63 ± 1.72 
Each value is the mean ± S.E.M. from five experiments (n = 5). 
aLevel of statistical significance: P < 0.01 versus the corresponding MAO-B inhibition 
before washing, as determined by ANOVA/Dunnett´s. 
 
The reversibility tests revealed the lack of enzyme activity 
restoration after repeated washing for compounds 3b, 6d and 6k. 
Similar results were obtained for selegiline a well-known irreversible 
MAO-B inhibitor. On the contrary, significant recovery of MAO-B 
activity was observed after repeated washing of isatin (reversible 
inhibitor) and compound 3g. The enzymatic inhibition lowered in a 
minor extent after repeated washing in the presence of 3h (table 3). 
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These results suggest that the novel potent hMAO-B inhibitors 3g and 
3h are reversible inhibitors. 
 
2.2.1.3. Molecular modeling studies  
 
With the aim to rationalize the different hMAO inhibition of the 
analogues 3g and 3h, molecular modeling studies were carried out. 
Following our previous experience6 we have adopted both molecular 
mechanics and quantum chemistry methods to elucidate the 
mechanism of inhibition of previously reported compounds. In 
particular, the recognition of hMAO-A and –B and the role of the p-
methoxy substituent, available into the 3g in replacement of the 3h 
hydroxy group, were investigated.  
In order to obtain reasonable configuration of both inhibitors 
into the hMAO-A and –B binding clefts, docking experiment were 
performed. The top ranked theoretical complex revealed remarkable 
similarities, actually, in all cases the ligands showed the phenolic ring 
and the p-chlorophenyl moieties respectively positioned towards the 
FAD cofactor and the entrance gorge surrounded by hydrophobic 
residues. With the aim to improve the analysis of 3g and 3h hMAO 
recognition, new complexes between our inhibitors and both target 
isoform models were manually built by means of a 180° rotation of 
the corresponding top ranked poses. Resulting structures, after energy 
optimisation and re-scoring procedure, revealed interaction energy 
remarkably weaker than the orginal top ranked poses (see table 1 in 
Supplementary content). Such a scenario and the docking score (see 
Figure S1 in Supplementary content) were not in agreement to the 
experimental IC50 data, as a consequence, each top ranked docking 
complex was submitted to 12 ns of molecular dynamics (MD). The 
resulting four trajectories were analyzed in terms of inhibitor target 
interaction energy and geometry (Experimental section) reporting a 
good qualitative agreement to the experimental inhibition data. 
Actually, hMAO-B·3g resulted as the most energy favored complex 
with an advantage of about 10 kcal/mol with respect to the hMAO-A 
3g, conversely predicted as the worst one. The hMAO-B binding 
energies of 3h indicated a disadvantage of 3.4 kcal/mol with respect 
to 3g on the contrary, into the hMAO-A, 1.2 kcal/mol demonstrated 
its better recognition than 3g (see figure S2 in Supplementary 
content). The hMAO-B selectivity of the selected compounds was 
also remarked by computing, during the molecular dynamics runs, the 
target backbone root mean square deviation (RMSd) with respect to 
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the corresponding starting structures (see figure S3 in Supplementary 
content). As reported by the average RMSd values, the target isoform 
B accommodate both inhibitors with lower perturbation (3g = 1.86 Å; 
3h = 2.44 Å) than hMAO-A (3g = 3.79 Å; 3h = 4.12 Å). Such data 
were not a surprise because it is known7 that hMAO-B active site 
(~700 Å3) is larger than hMAO-A one (~400 Å3), and contributed to 
rationalize the isoform selectivity of our compounds. With the aim to 
identify the most relevant residues interacting to 3g and 3h, all MD 
trajectory frames were investigated. The contribution of each residue 
to the inhibitor binding was expressed as percentage of frames 
reporting its interaction to the ligand (figure 1). 
 
 
Figure 1. Representative molecular dynamics binding modes of 3g (left side) and 
3h (right side) into the hMAO-A (top side) and hMAO-B (bottom side) active sites. 
Residues interacting to the inhibitors with a frequency higher than 60% are reported 
in green carbons sticks or spacefill, ligands are depicted in gray carbons balls and 
sticks. Yellow dotted lines indicate hydrogen bonds. 
 
Due to wide movements into the hMAO-A cleft, both 
compounds showed a larger number of interacting residues in this 
isozyme (see figures S4 and S5 in Supplementary content). The 
percentage of frames reporting 3g or 3h interacting to the FAD 
remarked that our ligands were located into the hMAO-B binding cleft 
(3g = 93.78%; 3h = 92.12%) deeper than into the hMAO-A (3g = 
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82.16%; 3h = 82.99%). Such an information suggested to investigate 
the stacking interaction among the phenolic ring of our compounds 
and the hMAO-A Tyr407 and 444 and the corresponding hMAO-B 
Tyr398 and 435. The compound 3g into the hMAO-B showed 
stacking with both residues for more than 90% of the simulation time, 
while in all other cases a preference for one of the two tyrosines was 
observed. The stacking stability could be attributed to the 3g p-
methoxy phenyl group. In order to deep investigate the role of such a 
moiety, quantum mechanics calculations of both ligands molecular 
orbital were performed (Experimental section). 
As expected, even if molecular orbital distribution of our 
compounds was similar, 3g revealed HOMO/LUMO areas 
surrounding the p-methoxy phenyl ring larger than 3h (see Figure S5 
in Supplementary content) suggesting stronger interaction to the 
tyrosine residues. Moreover, such a substituent highlighted a different 
role depending on the target. In the hMAO-A p-methoxy phenyl ring 
cannot interact to Tyr197 and allowed the hydrogen bonding between 
3g o-phenolic group and both Asn181 sidechain and Ile207 
backbone. Unlike 3h, the interaction network has forced the removal 
of the 3g aromatic ring from the FAD and consequently from the 
Tyr407-444 stacking. Into the hMAO-B, the substitution of the 
Asn181 with the Cys172 was mainly responsible of our compounds 
isoform selectivity. In fact, the flexibility of the Cys sidechain was 
lower than Asn and the hydrogen bond to Cys172 was unable to 
withdraw from the FAD both our inhibitors that, therefore, 
established stacking contacts to Tyr398 and 435. The hMAO-B active 
site, larger than hMAO-A, allowed the entrance of solvent water 
molecules that contributed to the complexes stabilization performing 
hydrogen bond bridge between the keto-group of our compounds and 
the Tyr326 side chain. 
 
2.2.1.4. Conclusion 
 
A new class of highly potent and selective hMAO-B inhibitors 
was identified. The most potent derivatives 3g and 3h showed 
inhibitory activity in the low nanomolar range coupled with high 
selectivity. Moreover, the results of reversibility tests suggest that 
these two compounds are reversible inhibitors of MAO-B. Based on 
their potent and selective MAO-B inhibitory properties, these 
compounds could be useful for the development of promising drug 
candidate for the therapy of neurodegenerative diseases. 
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2.2.1.5. Experimental section 
 
2.2.1.5.1. Chemistry  
 
Chemicals were purchased from Sigma-Aldrich and used 
without further purification. Melting points were determined on a 
Stenford Research Systems OptiMelt (MPA-100) apparatus and are 
uncorrected. 1H NMR and 13C NMR spectra were detected with a 
Bruker AM-400 spectrometer, using TMS as internal standard. IR 
spectra were recorded on a FT-IR PerkinElmer Spectrum 1000. All 
compounds were routinely checked by thin-layer chromatography 
(TLC) and 1H NMR. TLC was performed on silica gel or aluminium 
oxide fluorescent coated plates	   (Fluka, DC-Alufolien Kieselgel or 
aluminum oxide F254). Compound purity was determined by 
elemental analysis and was confirmed to be >95% for all the tested 
compounds. Analytical results are within ±0.40% of the theoretical 
values (Table 2 in Supplementary content). The synthetic 
intermediates 2-hydroxy-4-[(tetrahydro-2H-pyran-2-
yl)oxy]acetophenone (1f)3, 2-hydroxy-6-[(tetrahydro-2H-pyran-2-
yl)oxy]acetophenone (1g)8, (E)-3,4-dimethoxycinnamaldehyde (2e)9, 
and (E)-3-(4-acetoxy-3-methoxy)cinnamic acid (2f)10 were 
synthesized following the procedure previously described. (2E,4E)-1-
(2-Hydroxyphenyl)-5-phenylpenta-2,4-dien-1-ones (3a-f, 3i, 3k, 
3r)11,12, 2’-cinnamoyloxyacetophenones (5a-e, 5i, 5j) 12,13, (2Z,4E)-3-
hydroxy-1-(2-hydroxyphenyl)-5-phenylpenta-2,4-dien-1-ones (6a-e, 
6i, 6j, 6k)12,13 , and (E)-1-(5-fluoro-2-hydroxyphenyl)-3-phenylprop-
2-en-1-one (7) 12 were prepared as previously reported by us.  
 
2.2.1.5.2. General procedure for the synthesis of (2E,4E)-1-(2-
hydroxyphenyl)-5-phenylpenta-2,4-dien-1-ones (3j, 3l-q).  
An aqueous solution of 60% sodium hydroxide (50 mL) was 
added dropwise to a stirred suspension of the appropriate 2′-
hydroxyacetophenone (1a, 1c, 1d, 1g) (10 mmol) and substituted 
cinnamaldehyde (2c, 2e, 2f) (11 mmol) in methanol (50 mL), cooled 
in ice bath. The mixture was stirred at room temperature for 48 h (3j, 
3l, 3m, 3p, 3q) or heated at 60 °C for 5 h (3n, 3o). After that period, 
the suspension was diluted with ice and water and acidified with 2N 
hydrochloric acid. For the eventual deprotection of the hydroxyl group 
(synthesis of compounds 3n-q), the mixture was stirred at room 
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temperature for 1 h. The resulting suspension was filtered (3j) or 
extracted with AcOEt (3l-q). In the latter case, the combined organic 
phases were washed with saturated NaHCO3 solution and brine, then 
dried over Na2SO4, filtered and evaporated to dryness. The crude 
product was purified by crystallization from AcOEt (3j) or 
chromatographed on a silica gel column eluting with 
AcOEt/petroleum ether 1:1 (3l and 3m), AcOEt/petroleum ether 1:3 
(3p), AcOEt/petroleum ether 1:4 (3q) or CH2Cl2 (3n and 3o). 
 
2.2.1.5.2.1. (2E,4E)-1-(5-Fluoro-2-hydroxyphenyl)-5-(4-
methoxyphenyl)penta-2,4-dien-1-one (3j). Yield: 78%; mp 191-193 
°C from AcOEt. IR (KBr) 3450, 1620 cm-1. 1H NMR (CDCl3): δ 
(ppm) 12.70 (s, 1H, OH), 7.75 (dd, 1H, Hβ,  Jα-β = 14.5 Hz, Jβ-γ = 10.3 
Hz), 7.55-7.47 (m, 3H, H6, H2’, H6’), 7.23 (dt, 1H, H4, J4-F = 8.8 Hz, 
J3-4 = 8.8 Hz, J4-6 = 2.8 Hz), 7.12-6.86 (m, 6H, Hα, Hγ, Hδ, H3, H3’, 
H5’), 3.87 (s, 3H, OCH3). 13C NMR (CDCl3): δ (ppm) 192.8 (d, JC-F = 
2.3 Hz), 161.1, 159.7, 154.9 (d, JC-F = 236.1 Hz), 147.0, 143.6, 129.2, 
128.7, 124.4, 123.5 (d, JC-F = 23.7 Hz), 121.7, 119.7 (d, JC-F = 7.3 Hz), 
119.6 (d, JC-F = 6.1 Hz), 114.5, 114.4 (d, JC-F = 21.3 Hz), 55.4. 
 
2.2.1.5.2.2. (2E,4E)-5-(3,4-Dimethoxyphenyl)-1-(2-hydroxyphenyl) 
penta-2,4-dien-1-one (3l). Yield: 48%; mp 193-196 °C from acetone. 
IR (KBr) 1632 cm-1. 1H MNR (CDCl3): δ (ppm) 12.96 (s, 1H, 2OH), 
7.84 (dd, 1H, H6, J5-6 = 8.1 Hz, J4-6 = 1.6 Hz), 7.72 (dd, 1H, Hβ, Jα-β = 
14.6 Hz, Jβ-γ = 10.6 Hz), 7.47 (ddd, 1H, H4, J4-5 = 7.2 Hz, J3-4 = 8.5 
Hz, J4-6 = 1.6 Hz), 7.19 (d, 1H, Hα, Jα-β = 14.6 Hz), 7.08 (dd, 1H, H6’, 
J5’-6’ = 8.3 Hz, J2’-6’ = 1.9 Hz), 7.05-6.86 (m, 6H, Hγ, Hδ, H3, H5, 
H2’, H5’), 3.95 (s, 3H, OCH3), 3.93 (s, 3H, OCH3). 13C NMR 
(CDCl3): δ (ppm) 193.7, 163.6, 150.7, 149.4, 145.9, 143.0, 136.1, 
129.4, 129.2, 124.9, 122.5, 121.7, 120.2, 118.7, 118.6, 111.3, 109.5, 
56.0, 55.9. 
 
2.2.1.5.2.3 (2E,4E)-5-(3,4-Dimethoxyphenyl)-1-(2-hydroxy-6-
methoxyphenyl)penta-2,4-dien-1-one (3m). Yield: 48%; mp 136-
139 °C from AcOEt/petroleum ether. IR (KBr) 1621 cm-1. 1H MNR 
(CDCl3): δ (ppm) 13.28 (s, 1H, OH), 7.66 (dd, 1H, Hβ, Jα-β = 14.8 Hz, 
Jβ-γ = 10.4 Hz), 7.40 (d, 1H, Hα, Jα-β = 14.8 Hz), 7.34 (t, 1H, H4, J3-4 = 
J4-5 = 8.3 Hz), 7.08 (dd, 1H, H6’, J5’-6’ = 8.3 Hz, J2’-6’ = 1.9 Hz), 7.05 
(d, 1H, H2’, J2’-6’ = 1.9 Hz), 6.97 (d, 1H, Hδ, Jγ-δ = 15.3 Hz), 6.89 (dd, 
1H, Hγ, Jβ-γ = 10.4 Hz, Jγ-δ = 15.3 Hz), 6.86 (d, 1H, H5’, J5’-6’ = 8.3 
167	  	  
Hz), 6.60 (d, 1H, H5, J4-5 = 8.3 Hz), 6.41 (d, 1H, H3, J3-4 = 8.3 Hz), 
3.95 (s, 3H, OCH3), 3.94 (s, 3H, OCH3), 3.92 (s, 3H, OCH3). 13C 
NMR (CDCl3): δ (ppm) 194.2, 164.9, 160.9, 150.4, 149.3, 144.2, 
141.8, 135.6, 129.9, 129.5, 125.6, 121.5, 112.0, 111.3, 111.0, 109.5, 
101.5, 55.99, 55.96, 55.85.  
 
2.2.1.5.2.4. (2E,4E)-5-(4-Hydroxy-3-methoxyphenyl)-1-(2-
hydroxyphenyl)penta-2,4-dien-1-one (3n). Yield: 80%; mp 124-126 
°C from AcOEt/petroleum ether. IR (KBr) 3455, 1630 cm-1. 1H NMR 
(CDCl3): δ (ppm) 12.96 (s, 1H, 2OH), 7.84 (dd, 1H, H6, J4-6 = 1.5 Hz, 
J5-6 = 8.1 Hz ), 7.71 (dd, 1H, Hβ, Jα-β = 14.6 Hz, Jβ-γ = 10.7 Hz), 7.47 
(ddd, 1H, H4, J4-5 = 7.3 Hz, J3-4 = 8.5 Hz, J4-6 = 1.5 Hz), 7.18 (d, 1H, 
Hα, Jα-β = 14.6 Hz), 7.07 (dd, 1H, H6’, J5’-6’ = 8.2 Hz, J2’-6’ = 1.8 Hz), 
7.03-6.87 (m, 6H, Hγ, Hδ, H3, H5, H2’, H5’), 5.84 (s, 1H, 4’OH), 
3.95 (s, 3H, OCH3). 13C NMR (CDCl3): δ (ppm) 193.7, 163.6, 147.5, 
146.9, 146.0, 143.2, 136.1, 129.4, 128.7,124.6, 122.2, 122.1, 120.1, 
118.7, 113.6, 114.9, 109.1, 56.0. 
 
2.2.1.5.2.5. (2E,4E)-5-(4-Hydroxy-3-methoxyphenyl)-1-(2-
hydroxy-6-methoxyphenyl)penta-2,4-dien-1-one (3o). Yield: 58%; 
mp 113-115 °C from AcOEt/ petroleum ether. IR (KBr) 3443, 1620 
cm-1. 1H MNR (CDCl3): δ (ppm) 13.29 (s, 1H, 2OH), 7.65 (dd, 1H, 
Hβ, Jα-β = 14.8 Hz, Jβ-γ = 10.3 Hz), 7.39 (d, 1H, Hα, Jα-β = 14.8 Hz), 
7.33 (t, 1H, H4, J4-5 = J3-4 = 8.3 Hz), 7.06 (dd, 1H, H6’, J5’-6’ = 8.2 Hz, 
J2’-6’ = 1.9 Hz), 7.00 (d, 1H, H2’, J2’-6’ = 1.9 Hz), 6.95-6.83 (m, 3H, 
Hγ, Hδ, H5’), 6.60 (dd, 1H, H5, J4-5 = 8.3 Hz, J3-5 = 0.8 Hz), 6.40 (dd, 
1H, H3, J3-4 = 8.3 Hz, J3-5 = 0.8 Hz), 5.83 (s, 1H, 4’OH), 3.95 (s, 3H, 
OCH3), 3.93 (s, 3H, OCH3). 13C NMR (CDCl3): δ (ppm) 194.2, 164.9, 
160.9, 147.1, 146.8, 144.3, 142.0, 135.6, 129.7, 129.0, 125.3, 121.8, 
114.8, 112.0, 110.9, 109.1, 101.5, 56.0, 55.8. 
 
2.2.1.5.2.6.        (2E,4E)-1-(2,6-Dihydroxyphenyl)-5-(3,4-dimethoxy 
phenyl)penta-2,4-dien-1-one (3p). Yield: 38%; mp 185-189 °C from 
EtOH. IR (KBr) 3405, 1625 cm-1. 1H MNR (CD3COCD3): δ (ppm) 
11.58 (s, 2H, OH), 7.75-7.64 (m, 2H, Hα, Hβ), 7.31 (d, 1H, H2’, J2’-6’ 
= 2.0 Hz), 7.26 (t, 1H, H4, J3-4 = 8.2 Hz), 7.17-7.10 (m, 3H, Hγ, Hδ, 
H6’), 6.97 (d, 1H, H5’, J5’-6’ = 8.3 Hz), 6.43 (d, 2H, H3, H5, J3-4 = 8.2 
Hz), 3.87 (s, 3H, OCH3), 3.85 (s, 3H, OCH3). 13C NMR (DMSO D6): 
δ (ppm) 194.0, 160.6, 150.2, 149.0, 144.7, 142.2, 134.8, 129.5, 129.0, 
125.4, 121.8, 111.7, 111.6, 109.8, 107.1, 55.56, 55.57. 
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2.2.1.5.2.7. (2E,4E)-1-(2,6-Dihydroxyphenyl)-5-(4-hydroxy-3-
methoxyphenyl)penta-2,4-dien-1-one (3q). Yield: 45%; mp 176-179 
°C from AcOEt/petroleum ether. IR (KBr) 3374, 1628 cm-1. 1H MNR 
(CD3COCD3): δ (ppm) 11.5 (s, 2H, OH), 8.05 (s, 1H, OH), 7.73-7.64 
(m, 2H, Hα, Hβ), 7.31 (d, 1H, H2’, J2’-6’ = 1.9 Hz), 7.26 (t, 1H, H4, J3-
4 = 8.2 Hz), 7.12-7.09 (m, 3H, Hγ, Hδ, H6’), 6.85 (d, 1H, H5’‚ J5’-6’ = 
8.2 Hz), 6.43 (d, 2H, H3, H5, J3-4 = 8.2 Hz), 3.91 (s, 3H, OCH3). 13C 
NMR (DMSO D6): δ (ppm) 194.0, 160.6, 148.5, 148.0, 145.0, 142.8, 
134.8, 128.9, 127.8, 124.5, 122.1, 115.6, 111.6, 110.5, 107.1, 55.7. 
 
2.2.1.5.3. Synthesis of (2E,4E)-5-(4-chlorophenyl)-1-(2-hydroxy-4-
methoxyphenyl)penta-2,4-dien-1-one (3g). Barium hydroxide 
octahydrate (15 mmol) was added to a mixture of 2-hydroxy-4-
methoxyacetophenone (1e) (10 mmol) and 4-chlorocinnamaldehyde 
(2b) (10 mmol) in EtOH (200 mL). The mixture was stirred at 50 °C 
for 5 h and at room temperature overnight. After removal of ethanol in 
vacuum, water was added to the residue and the pH was adjusted to 2 
with 2N HCl. The mixture was extracted with AcOEt. The combined 
organic phases were washed with saturated NaHCO3 solution and 
brine, than dried over Na2SO4, filtered and evaporated to dryness. The 
residue was purified by silica gel column chromatography eluting with 
AcOEt/petroleum ether 1:4. Yield: 40%; mp 182-183 °C from AcOEt. 
IR (KBr) 3454, 1621 cm-1. 1H MNR (DMSO D6): δ (ppm) 13.46 (s, 
1H, OH), 7.92 (d, 1H, H6, J5-6 = 9.4 Hz), 7.65 (dd, 1H, Hβ, Jα-β = 14.8 
Hz, Jβ-γ = 8.4 Hz), 7.43 (d, 2H, H2’, H6’, J2’-3’ = 8.4 Hz), 7.34 (d, 2H, 
H3’, H5’, J2’-3’ = 8.4 Hz), 7.14 (d, 1H, Hα, Jα-β = 14.8 Hz), 7.03-6.94 
(m, 2H, Hγ, Hδ), 6.48-6.45 (m, 2H, H3, H5), 3.85 (s, 3H, OCH3). 13C 
MNR (DMSO D6): δ (ppm) 191.7, 166.7, 166.2, 144.0, 140.5, 135.1, 
134.6, 131.1, 129.1, 128.5, 127.4, 124.3, 114.1, 107.7, 101.1, 55.6. 
 
2.2.1.2.3.1. Synthesis of (2E,4E)-5-(4-chlorophenyl)-1-(2,4-
dihydroxyphenyl)penta-2,4-dien-1-one (3h). Barium hydroxide 
octahydrate (15 mmol) was added to a mixture of 2-hydroxy-4-
[(tetrahydro-2H-pyran-2-yl) oxy]acetophenone (1g)3 (10 mmol) and 
4-chlorocinnamaldehyde (2b) (10 mmol) in EtOH (200 mL). The 
mixture was stirred at 50 °C for 5 h and at room temperature 
overnight. After removal of ethanol in vacuum, water was added to 
the residue, the pH was adjusted to 2 with 2N HCl, and the mixture 
was stirred at room temperature for 1 h. After this period, the solid 
169	  	  
was removed by filtration, washed with water and purified by silica 
gel column chromatography eluting with AcOEt/ petroleum ether 1:4. 
Yield: 61%; mp 217-220 °C from AcOEt/ petroleum ether. IR (KBr) 
3440, 3241, 1636 cm-1. 1H MNR (DMSO D6): δ (ppm) 13.36 (s, 1H, 
OH), 10.80 (bs, 1H, OH), 7.92 (d, 1H, H6, J5-6 = 8.9 Hz), 7.62 (d, 2H, 
H2’, H6’, J2’-3’ = 8.4 Hz), 7.58 (dd, 1H, Hβ, Jα-β = 14.8 Hz, Jβ-γ = 9.6 
Hz), 7.50-7.46 (m, 3H, Hα, H3’, H5’), 7.27 (dd, 1H, Hγ, Jγ-δ = 15.5 
Hz, Jβ-γ = 9.6 Hz), 7.22 (d, 1H, Hδ, Jγ-δ = 15.5 Hz), 6.42 (dd, 1H, H5, 
J5-6 = 8.9 Hz, J3-5 = 2.3 Hz), 6.30 (d, 1H, H3, J3-5 = 2.3 Hz). 13C MNR 
(DMSO D6): δ (ppm) 191.1, 165.6, 165.1, 143.5, 140.1, 134.9, 133.6, 
132.3, 128.9, 128.8, 127.9, 125.1, 112.9, 108.3, 102.6. 
 
2.2.5.2. General procedure for the synthesis of 2-acetylphenyl (E)-
cinnamates (5f-h). 
 
Phosphorus oxychloride (30 mmol) were added to a solution of the 
appropriate 2-hydroxyacetophenone (1a, 1d) (10 mmol) and 
substituted cinnamic acid (4f, 4g) (12 mmol) in dry pyridine (20 mL) 
cooled in ice bath. The solution was stirred at room temperature for 4 
h, than it was poured into ice and water and acidified with 2N HCl. 
The precipitate was removed by filtration, washed with water and 
purified by silica gel column chromatography eluting with 
AcOEt/light petroleum (1:3).  
 
2.2.5.2.1. 2-Acetylphenyl(E)-3,4-dimethoxycinnamate (5f). Yield: 
73%; mp 102-104 °C from EtOH. The compound exhibited 
spectroscopic data identical to those previously reported14. 
 
2.2.5.2.2. 2-Acetyl-3-methoxyphenyl(E)-3,4-dimethoxycinnamate 
(5g). Yield: 90%; mp 96-98 °C from EtOH. The compound exhibited 
spectroscopic data identical to those previously reported14. 
2.2.5.2.3. 2-Acetyl-3-methoxyphenyl(E)-4-acetoxy-3-
methoxycinnamate (5h). Yield: 48%; mp 143-146 °C from AcOEt/ 
petroleum ether. IR (KBr) 1767, 1715, 1633 cm-1. 1H MNR (CDCl3): 
δ (ppm) 7.78 (d, 1H, Hβ, Jα-β = 15.9 Hz), 7.38 (t, 1H, H5, J4-5 = J5-6 = 
8.3 Hz), 7.18-7.14 (m, 2H, H6’, H2’), 7.07 (d, 1H, H5’, J5’-6’ = 8.4 
Hz), 6.85 (d, 1H, H4, J4-5 = 8.3 Hz), 6.81 (d, 1H, H6, J3-4 = 8.3 Hz), 
6.52 (d, 1H, Hα, Jα-β = 15.9 Hz), 3.89 (s, 3H, OCH3), 3.90 (s, 3H, 
OCH3), 2.51 (s, 3H, COCH3), 2.32 (s, 3H, OCOCH3).  
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2.2.5.2.4. General procedure for the synthesis of (2Z,4E)-3-hydroxy-
1-(2-hydroxyphenyl)-5 phenylpenta-2,4-dien-1-ones (6f, 6g)  
 
Anhydrous K2CO3 (50 mmol) was added to a solution of the 
appropriate 2-acetylphenyl (E)-cinnamate (5f, 5g) (10 mmol) in dry 
acetone (100 mL), and the mixture was refluxed for 24 h with stirring. 
After cooling, the mixture was poured into ice and the pH was 
adjusted to 4 with 2N HCl. The solid was removed by filtration, 
dissolved in chloroform and washed with brine. The organic phase 
was dried over Na2SO4, filtered and evaporated to dryness. The 
residue was purified by crystallization. 
2.2.5.2.5. (2Z,4E)-5-(3,4-Dimethoxyphenyl)-3-hydroxy-1-(2-
hydroxyphenyl)penta-2,4-dien-1-one (6f) Yield: 40%; mp 126-128 
°C from EtOH. The compound exhibited spectroscopic data identical 
to those previously reported.14 
 
2.2.5.2.6. (2Z,4E)-5-(3,4-Dimethoxyphenyl)-3-hydroxy-1-(2-
hydroxy-6-methoxyphenyl)penta-2,4-dien-1-one (6g). Yield: 40%; 
mp 131-132 °C from AcOEt. The compound exhibited spectroscopic 
data identical to those previously reported.14 
 
2.2.5.2.7. (2Z,4E)-3-Hydroxy-5-(4-hydroxy-3-methoxyphenyl)-1-(2-
hydroxy-6-methoxyphenyl) penta -2,4-dien-1-one (6h). Anhydrous 
K2CO3 (50 mmol) was added to a solution of 2-acetyl-3-
methoxyphenyl (E)-3-(4-acetoxy-3-methoxyphenyl) cinnamate (5h) 
(10 mmol) in dry acetone (100 mL), and the mixture was refluxed for 
24 h with stirring. After cooling, the mixture was poured into ice (50 g) 
and water (50 mL), and stirred at room temperature for 1 h. After that 
period, the pH was adjusted to 4 with 2N HCl, the solid was removed 
by filtration and purified by silica gel column chromatography eluting 
with CH2Cl2. Yield: 25%; mp 162-164 °C from AcOEt/ petroleum 
ether. IR (KBr) 3406 1626 cm-1. 1H MNR (CDCl3): δ (ppm) (CDCl3): 
14.85 (s, 1H, OH), 12.77 (s, 1H, OH), 7.58 (d, 1H, Hδ, Jγ-δ = 15.8 Hz), 
7.32 (t, 1H, H4, J3-4 = J4-5 = 8.3 Hz), 7.15 (dd, 1H, H6’, J5’-6’ = 8.2 Hz, 
J2’-6’ = 1.9 Hz), 7.06 (d, 1H, H2’, J2’-6’ = 1.9 Hz), 6.95 (d, 1H, H5’, J5’-6’ 
= 8.2 Hz), 6.77 (s, 1H, Hα), 6.60 (d, 1H, H3, J3-4 = 8.3 Hz), 6.45 (d, 
1H, Hγ, Jγ-δ = 15.8 Hz), 6.43 (d, 1H, H5, J4-5 = 8.3 Hz), 5.99 (s, 1H, 
OH),	  3.97 (s, 3H, OCH3), 3.96 (s, 3H, OCH3). 13C NMR (CDCl3): δ 
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(ppm) 194.7, 175.2, 164.0, 160.3, 147.8, 146.8, 139.6, 134.9, 127.9, 
122.7, 120.4, 114.9, 111.1, 110.7, 109.7, 103.2, 101.7, 56.0, 55.9. 
 
2.2.5.3. (2Z,4E)-5-(3,4-Dihydroxyphenyl)-3-hydroxy-1-(2-
hydroxyphenyl)penta-2,4-dien-1-one (6m). 
 
A solution 1M of boron tribromide in dichloromethane (100 mL) 
was added dropwise to a stirred solution of 6f (10 mmol) in dry 
dichloromethane (200 mL) cooled in ice bath. The reaction mixture 
was stirred in ice bath for 1h and then at room temperature for 20 h. 
After this period, the mixture was poured into ice and water and 
vigorously stirred. The obtained precipitate was filtered, washed with 
water, and purified by silica gel column chromatography eluting with 
AcOEt/petroleum ether 1:1. Yield: 40%; mp 200-201 °C from AcOEt. 
IR (KBr) 3385, 1635 cm-1. 1H MNR (acetone D6): δ (ppm) 14.73 (s, 
1H, OH), 12.21 (s, 1H, OH), 8.45 (bs, 2H, 2OH), 7.92 (dd, 1H, H6, J5-
6 = 8.3 Hz, J4-6 = 1.5 Hz), 7.60 (d, 1H, Hδ, Jγ-δ = 15.8 Hz), 7.51 (ddd, 
1H, H4, J3-4 = 8.4 Hz, J4-5 = 7.2 Hz, J4-6 = 1.5 Hz), 7.21 (d, 1H, H2’, 
J2’-6’ = 2.0 Hz), 7.09 (dd, 1H, H6’, J5’-6’ = 8.2 Hz, J2’-6’ = 2.0 Hz), 6.97-
6.94 (m, 2H, H3, H5), 6.90 (d, 1H, H5’, J5’-6’ = 8.2 Hz), 6.69 (d, 1H, 
Hγ, Jγ-δ = 15.8 Hz), 6.68 (s, 1H, Hα). 13C MNR (DMSO D6): δ (ppm) 
191.4, 177.7, 159.9, 148.5, 145.7, 140.5, 134.9, 129.2, 126.3, 121.6, 
120.1, 119.2, 117.7, 115.8, 114.7, 114.4, 98.5. 
 
2.2.5.4. Biochemistry.  
 
2.2.5.4.1. Determination of hMAO Isoform Activity. 
 
The effects of the tested compounds on hMAO isoform enzymatic 
activity were evaluated by measuring their effects on the production 
of hydrogen peroxide from p-tyramine using the Amplex Red MAO 
assay kit (Molecular Probes, Inc., Eugene, Oregon, USA) and 
microsomal MAO isoforms prepared from insect cells (BTI-TN-5B1-
4) infected with recombinant baculovirus containing cDNA inserts for 
hMAO-A or hMAO-B (Sigma-Aldrich Química S.A., Alcobendas, 
Spain). Briefly, various concentrations of the test drugs or reference 
inhibitors and adequate amounts of recombinant hMAO-A or hMAO-
B (required to obtain the same reaction velocity) were incubated for 
15 min at 37 ºC in a sodium phosphate buffer (0.05 M, pH 7.4). The 
reaction was started by adding (final concentrations) 200 µM Amplex 
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Red reagent, 1 U/mL horseradish peroxidase and 1 mM p-tyramine 
which is totally sufficient to saturate both MAO isoforms in these 
experimental conditions. The hMAO activity was evaluated by 
measuring the fluorescence generated by resorufin using the general 
procedure described previously by us.5 The possible capacity of the 
above test drugs to modify the fluorescence due to non-enzymatic 
inhibition (e.g., for directly reacting with Amplex Red reagent) was 
determined by adding these drugs to solutions containing only the 
Amplex Red reagent in a sodium phosphate buffer. For fluorescent 
compounds, incubations with 60 µM kynuramine (Sigma-Aldrich 
Química S.A., Alcobendas, Spain) were performed at 37 ºC and pH 
7.4 in a sodium phosphate buffer (Na2HPO4/KH2PO4 isotonized with 
KCl). The rate of oxidation of the non selective substrate into 4-
hydroxyquinolone was monitored at 314 nm using a Pharmacia 
Biotech Ultrospec 4000 UV/Visible Spectrophotometer.15 IC50 values 
were estimated by non-linear regression analysis using GraphPad 
Prism software (San Diego, USA), with X = log molar concentration 
of tested compound and Y = percentage of inhibition of control 
resorufin production. This regression was performed using data 
obtained with 4–6 different concentrations of each tested compound. 
IC50 values are the mean ± S.E.M. from five experiments. 
 
2.2.5.4.2. Reversibility and Irreversibility Experiments.  
 
To evaluate whether some of the tested compounds (3b, 3g, 3h, 6d 
and 6k) are reversible or irreversible hMAO-B inhibitors, an effective 
centrifugation-ultrafiltration method (so-called repeated washing) was 
used.3 
 
2.2.5.4.3. Molecular Modeling.  
Theoretical 3D models of the most active and hMAO-B selective 
compounds, 3g and 3h were built by means of Maestro16 GUI version 
9.1. The inhibitor structures were optimized by means of energy 
minimization carried out with the OPLS-2005 force field17 and the 
GB/SA18 water implicit solvation model. All these preliminary 
calculation were computed by the version 9.8 of the MacroModel19 
software. Docking simulation were performed using the ligand 
flexible algorithm of Glide20 at XP precision level. The target models 
of hMAO-A and hMAO-B were two high resolution crystal structures 
corresponding to the Protein Data Bank codes 2Z5X21 and 2V5Z22 
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respectively. Co-crystallized ligands, harmine for 2Z5X and 
safinamide for 2V5Z, and water molecules were removed from both 
target models and their binding clefts were defined by means of a 
regular box of about 1,000 Å3, centred onto the N5 FAD cofactor. 
Molecular dynamics (MD) simulations were carried out, up to 12 ns at 
300 °K, applying the version 2.4 of the DESMOND23 package and the 
OPLS-AA force field onto the most stable complex of both inhibitors 
in hMAO-A and -B. The explicit solvation model TIP3 was adopted 
for taking into account water solvent effects. The four MD 
trajectories, each consisting of 240 structures sampled at regular 
interval equal to 5 ps, were graphical inspected and analysed using 
VMD version 1.8.7.24 The molecular orbital (MO) analysis of 
compounds 3g and 3h was carried out at DFT level of theory using the 
hybrid functional B3LYP and the 6-31G** basis set. For mimicking 
the enzyme environment, the implicit solvation model PBF 
chloroform was adopted. The structure of both inhibitors, selected for 
the MO study, were obtained from the last molecular dynamics 
sampled frame and energy minimized during the DFT calculation. 
Quantum mechanics calculations were performed by means of the 
Jaguar.25 Molecular modelling figures were depicted by PyMol 
version 1.3.26 
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Supplementary content 
 
 
Figure S1. Top ranked docking pose of 3g and 3h into hMAO-A (a, 
b) and hMAO-B (c, d) respectively. Inhibitors are depicted in white 
carbons balls & sticks, interacting residues are in green carbons 
sticks, FAD cofactor in spacefill. Yellow dotted lines indicate 
intermolecular hydrogen bonds. GScore is the Glide XP score value. 
 
 
 
Figure S2. 3g and 3h molecular dynamics average interaction 
energies and the corresponding deviations with respect to 
hMAO-A and -B. 
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Figure S3. Molecular dynamics 3g and 3h induced perturbation 
of the target backbone conformation. The measurement was 
computed as average RMSd with respect to the starting 
structures.  
 
 
 
 
 
 
Figure S4. Contribution (%) of each hMAO-A 3g and 3h 
interacting residue. Ligand hydrogen bonding aminoacids are 
violet, brown and white highlighted to indicate their involvement 
in 3g/3h/both inhibitors recognition respectively. 
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Figure S5. Contribution (%) of each hMAO-B 3g and 3h 
interacting residue. Ligand hydrogen bonding aminoacids are 
violet, brown and white highlighted to indicate their involvement in 
3g/3h/both inhibitors recognition respectively. 
 
 
 
Figure S6. Mesh representation of compounds 3g (left) and 3h (right) 
highest occupied (blue) and lowest unoccupied (red) molecular 
orbitals.  
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Table 1. Inhibitor target interaction energy gap between the top ranked docking 
poses and their corresponding, manually built, head-tail configuration. Values are 
reported in kcal/mol. 
 
 
 
 
 
 
 
Table 2. Elemental analyses of derivatives 3a-r and 6a-l. 
 
 
 
 hMAO-A hMAO-B 
3g 8.0 3.4 
3h 22.8 10.2 
Comp C H F Cl N 
 Calc Found Calc Found Calc Found Calc Found   
3a 81.58 81.55 5.64 5.60       
3b 71.71 71.67 4.60 4.56   12.45 12.47   
3c 68.68 68.65 4.80 4.77   11.26 11.28   
3d 61.92 61.89 3.67 3.64   10.75 10.77 4.25 4.25 
3e 63.93 64.01 3.79 3.76   22.21 22.25   
3f 71.71 71.67 4.60 4.56   12.45 12.47   
3g 68.68 68.65 4.80 4.77   11.26 11.28   
3h 67.89 67.86 4.36 4.32   11.79 11.81   
3i 76.11 76.08 4.88 4.85 7.08 7.09     
3j 72.47 72.45 5.07 5.03 6.37 6.37     
3k 77.13 77.10 5.75 5.71       
3l 73.53 73.51 5.85 5.81       
3m 70.57 70.55 5.92 5.88       
3n 72.96 72.93 5.44 5.40       
3o 69.93 69.90 5.56 5.52       
3p 69.93 69.90 5.56 5.52       
3q 69.22 69.19 5.16 5.13       
3r 69.15 69.12 4.44 4.40     4.74 4.74 
6a 76.68 76.65 5.30 5.26       
6b 60.92 60.87 3.61 3.58   21.15 21.19   
6c 67.89 67.85 4.36 4.32   11.79 11.81   
6d 71.82 71.80 4.61 4.57 6.69 6.69     
6e 72.96 72.93 5.44 5.40       
6f 69.93 69.90 5.56 5.52       
6g 67.41 67.34 5.66 5.61       
6h 66.66 66.63 5.30 5.26       
6i 65.59 65.56 4.21 4.20     4.50 4.50 
6j 77.12 77.09 5.75 5.71       
6k 72.33 72.30 5.00 4.96       
6l 68.42 68.43 4.73 4.69       
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